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Smoking cessation medicines and e-cigarettes: a systematic
review, network meta-analysis and cost-effectiveness analysis
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Edna Keeney ,1 David Phillippo ,1 Marcus R Munafò ,2,3,4
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4UK Centre for Tobacco and Alcohol Studies, University of Bristol, Bristol, UK
5Health Economics and Decision Science, School of Health and Related Research, University of
Sheffield, Sheffield, UK
*Corresponding author kyla.thomas@bristol.ac.uk
Background: Cigarette smoking is one of the leading causes of early death. Varenicline [Champix (UK),
Pfizer Europe MA EEIG, Brussels, Belgium; or Chantix (USA), Pfizer Inc., Mission, KS, USA], bupropion
(Zyban; GlaxoSmithKline, Brentford, UK) and nicotine replacement therapy are licensed aids for
quitting smoking in the UK. Although not licensed, e-cigarettes may also be used in English smoking
cessation services. Concerns have been raised about the safety of these medicines and e-cigarettes.
Objectives: To determine the clinical effectiveness, safety and cost-effectiveness of smoking cessation
medicines and e-cigarettes.
Design: Systematic reviews, network meta-analyses and cost-effectiveness analysis informed by the
network meta-analysis results.
Setting: Primary care practices, hospitals, clinics, universities, workplaces, nursing or residential homes.
Participants: Smokers aged ≥ 18 years of all ethnicities using UK-licensed smoking cessation therapies
and/or e-cigarettes.
Interventions: Varenicline, bupropion and nicotine replacement therapy as monotherapies and in
combination treatments at standard, low or high dose, combination nicotine replacement therapy and
e-cigarette monotherapies.
Main outcome measures: Effectiveness – continuous or sustained abstinence. Safety – serious adverse
events, major adverse cardiovascular events and major adverse neuropsychiatric events.
Data sources: Ten databases, reference lists of relevant research articles and previous reviews.
Searches were performed from inception until 16 March 2017 and updated on 19 February 2019.
Review methods: Three reviewers screened the search results. Data were extracted and risk of bias
was assessed by one reviewer and checked by the other reviewers. Network meta-analyses were
conducted for effectiveness and safety outcomes. Cost-effectiveness was evaluated using an amended
version of the Benefits of Smoking Cessation on Outcomes model.
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Results: Most monotherapies and combination treatments were more effective than placebo at achieving
sustained abstinence. Varenicline standard plus nicotine replacement therapy standard (odds ratio 5.75,
95% credible interval 2.27 to 14.90) was ranked first for sustained abstinence, followed by e-cigarette low
(odds ratio 3.22, 95% credible interval 0.97 to 12.60), although these estimates have high uncertainty.
We found effect modification for counselling and dependence, with a higher proportion of smokers who
received counselling achieving sustained abstinence than those who did not receive counselling, and higher
odds of sustained abstinence among participants with higher average dependence scores. We found that
bupropion standard increased odds of serious adverse events compared with placebo (odds ratio 1.27, 95%
credible interval 1.04 to 1.58). There were no differences between interventions in terms of major adverse
cardiovascular events. There was evidence of increased odds of major adverse neuropsychiatric events
for smokers randomised to varenicline standard compared with those randomised to bupropion standard
(odds ratio 1.43, 95% credible interval 1.02 to 2.09). There was a high level of uncertainty about the
most cost-effective intervention, although all were cost-effective compared with nicotine replacement
therapy low at the £20,000 per quality-adjusted life-year threshold. E-cigarette low appeared to be most
cost-effective in the base case, followed by varenicline standard plus nicotine replacement therapy
standard.When the impact of major adverse neuropsychiatric events was excluded, varenicline standard
plus nicotine replacement therapy standard was most cost-effective, followed by varenicline low plus
nicotine replacement therapy standard. When limited to licensed interventions in the UK, nicotine
replacement therapy standard was most cost-effective, followed by varenicline standard.
Limitations: Comparisons between active interventions were informed almost exclusively by indirect
evidence. Findings were imprecise because of the small numbers of adverse events identified.
Conclusions: Combined therapies of medicines are among the most clinically effective, safe and
cost-effective treatment options for smokers. Although the combined therapy of nicotine replacement
therapy and varenicline at standard doses was the most effective treatment, this is currently unlicensed
for use in the UK.
Future work: Researchers should examine the use of these treatments alongside counselling and
continue investigating the long-term effectiveness and safety of e-cigarettes for smoking cessation
compared with active interventions such as nicotine replacement therapy.
Study registration: This study is registered as PROSPERO CRD42016041302.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 25, No. 59. See the NIHR Journals Library website for further project information.
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C igarette smoking is one of the main causes of early death both in the UK and worldwide.Three medicines, varenicline, bupropion and nicotine replacement therapy, are licensed in the
UK to help people stop smoking. E-cigarettes can also be used as a stop smoking aid. We combined
information from previous studies, including clinical trials, to determine which product was the safest,
most effective and best value for money for the NHS. We compared treatments that were given alone
as well as treatments that were combined with others, such as combination nicotine replacement
therapy, varenicline combined with nicotine replacement therapy, varenicline combined with bupropion
and bupropion combined with nicotine replacement therapy. The last three combined treatments are
not currently licensed in the UK for smoking cessation. We also compared different treatment doses
(low, high and standard doses). We found that most treatments were more effective than placebo in
helping people to quit smoking. One of the combination treatments (varenicline at standard dose
combined with nicotine replacement therapy at standard dose) was the most effective at getting
people to quit smoking, followed by e-cigarette at low dose, varenicline at standard dose combined
with bupropion at standard dose, and e-cigarette at high dose. We also found that smokers with higher
tobacco dependence and smokers treated with counselling alongside medicines achieved a higher
proportion of continuous quitting. We also found evidence that the standard dose of bupropion was
associated with an increased risk of serious side effects compared with placebo. There was inconclusive
evidence that any of the treatments increased the risk of major cardiovascular side effects. There was
some evidence that smokers who received a standard dose of varenicline had an increased risk of
major neurological and psychiatric side effects compared with those receiving a standard dose of
bupropion. E-cigarette at low dose, varenicline standard plus nicotine replacement therapy standard
and varenicline standard plus bupropion standard were the best value for money interventions, but
further clinical trials comparing treatments against each other are needed to increase confidence in
these findings.
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Cigarette smoking is one of the leading causes of death in the UK and worldwide. In 2017, an estimated
77,800 deaths in England were attributable to smoking. Smoking costs the NHS between £2.6B and
£5B per year. Varenicline, bupropion and nicotine replacement therapy are recommended by the National
Institute for Health and Care Excellence and are licensed in the UK as medicines for smoking cessation.
Although electronic cigarettes (e-cigarettes) are not licensed medicines, they may also be used in quit
attempts in English smoking cessation services. All of the currently licensed smoking cessation medicines
have been shown to be more effective than placebo in helping people quit smoking. However, concerns
have been raised about the safety of smoking cessation medicines, particularly with respect to the
neuropsychiatric safety of varenicline and the cardiovascular safety of varenicline and nicotine
replacement therapy. There are also emerging concerns regarding the safety of e-cigarettes.
Objectives
The main research question addressed by this assessment is ‘How do smoking cessation medicines
compare with respect to their neuropsychiatric safety: a systematic review, network meta-analysis
and cost effectiveness analysis?’ The specific objectives of the assessment were:
l to perform a comprehensive systematic review and network meta-analysis of the clinical
effectiveness and safety of varenicline, bupropion, nicotine replacement therapy and e-cigarettes
as monotherapies and combination therapies in relation to each other, to placebo or to usual care
l to adapt a previously published economic model to incorporate the disutilities and costs resulting
from adverse events in order to estimate the cost-effectiveness of monotherapies and combination
therapies of smoking cessation medicines and e-cigarettes in the context of the NHS and primary
care settings in the UK.
Methods
Clinical effectiveness and safety
Data sources
The data sources were MEDLINE, EMBASE™ (Elsevier, Amsterdam, the Netherlands), PsycInfo®
(American Psychological Association, Washington, DC, USA), Web of Science™ (Clarivate Analytics,
Philadelphia, PA, USA), ClinicalTrials.gov and Cochrane Databases including the Cochrane Database
of Systematic Reviews, the Database of Abstracts of Reviews of Effects (DARE; updated until March
2015), the Cochrane Central Register of Controlled Trials (CENTRAL), the NHS Economic Evaluation
Database (NHS EED) and the Health Technology Assessment (HTA) database, and reference lists of
relevant research articles and previous reviews. The searches were performed from inception until
16 March 2017 and updated on 19 February 2019.
Study selection
For the review of studies reporting effectiveness, we included randomised controlled trials with
durations of ≥ 6 months (≥ 22 weeks) in any setting, including, but not limited to, primary care
practices, hospitals, including inpatient and outpatient clinics, universities, workplace clinics, and
nursing or residential homes. Trials with two or more study arms were included in the effectiveness
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analyses, whereas crossover trials, non-randomised trials, quasi-randomised trials, large factorial
studies and interrupted time series analyses were excluded.
For the review of studies examining safety, randomised controlled trials of any duration were included
in addition to non-randomised (observational) studies with control groups. Uncontrolled observational
studies (e.g. case reports and case series) were excluded, as were large factorial studies.
In both reviews, we included smokers aged ≥ 18 years of all ethnicities using UK-licensed smoking
cessation therapies and/or electronic cigarettes. This included adult smokers accessing local authority
stop smoking services. We also included smokeless-tobacco users. We excluded studies involving
participants aged < 18 years, as varenicline, bupropion and electronic cigarettes are licensed for use
only in adults in the UK. Non-smoking populations were excluded, as were pregnant and breastfeeding
women, as varenicline and bupropion are not licensed for use in these groups in the UK.
Data extraction
Three reviewers screened the search results. Data were extracted and the risk of bias was assessed
using the Cochrane risk-of-bias tool by one reviewer and checked by the other reviewers.
Outcomes
The main outcome measures were as follows:
l primary effectiveness outcome – continuous (or sustained abstinence)
l secondary effectiveness outcome – prolonged abstinence, any abstinence, 7-day point
prevalence abstinence
l primary safety outcome – serious adverse events
l secondary safety outcome – major neuropsychiatric adverse events and major adverse
cardiovascular events
l tertiary neuropsychiatric and cardiovascular outcomes
l other safety outcomes, including nausea, skin rash, headache and dry mouth.
Methods of data synthesis
Network meta-analyses were performed for the primary and secondary effectiveness and safety outcomes
and the most frequently occurring other outcomes. The remaining outcomes were described narratively
in tables. A sensitivity analysis was carried out to combine the safety outcomes from randomised and
non-randomised evidence. Three different network meta-analysis models were considered: intervention
effects defined by mode of delivery and dose (full interaction model), intervention effects defined by
dose but assumed equal for different modes of delivery within an intervention and dose class (fixed-class
model) and intervention effects defined by dose but effects of different modes of delivery assumed similar
within an intervention and dose class (random-class model).
Cost-effectiveness
The model structure was based on the Sheffield model used in a previous Health Technology Assessment
report on the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking
cessation. The Sheffield model was based on the Benefits of Smoking Cessation on Outcomes model. The
population considered in the decision was adult smokers in the UK who were motivated to quit smoking.
The perspective taken was that of the NHS for costs and health effects on the individual for outcomes, in
line with National Institute for Health and Care Excellence guidance. A lifetime time horizon was taken,
using a cohort simulation model to predict costs and utilities over a participant's lifetime.
SCIENTIFIC SUMMARY
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Results
Results of the clinical effectiveness review
Three hundred and sixty-three trials reported on one or more effectiveness outcomes involving
201,045 participants across a range of settings. There was evidence that most monotherapies and
combination treatments were more effective than placebo at helping participants achieve sustained
(or continuous) abstinence. The three most effective treatments compared with placebo were varenicline
standard plus nicotine replacement therapy standard (odds ratio 5.75, 95% credible interval 2.27 to
14.88), varenicline low plus nicotine replacement therapy standard (odds ratio 5.70, 95% credible interval
1.57 to 21.12) and e-cigarette low (odds ratio 3.22, 95% credible interval 0.97 to 12.55), although these
estimates were very uncertain. Smokers randomised to varenicline standard plus nicotine replacement
therapy standard were more likely to achieve sustained abstinence than participants receiving nicotine
replacement therapy standard or bupropion standard. We also found that varenicline standard resulted in
higher odds of sustained abstinence than nicotine replacement therapy standard or bupropion standard,
and weak evidence that e-cigarette high may increase the odds of sustained abstinence compared with
bupropion standard. Counselling delivered alongside medicines was associated with a higher proportion
of smokers achieving sustained abstinence than medicines alone (additional log-odds ratio 0.86, 95%
credible interval 0.45 to 1.27), and there was inconclusive evidence that this effect was synergistic (more
effective than would be expected based on the sum of the pharmacological and counselling effects alone)
(additional log-odds ratio 0.16, 95% credible interval –0.05 to 0.37). We also found a higher odds ratio of
sustained abstinence among participants with higher average dependence scores (additional log-odds
ratio 0.23, 95% credible interval 0.02 to 0.43).
The results for the secondary effectiveness outcomes were largely similar to those for sustained
abstinence. Although reported in fewer studies and for fewer interventions, we found evidence that
smokers treated with nicotine replacement therapy high, bupropion standard, varenicline standard and
varenicline standard plus bupropion standard were more likely to achieve prolonged abstinence than
those using placebo. Bioverified prolonged abstinence data at ≥ 6 months for e-cigarette or varenicline
standard plus nicotine replacement therapy standard were not available. There was inconclusive evidence
that bupropion standard, varenicline standard and varenicline standard plus bupropion standard differed
from each other in the odds of achieving prolonged abstinence.
For our ‘any abstinence’ outcome, as for sustained abstinence, we found that most interventions were
more effective than placebo at helping participants abstain from smoking, including e-cigarette at low
and high doses. The three most effective treatments compared with placebo were bupropion low plus
nicotine replacement therapy high, varenicline standard plus nicotine replacement therapy standard and
varenicline not specified. Pairwise comparisons between interventions for ‘any abstinence’ indicated that
smokers randomised to varenicline standard were more likely to achieve abstinence than those allocated
to nicotine replacement therapy standard or bupropion standard. We also found that varenicline standard
plus nicotine replacement therapy standard led to higher odds of abstinence than nicotine replacement
therapy standard, bupropion standard, and bupropion standard plus nicotine replacement therapy
standard, while varenicline standard plus bupropion standard led to higher odds of abstinence than
bupropion standard alone.
Finally, there was evidence that a number of interventions were more effective than placebo at attaining
7-day point prevalence abstinence, including e-cigarette high. The three most effective treatments
compared with placebo were bupropion low plus nicotine replacement therapy high, varenicline standard
plus nicotine replacement therapy standard and varenicline not specified. In terms of 7-day point
prevalence abstinence, our network meta-analysis indicated that smokers allocated to varenicline
standard achieved abstinence more often than those using nicotine replacement therapy standard or
bupropion standard. We also found that varenicline standard plus nicotine replacement therapy standard
led to higher odds of abstinence than nicotine replacement therapy standard, bupropion standard or
varenicline standard.
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Ranking the interventions across primary and secondary effectiveness outcomes, varenicline standard
plus nicotine replacement therapy standard showed a high probability of being ranked as the best or
second-best intervention for all outcomes except prolonged abstinence, for which there were no data.
Varenicline standard plus bupropion standard had the highest probability of being ranked as best for
prolonged abstinence, but its rankings for other outcomes were less certain. Finally, varenicline standard
showed high probabilities of being ranked second- to fourth-best across outcomes, while e-cigarette
rankings were uncertain and placebo was consistently ranked last.
Results of the safety review
Three hundred and fifty-five trials reported on one or more safety outcomes involving 159,101 participants,
and 53 observational studies involving 8,783,403 participants took place across a range of settings. There
was evidence that, compared with placebo, bupropion standard increased the odds of experiencing serious
adverse events (odds ratio 1.27, 95% credible interval 1.04 to 1.58).
Regarding secondary outcomes, we could not find any differences between interventions for major
adverse cardiovascular events because of the rarity of events reported across studies, resulting in effect
estimates with very wide confidence intervals. This did not change with the addition of 10 observational
studies to our analyses; there was substantial uncertainty regarding the relative cardiovascular safety of
the treatments. For major adverse neuropsychiatric events, there was evidence that smokers receiving
nicotine replacement therapy not specified, bupropion standard, bupropion standard plus nicotine
replacement therapy high or varenicline standard plus bupropion standard were less likely to report
major adverse neuropsychiatric events than smokers treated with placebo. There was evidence of
an increased odds of major adverse neuropsychiatric events for smokers randomised to varenicline
standard compared with those using bupropion standard. Although 16 observational studies reported
one or more major adverse neuropsychiatric events, our analyses incorporating these studies produced
similar results to that of the randomised evidence. We found that bupropion standard, bupropion
standard plus nicotine replacement therapy high and varenicline standard plus bupropion standard
were associated with lower odds of experiencing a major adverse neuropsychiatric event than placebo.
Intervention rankings have not been reported because they are unlikely to be robust as a result of the
high levels of uncertainty associated with the safety outcomes.
Results of the cost-effectiveness review
There was a high level of uncertainty as to the most cost-effective intervention, although all of the
interventions were cost-effective compared with nicotine replacement therapy low at the threshold
for cost-effectiveness of £20,000 per quality-adjusted life-year. At this threshold, e-cigarette low
appeared to be the most cost-effective intervention in the base case (expected net benefit £7085)
followed by varenicline standard plus bupropion standard (expected net benefit £6756) and then
varenicline standard plus nicotine replacement therapy standard (expected net benefit £6591).
However, the probability of being the most cost-effective intervention was < 0.3 for all interventions.
When the impact of major adverse neuropsychiatric events was excluded, varenicline standard plus
nicotine replacement therapy standard was the most cost-effective intervention (expected net benefit
£9895), followed by varenicline low plus nicotine replacement therapy standard (expected net benefit
£9759). These results are also uncertain, with the probability of being the most cost-effective intervention
being < 0.4 for all interventions. When the analysis was limited to interventions that are licensed in the
UK, varenicline standard was the most cost-effective intervention (expected net benefit £3697), followed
by nicotine replacement therapy standard (expected net benefit £3663).
The value-of-information analysis found that a large, adequately powered, randomised controlled trial of
e-cigarettes against an active comparator such as varenicline standard plus nicotine replacement therapy
standard or nicotine replacement therapy standard is likely to be a cost-effective use of research resources
(population expected value of partial perfect information over a 5-year horizon = £3209M).
SCIENTIFIC SUMMARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxx
Conclusions
Our findings suggest that combined therapies of smoking cessation medicines are among the most
clinically effective, safe and cost-effective treatment options for smokers. Although combination
nicotine replacement therapy is commonly prescribed, combined therapy of nicotine replacement
therapy delivered alongside varenicline at standard doses (currently unlicensed) was shown to be
the most effective treatment for most cessation outcomes. Using combined therapies instead of
monotherapy treatments may offer smokers a better chance of successfully quitting smoking over
both short and long periods of time.
Although the use of bupropion standard may increase the odds of serious adverse events compared
with placebo, we did not find strong evidence of any other negative associations between medicines
and serious adverse events, major adverse cardiovascular events or major neuropsychiatric adverse
events relative to placebo. Although e-cigarettes showed promise as cessation tools that are likely
to be cost-effective, their safety profile remains uncertain and no existing model of the devices has
been licensed as a medicine. This study has used the most up-to-date information to give an estimate
of the most cost-effective intervention for smoking cessation in the UK today. This analysis showed
that, in the base case, e-cigarette low, varenicline standard plus nicotine replacement therapy and
varenicline standard plus bupropion standard appeared to be the most cost-effective interventions,
although these results were uncertain. When the impact of the safety outcomes of depression and
self-harm was excluded, varenicline standard plus nicotine replacement therapy standard was the
most cost-effective intervention.
The research recommendations are as follows:
l Study authors should ensure complete and accurate reporting of their study methodology to reduce
the number of domains identified as being at unclear risk of bias owing to a lack of detailed
description of study motives.
l There should be improved reporting of safety data in studies. Consideration should be given to
creating a core outcome set for safety outcomes in studies of smoking cessation to ensure the
systematic recording and reporting of adverse events.
l A large randomised controlled trial comparing e-cigarettes with active comparators is needed,
with long follow-up to enable the collection of sufficient safety data.
Study registration
This study is registered as PROSPERO CRD42016041302.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 59.
See the NIHR Journals Library website for further project information.
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Description of the health problem
Cigarette smoking is one of the leading causes of early death both in the UK and worldwide.1,2
Although smoking is now down to fewer than 1 in 6 adults (14.4%) in the UK, this still equates to
approximately 7.35 million people in the population.3 In 2017, 77,800 deaths were estimated to be
attributable to smoking in England, representing 16% of all deaths and 33% of deaths from conditions
that can be caused by smoking.3 The cost of smoking to the NHS has been estimated at between
approximately £2.6B and £5B per year,4,5 with the total cost to society in England estimated at
approximately £12.9B per year.6
Description of the interventions under assessment
Smoking cessation medicines and electronic cigarettes
National Institute for Health and Care Excellence (NICE) public health guidance recommends the
use of three medicines, varenicline, bupropion and nicotine replacement therapy (NRT), as aids to
quitting smoking in the UK.7 Varenicline is a partial agonist selective for alpha-4 beta-2 nicotinic
receptor subtypes. It binds to these receptors, causing a dopamine release, albeit less than that from
smoking, while simultaneously blocking the action of nicotine itself.8,9 Therefore, it acts to both
limit the reward experienced by smoking and counteract the withdrawal symptoms experienced
during smoking cessation attempts that result from low dopamine release in the absence of nicotine.
Varenicline was approved as a prescription smoking cessation aid in 2006 by the US Food and Drug
Administration (FDA) as Chantix (Pfizer Inc., Mission, KS, USA), and by the European Medicines Agency
(EMA) as Champix (Pfizer Europe MA EEIG, Brussels, Belgium). It was recommended by NICE in
July 2007 as an option for smokers who had expressed a desire to quit smoking as part of a programme
of behavioural support.10,11
Bupropion, or Zyban (GlaxoSmithKline, Brentford, UK), was licensed by the FDA in 1997 and by the
Medicines and Healthcare products Regulatory Agency (MHRA) in June 2000 as a stop-smoking
medicine. It is also used off-licence in the UK and in the USA as an antidepressant.12 It has both
dopaminergic and adrenergic actions and also appears to be an antagonist at the nicotinic acetylcholine
receptor.13 The drug promotes smoking cessation by blocking nicotine effects, relieving withdrawal
symptoms,14,15 or, in its antidepressant role, by blocking the neuronal reuptake of dopamine and
noradrenaline, thereby reducing low mood.16
Nicotine replacement therapy (NRT) refers to products used to assist with a quit attempt by delivering
nicotine to satisfy tobacco cravings and preventing withdrawal symptoms. NRT can come in fast-acting
forms, such as gum, lozenge, spray, inhalator and tablet, or as slow-acting patches, and are often used
in combination, to deliver varying doses of nicotine based on one’s level of tobacco dependence,
as standard care in the UK.
In late 2015, the MHRA approved the use of the first electronic cigarette, British American Tobacco’s
‘e-Voke’, as a smoking cessation medicine.17 Electronic cigarettes (also known as e-cigarettes, e-cigs,
electronic nicotine delivery systems or vapes) are battery-powered devices that heat a liquid, typically
containing nicotine, flavourings and additives, to generate an aerosol or a ‘vapour’, which the user then
inhales.18 However, e-Voke’s development was terminated before the product could come to market.
Although no e-cigarettes are currently licensed as medicines, NICE guidance recognises that e-cigarettes
may help people to quit smoking cigarettes.7,19 An independent expert review of e-cigarettes published
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by Public Health England in 201520 advised that e-cigarettes should be considered as an option for
smokers who have failed to quit smoking by other methods. The report’s statement that e-cigarettes
are 95% safer than tobacco smoking remains controversial. An updated report published in 2018
recommended improved access to e-cigarettes for people in disadvantaged groups and the importance
of facilitating the regulation of some e-cigarettes as medicines via the MHRA.21
Changes in prescribing patterns
The number of prescriptions of all smoking cessation medicines has shown an overall reduction over
the past 10 years, which may reflect the decrease in smoking prevalence and/or the increased use of
e-cigarettes. Prescription data from 2018/19 show 740,000 total prescriptions of smoking cessation
medicines, with 396,000 prescriptions of NRT (note that NRT is also available over the counter without
a prescription), 24,000 prescriptions of bupropion and 320,000 prescriptions of varenicline.3 In 2018,
there were an estimated 3.2 million adult users of e-cigarettes in Great Britain.22 Notably, the number
of prescription items of varenicline dispensed in England decreased by 51% from a peak of 987,000
prescriptions in 2011 to 489,000 prescriptions in 2016,23 possibly reflecting ongoing fears among
prescribers and patients about varenicline’s neuropsychiatric safety as a result of the safety warnings
on varenicline’s product labelling during that time (see Adverse events).
Effectiveness
All of the currently licensed smoking cessation medicines have been shown to improve people’s chances
of quitting smoking compared with placebo.24–27 Varenicline has been shown to be the most clinically
effective monotherapy for long-term smoking abstinence (i.e. > 6 months).25 However, combination
NRT has been shown to be just as effective as varenicline as an aid to quitting smoking.25
Adverse events
Concerns have been raised about the safety of smoking cessation medicines, particularly with respect
to the neuropsychiatric safety of varenicline and the cardiovascular safety of varenicline and NRT.
There are emerging concerns about the safety of e-cigarettes. Severe safety warnings about a potential
increased risk of serious neuropsychiatric adverse events (AEs) (depression, suicidal ideation and suicidal
behaviour) in patients prescribed varenicline have previously been issued by regulatory agencies.28,29
A black-box warning, the FDA’s most serious safety warning, was placed on varenicline’s product labelling
between 2009 and 2016.30,31 These safety warnings were based on spontaneous reports to the MHRA’s
Yellow Card Scheme in the UK and the FDA’s Adverse Events Reporting System in the USA.
Previous research into the neuropsychiatric safety of varenicline has provided inconsistent findings,
adding to the debate.32 In April 2016, the results of the EAGLES trial,33 a randomised controlled trial
(RCT), were published. This study randomised 8144 smokers to receive varenicline, transdermal NRT
patch, bupropion or placebo. The trial’s findings provided evidence suggesting that neither varenicline
nor bupropion were associated with an increase in neuropsychiatric AEs relative to nicotine patch
or placebo. Subsequently, the EMA lifted the warning about possible suicidal risks from varenicline
in April 2016,34 which was followed by the FDA’s decision to remove the black-box warnings on
varenicline’s labelling in December 2016.35 In terms of neuropsychiatric events, bupropion use has
been specifically associated with an elevated risk of seizures.36 However, a review by Hughes et al.26
determined that, despite reported events, seizures remained rare, as the average rate was lower than
the 1 : 1000 estimated risk reported in the product’s safety information.
Previous systematic reviews comparing varenicline with placebo have reported inconsistent findings
regarding varenicline’s cardiovascular safety.37,38 Mills et al.39 conducted a network meta-analysis (NMA) to
investigate the comparative safety of varenicline, bupropion and NRT for cardiovascular events, including
major adverse cardiovascular events (MACEs) such as cardiovascular death, non-fatal myocardial infarction
and non-fatal stroke. Although the authors found no clear evidence that varenicline or bupropion use
was associated with an elevated risk of any cardiovascular events, NRT use was associated with an
increased risk of events. This finding was driven by lower-risk events, typically tachycardia or arrhythmia.
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However, NRT use was not associated with an increased risk of experiencing a MACE.39 Similarly, based on
the EAGLES trial and a 28-week extension that followed a subset of 4595 participants, Benowitz et al.40
found inconclusive evidence that varenicline, bupropion or NRT increased the risk of MACEs.
Safety concerns about e-cigarettes include the risks associated with the devices being manufactured
to variable standards, the risks of specific flavouring components, potentially harmful constituents
found in the vapour and uncertainty about the long-term health impact on e-cigarette users.41–43
More recently, there have been reports of an outbreak of lung injury associated with e-cigarette
use in the USA, with seven confirmed deaths.44 A similar outbreak has not been observed in the
UK. However, in general, there is limited research and a lack of evidence regarding the safety of
e-cigarettes compared with licensed smoking cessation medicines. Nonetheless, concerns about
safety have led to a wide variety of regulatory decisions regarding the sale and use of e-cigarettes
worldwide. Whereas e-cigarettes are widely available for sale as consumer products in the UK, their
use is restricted in several countries.45 Some countries (India, Uruguay, Jordan and Saudi Arabia) have
banned the devices; in Thailand, possessing the devices can result in a 10-year prison conviction.45,46
Reasons for conducting this review
The ongoing debate regarding the safety of drugs for smoking cessation may be a result of the
inconsistent research findings in this area.32 Studies without control groups (those using AE reporting
data and case studies)47–49 have reported increased neuropsychiatric risks of varenicline and bupropion,
whereas studies with control groups (observational cohort studies, RCTs, and systematic reviews of
RCTs) have reported the opposite, and found inconclusive evidence of an increased risk of severe
outcomes in patients prescribed these medicines.50–56 Although large RCTs such as the EAGLES trial
(the largest RCT comparing the neuropsychiatric safety of smoking cessation medicines) provide better
evidence than non-randomised studies, even its sample size, and thereby its statistical power, was
limited relative to that of much larger observational cohort studies.53,57
There have also been inconsistent findings regarding the cardiovascular safety of these medicines.
A 2011 meta-analysis38 of 14 trials reported an increased risk of serious adverse cardiovascular
events. However, a larger meta-analysis37 published the following year found no significant increase in
serious cardiovascular AEs associated with varenicline use. The largest meta-analysis39 of cardiovascular
safety to date found no clear evidence that varenicline or NRT were associated with major adverse
cardiovascular events. Bupropion was shown to be protective. However, NRT was associated with
an elevated risk of less serious AEs, including tachycardia and palpitations.
To date, studies have focused mainly on comparing the safety of varenicline monotherapy with
placebo.50–52,58 However, making comparisons with other smoking cessation drugs is likely to be of
greater relevance to patients, prescribers and regulators. Additionally, in the UK, although e-cigarettes
are not licensed medicines, they are also used in smoking cessation, and, given their popularity,
it is important to review their safety and effectiveness as smoking cessation aids.22 Updated cost-
effectiveness analyses of these medicines in UK settings will also be conducted to inform the overall
risk–benefit evaluation of the different smoking cessation medicines and to determine which treatment
represents the best ‘value for money’ to the NHS.
Clinical trials in this area have the following limitations:
l Relatively few smoking cessation trials compare medicines against each other or in combination,
which can be addressed using NMA to estimate the comparative effectiveness and safety of
medicines tested against a common comparator (placebo).
l Safety reporting varies greatly across trials.
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The limitations of previous synthesis research in this area are as follows:
l There have been no comprehensive reviews of the neuropsychiatric safety of the smoking cessation
medicines in relation to each other, as existing reviews mainly compare monotherapies with placebo.
l Previous reviews have failed to comprehensively investigate the safety of smoking cessation
medicines in a NMA by not including data from all RCTs irrespective of their duration. As AEs
may occur within hours or days of starting treatment,59 the previous NMAs that excluded RCTs of
< 6 months58,60 may have failed to capture AEs reported in shorter-duration trials.
l There is a lack of sufficient data for nodes in the previous neuropsychiatric safety NMAs.58,60
l None of the previously published NMAs has examined combined therapies of smoking cessation
medicines,25,58,60 not currently licensed for use in the UK, although the effectiveness and safety of
combined treatments are increasingly being examined in trials.
l No recent cost-effectiveness analyses have fully accounted for AEs in order to determine which
UK-licensed smoking cessation medicine is estimated to be the most cost-effective in UK settings.
The limitations of previous cost-effectiveness analyses in this area are as follows:
l No previous cost-effectiveness analysis could be identified that compared the full range of available
pharmacological interventions, comparing the standard licenced interventions with combination
therapies and e-cigarettes.
l No previous cost-effectiveness analysis has incorporated safety outcomes.
l Only one previous study has compared the cost-effectiveness of e-cigarettes with that of NRT61
but, to our knowledge, no previous study has assessed the cost-effectiveness of e-cigarettes
compared with all other interventions available in the UK.
There is, therefore, a need for an updated and comprehensive review of the evidence for the safety
and effectiveness of licensed smoking cessation medicines and electronic cigarettes to allow patients,
prescribers and regulators to make informed decisions about treatment choice and to establish the
cost-effectiveness of these treatments in UK settings.
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Chapter 2 Research questions
Objectives of the evidence review
Our specific objectives were:
l to perform a comprehensive systematic review and NMA of the clinical effectiveness and safety
of varenicline, bupropion, NRT and e-cigarettes as monotherapies and combination therapies in
relation to each other, placebo or usual care
l to adapt a published economic model to incorporate the disutilities and costs resulting from AEs
in order to estimate the cost-effectiveness of monotherapy and combination therapies of smoking
cessation medicines and e-cigarettes in the context of the NHS and primary care settings in the UK
l where sufficient data are available, to explore the following subgroups in the NMA: those with
psychiatric illness, those with comorbid conditions, heavy smokers (defined as people who smoke
> 20 cigarettes per day), smokeless-tobacco users and smokers not willing to quit.
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Chapter 3 Review methods: assessment
of clinical effectiveness and safety
Introduction
We conducted systematic reviews with NMAs of:
l effectiveness of smoking cessation medicines and e-cigarettes using RCTs
l safety of smoking cessation medicines and e-cigarettes using RCTs and non-randomised
(observational) studies.
We undertook these reviews in accordance with the Centre for Reviews and Dissemination (CRD)
guidelines for undertaking systematic reviews62 and the Cochrane Handbook for Systematic Reviews of
Interventions63 (as updated online during 2011: www.cochrane-handbook.org; accessed September 2019).
We prospectively registered the reviews in the PROSPERO (international prospective register of
systematic reviews) database (www.crd.york.ac.uk/prospero; accessed September 2019), with registration
number CRD42016041302. A protocol of the review has also been published as a journal article.64
Eligibility criteria
Study designs
For the review of studies reporting effectiveness, we included RCTs with duration of ≥ 6 months
(≥ 22 weeks) in any setting, including, but not limited to, primary care practices, hospitals, including
inpatient and outpatient clinics, universities, workplace clinics, nursing or residential homes. Trials
with two or more study arms were included in the effectiveness analyses, whereas crossover trials,
non-randomised trials, quasi-randomised trials, large factorial studies and interrupted time series
analyses were excluded.
For the review of studies examining safety, RCTs of any duration were included in addition to
non-randomised (observational) studies with control groups. Uncontrolled observational studies
(e.g. case reports and case series) were excluded, as were large factorial studies.
Participants
In both reviews, we included smokers aged ≥ 18 years of all ethnicities using UK-licensed smoking
cessation therapies and/or electronic cigarettes. This included adult smokers accessing local authority
stop-smoking services. We also included smokeless-tobacco users irrespective of whether or not
they smoked. We excluded studies with participants aged < 18 years, as varenicline, bupropion and
electronic cigarettes are licensed for use only in adults in the UK. Non-smoking populations were
excluded, as were pregnant and breastfeeding women, as varenicline and bupropion are not licensed
for use in these groups in the UK.
Interventions and comparators
Three smoking cessation medicines were the focus of all reviews, varenicline, bupropion and nicotine
replacement therapy (NRT), as monotherapies as well as in combination treatments (e.g. varenicline
combined with NRT, varenicline combined with bupropion and bupropion combined with NRT). We also
assessed e-cigarette monotherapies as e-cigarettes are used in smoking cessation, although they are
not licensed medicines in the UK. For NRT, combinations of different formulations given concurrently,
for example patch and gum, were also included. Different dosages of treatments were also examined,
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classified into low, standard and high, as described below. The dose categories for active interventions
were determined using the British National Formulary (BNF)65 and the MHRA public assessment report
for the ‘e-Voke’66 (Table 1).
We also identified two additional NRT treatments: NRT combination, whereby two or more NRT
products were administered in combination in a single arm, and NRT choice, whereby participants
were given a choice of NRT products they could select to use. The dosage for NRT combination was
indicated based on the highest dose among assigned products, while the dosage for NRT choice was
indicated only when dosages for every offered product were reported.
We excluded trial arms of interventions in which patients could receive more than one intervention
but where these were undefined (i.e. ‘mixed’ rather than ‘combination’ interventions). We also
excluded alternative and complementary therapies (e.g. hypnotherapy, acupuncture, aromatherapy
and herbal therapies).
As the reviews were conducted to inform NMAs, we determined the comparator interventions to
ensure that they would provide information on the relative effectiveness/safety of the interventions
of interest. Comparators were chosen based on the possibility of informing indirect evidence on
the relative effectiveness of the interventions; and on the ‘distance’ of these comparators from
our interventions of interest in the network, which relates to the likely increase in precision in
the estimates of relative effectiveness and safety. We defined the following comparators:
l placebo (reference comparator for the NMAs)
l no drug treatment (including brief advice)
l usual care
l waitlist.
Where psychotherapies were included in each arm of a study (e.g. studies of a pharmacological
treatment plus psychotherapy vs. psychotherapy alone), these studies were included and were analysed
TABLE 1 Interventions by formulation and dosage
Treatment (formulation) Low dose Standard dose High dose
Bupropion (oral extended-release tablets) < 150mg b.i.d. 150 mg b.i.d. > 150mg b.i.d.
Varenicline (tablets) < 1mg b.i.d. 1 mg b.i.d. > 1mg b.i.d.
E-cigarette (electronic inhaler, five cartridges/day) 10 mg 15mg
NRT
NRT patch (16 hours) < 15mg 15mg > 15mg
NRT patch (24 hours) < 14mg 14mg > 14mg
NRT gum (15/day) 2 mg 4mg
NRT nasal spray (2 sprays/hour, 64/day) 0.5 mg
NRT mouth spray (4 sprays/hour, 64/day) 1 mg
NRT lozenge (1 lozenge/1–2 hours, 15/day) < 2mg 2mg 4mg
NRT sublingual tablet (2 mg/tablet, 40/day) 1/hour 2/hour
NRT inhalator 10 mg (12/day) 15 mg (6/day)
b.i.d., twice a day.
This table is reproduced with permission from Thomas et al.67 This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and
build upon this work, for commercial use, provided the original work is properly cited. See: https://creativecommons.org/
licenses/by/4.0/. The table includes minor additions and formatting changes to the original table.
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as pharmacological treatment compared with no drug treatment, under the assumption of no interaction
between pharmacological and psychotherapies when given together. Where psychotherapies were
given as an adjunct to pharmacological treatments, but not in all arms of the study (e.g. studies of
pharmacological treatment plus psychotherapy vs. usual care), these studies were included in the base
case analysed as pharmacological treatment compared with no drug treatment, and the impact of the
addition of psychotherapy was estimated using meta-regression. We assessed the sensitivity of our
findings to excluding such studies in a sensitivity analysis. Although the efficacy of psychotherapies was
not the focus of this review, studies in which psychotherapy was used as a comparator (e.g. studies of
pharmacological treatment vs. psychotherapy) could potentially provide useful indirect evidence for
estimates between pharmacological therapies. However, only four trials were identified in which this
could have been possible and the psychotherapies used were very different across these studies, making
such a comparison unreliable. We, therefore, did not include psychotherapy as a comparator in the NMA.
Outcomes of interest
Effectiveness
We only included bioverified events in our main analyses reported at ≥ 6 months’ follow-up. We used
Cochrane definitions for all outcomes.68 Our primary effectiveness outcome was continuous (or sustained)
abstinence defined as avoidance of all tobacco use since the quit day until the time the assessment was
made, occasionally allowing for lapses where specified. Secondary effectiveness outcomes included:
l Prolonged abstinence – a measure of cessation that typically allows a ‘grace period’ following the
quit date (usually of about 2 weeks) to allow for slips/lapses during the first few days when the
effect of treatment may still be emerging.
l Any abstinence – an outcome where we included abstinence by any definition reported at 6 months.
Where studies reported more than one cessation outcome, we preferred continuous/sustained
abstinence, followed by prolonged abstinence, 30-day point prevalence abstinence (PPA), 7-day PPA
and any other abstinence.
l 7-day PPA – a measure of cessation based on behaviour over a 7-day period.
Safety
The primary composite safety outcome was serious adverse events (SAEs), defined as events that resulted
in death, were life-threatening, required hospitalisation or resulted in significant disability.69 We also
recorded hospitalisation, treatment discontinuation and withdrawal from study as a result of AEs.
Furthermore, we sought data on the following outcome categories.
l Cardiovascular outcomes:
¢ Secondary composite outcome – MACEs, including cardiovascular death, non-fatal myocardial
infarction (excluding unstable angina), and fatal and non-fatal stroke.70
¢ Tertiary outcomes – arrhythmias, congestive heart failure, unstable angina, palpitations,
thromboembolism (deep-vein thrombosis or pulmonary embolism), and transient ischaemic attack.
l Neuropsychiatric outcomes:
¢ Secondary composite outcome – major adverse neuropsychiatric events (MANEs), comprising
suicide, attempted suicide, suicidal ideation, depression and seizures.51
¢ Tertiary outcomes – abnormal dreams, aggression, anxiety, insomnia, irritability, sleep disorders
and somnolence.
l Other outcomes: chronic obstructive pulmonary disease (COPD), dry mouth, fatigue, headache,
nausea, pruritus, skin rash and all-cause death.
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For the systematic review of RCTs, primary and secondary composite outcomes and the most
frequent other outcomes were addressed in NMAs, whereas the remaining outcomes were reported
in tables. Conversely, the systematic review of non-randomised studies retrieved a much smaller
number of interventions; therefore, we decided to combine safety outcomes from randomised and




We searched the following databases: MEDLINE, EMBASE™ (Elsevier, Amsterdam, the Netherlands),
PsycInfo® (American Psychological Association, Washington, DC, USA), Web of Science™ (Clarivate
Analytics, Philadelphia, PA, USA), ClinicalTrials.gov and the Cochrane databases including the Cochrane
Database of Systematic Reviews, the Database of Abstracts of Reviews of Effects (DARE; updated
until March 2015), the Cochrane Central Register of Controlled Trials (CENTRAL), the NHS Economic
Evaluation Database (NHS EED) and the Health Technology Assessment (HTA) database. Searches
were conducted with the help of information specialists and did not include any language restrictions.
Non-English-language articles were reviewed by native speakers before a full translation was obtained.
We also manually searched the reference lists of relevant research articles and previous reviews and
communicated with authors to identify unpublished information.
To identify studies for the effectiveness NMAs, the search strategies from recent Cochrane reviews24,26,71,72
were used to create an updated strategy to identify more recent trials for inclusion in the current study
in addition to trials identified by past reviews. To identify studies for the safety NMAs, we built on the
basic search strategy included in the cardiovascular NMA by Mills et al.39 Searches for non-randomised
studies were not date-limited. We completed our original searches on 16 March 2017 and our update
searches were completed on 19 February 2019. For the search terms we used for our MEDLINE searches,
see Appendix 1.
Assessing relevance and inclusion
Search results were uploaded to Covidence,73 which we used to screen abstracts and full texts and to
resolve disagreements. Three reviewers independently screened abstracts to determine whether or
not full-text reports should be obtained. The same reviewers independently identified eligible full-text
reports for inclusion. Each record was screened by at least two reviewers at each stage. Discrepancies
were resolved by reaching consensus among reviewers.
Data extraction
Data for included studies were extracted by one reviewer and checked by co-reviewers. Information was
collected on study design (duration of treatment, description of allocation concealment and blinding),
study participants (country, region and population studied), baseline characteristics (e.g. ethnicity, sex
and smoking history), intervention and comparison groups (including the smoking cessation intervention,
whether or not there was cotreatment, dosage and formulation), our predefined primary and secondary
outcomes of interest including measures of effectiveness and safety outcomes, losses to follow-up and
study sponsor. In the event of missing data, we contacted authors by e-mail to ask for original data.
Authors of all identified studies with randomised controlled designs were contacted to verify the
accuracy of the extracted data and/or to provide safety data.
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Assessment of risk of bias in included trials
For all studies, the Cochrane tool for assessing the risk of bias74 was used to determine whether
there was a high, low or unclear risk of bias in the following domains: random sequence generation,
allocation concealment, blinding of participants and personnel, blinding of outcome assessment,
incomplete outcome data, selective outcome reporting and other sources of bias. An overall risk of
bias was also determined by selecting the highest rating of bias across domains, with the exception of
selective outcome reporting. Reviewers independently assessed the risk of bias in each of the trials.
Discrepancies were resolved by referring to the original publication and reaching consensus among
reviewers. To aid with the risk-of-bias assessment, study authors of RCTs were contacted to obtain
study protocols and additional information that may not have been published.
Selection of data for analysis
Intervention definitions
To perform NMAs, we had to allocate each intervention group in each trial to a category, with each
intervention category forming a ‘node’ in the network. We defined intervention nodes according to
the type and intensity of treatment and/or NRT received.
Quantitative synthesis (including network meta-analysis)
We performed a NMA for each outcome. NMA is a methodology that enables the quantitative integration
of a collection of primary studies by pooling evidence from all intervention comparisons considered in
those primary studies. Results for each pairwise comparison combine both the direct evidence, based
on the head-to-head intervention comparisons made in primary studies, and the indirect evidence, which
refers to the intervention comparisons inferred from the network via comparator interventions.75,76
NMA thus enables an estimation of relative intervention effect estimates for every pair of interventions,
regardless of whether or not they have been compared directly in a RCT. It also enables the inference of
the ranking of treatments for a given outcome.
To be included in the analyses, studies were required to report the proportion of events for each arm
(or enough information to calculate it manually), and to report at least one event in one of the arms
for the outcome analysed. We considered three different NMA models:
1. Full interaction model – this is the standard NMA model in which each different combination of
drug type, drug intensity, NRT type and NRT intensity is considered as a separate intervention.
2. Fixed-class model – this model assumes that the interventions can be grouped into classes, with
treatment effects in the same class assumed to be identical.77 We defined classes according to type
of treatment and delivery.
3. Random-class model – this model also groups treatments into classes, but treatment effects in the
same class are now assumed to be centred around a class mean effect with between-treatment
variability within class.77 This model yields both treatment and class effects. We defined classes
according to type of treatment and delivery.
We chose between different models using the posterior mean deviance as an indicator of model fit
and the deviance information criterion (DIC) as a measure of parsimony (with a preference for lower
values of each). We created network plots to provide visual images of the data structure in each
analysed outcome. The node sizes of the network plots are proportional to the number of patients
randomised to each intervention, whereas the thickness of the edges (lines) is proportional to the
number of patients contributing to that comparison. Therefore, the edges in the network plots connect
interventions for which direct evidence was available. We plotted the networks to illustrate the data
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structure for each analysed outcome. Interventions not included in the analysis have their names
written between square brackets. Interventions were excluded if they were disconnected from
the main network or if they caused convergence problems in the statistical estimation (typically
owing to small numbers, with zero events in one or more arms of a study). Our NMAs treat data as
binomial, modelling the number of events out of the total number of participants (number randomised)
using a logistic model.77 For each outcome, we defined the denominator for each group using the
intention-to-treat principle (i.e. the number of randomised patients as the denominator of the formula,
irrespective of attrition). Where outcome data were presented for multiple time points, we took the
longest period of follow-up. For some effectiveness outcomes (sustained and prolonged abstinence),
we included only observations with a minimum follow-up period of 24 weeks.
We excluded studies that had insufficient information about the numbers of events per arm (i.e.
the number of events was not reported and it was not possible to calculate this using the available
information in the paper) and we also excluded studies with no events in any arm from the analyses.
Where there were events in at least one arm of a trial but no events in one or more other arms,
we added 0.5 events to all cells in the 2 × 2 table for that trial.78
Owing to the anticipation of heterogeneity,79 we took a random-effects approach to the meta-analyses,
assuming a common heterogeneity variance across all comparisons.75 We conducted the statistical
analyses within a Bayesian framework using OpenBUGS (version 3.2.3; Andrew Thomas, OpenBUGS
Foundation; Cambridge), simulating two Markov chains with 30,000 iterations for each chain
(plus 15,000 burning iterations). We monitored the treatment effects, between-study and between-
treatment (within-class) standard deviation (SD). Furthermore, we examined ranking of classes of
monotherapies or combinations of therapies by estimating the probability that each intervention is
best, second best, and so on, across safety and effectiveness outcomes. We included only standard
doses, except for e-cigarettes.
We assessed convergence of the Markov chains by using the potential scale reduction factor80 and
examining the history and autocorrelation plots for each estimated parameter. We appraised goodness
of fit by calculating the posterior mean residual deviance, whereby smaller values indicate better-fitting
models and values close to the number of unconstrained parameters indicate a well-fitting model.
Comparisons of models were made using the DIC.81 The DIC penalises the posterior mean residual
deviance (a measure of model fit) by the effective number of parameters in the model (as measure of
complexity) and can, therefore, be viewed as a trade-off between the fit and complexity of the model.
Smaller values are preferred, with differences of three or more considered meaningful. When two
models fit the data similarly, we interpreted results from the most parsimonious model.
The validity of NMA depends on the assumption that there is no effect modification of the pairwise
intervention effects or that the prevalence of effect modifiers is similar in the different studies.
This key assumption has been referred to variously as exchangeability, transitivity, similarity and
consistency.80,82–84 We examined the tenability of the consistency assumption for different networks
by comparing the posterior mean residual deviance, DIC, and between-study SD for the NMA model
that assumes consistency with an inconsistency model that relaxes this assumption (an unrelated mean
effects model).85 When both direct and NMA effect estimates were available and differed (up to the
second decimal place of the standard error), we used both to back-calculate the indirect estimates,
while making the assumption that the NMA estimates (from the consistency model) are the result of
a weighted average of normally distributed direct estimates (from the unrelated mean effects model)
and the indirect estimates. A local measure of inconsistency for a specific comparison can be obtained
by comparing the direct and indirect estimates for that comparison. Note that for many comparisons
there was either only direct evidence or only indirect evidence, so that the NMA estimates correspond
to one of these.
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Further analyses
We performed meta-regression86 to explore the influence of several covariates as potential effect
modifiers for the primary effectiveness and safety outcomes, namely:
l Dependence – we combined average scores of several scales at the arm level with a hierarchy
of preferred measurements. Specifically, we used scores on the Fagerström Test for Nicotine
Dependence87 in preference to the Fagerström Tolerance Questionnaire,88 with Heaviness of
Smoking Index89 as a third alternative. The average scores from each arm were standardised to
make the numbers comparable across different scales.
l Funding source – industry compared with non-industry sponsorship.
l Counselling – interventions that included pharmacological treatment plus counselling compared
with pharmacological treatment alone.
l Type of placebo – for placebo arms, we examined the influence of including a drug placebo
(alone or combined with NRT placebo) in comparison with NRT-only placebo arms.
l Duration of treatment in each arm (in weeks).
l Studies including samples in which all (or most) participants had one or more current psychiatric
condition (e.g. depression, schizophrenia, bipolar disorder or substance misuse), compared with
other studies.
l Studies including samples in which all (or most) participants had one or more of the 17 comorbidities
specified by the Charlson Comorbidity Index,90 compared with other studies.
l Studies in which patients were not required to make a quit attempt, compared with other studies.
l Studies focused on smokeless-tobacco consumers, compared with other studies.
l Studies in which patients were heavy smokers, compared with other studies. We defined samples of
heavy smokers as those in which the average of smoked cigarettes was > 20 per day.
l Publication year.
Furthermore, we performed sensitivity analyses excluding different subsets of studies assessed as
being at high risk of bias on any domain, and also a sensitivity analysis excluding studies that compared
a pharmacological intervention plus counselling with control (where counselling was not given in
each arm). Threshold analysis, a form of sensitivity analysis, was also performed to determine the
robustness of our treatment recommendations for the primary effectiveness and safety outcomes to
changes in the evidence provided by the individual studies.91–93 Threshold analysis determines how
much the evidence could change for any reason, such as bias or random error, before the treatment
recommendation changes, and describes this using a set of thresholds. These thresholds can be
compared with judgements of the plausible magnitude of potential biases and with estimates of
uncertainty [e.g. confidence intervals (CIs)]. In this manner, we may have more confidence in conclusions
that are shown to be robust, and can appropriately acknowledge where conclusions are shown to be
sensitive to plausible biases or uncertainty in the evidence.
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Chapter 4 Economic evaluation methods:
assessment of cost-effectiveness
Introduction
The economic evaluation aimed to compare the cost-effectiveness of pharmacological treatments to
aid smoking cessation, including NRT and e-cigarettes. The population considered in the decision was
smokers in the UK aged ≥ 18 years who were motivated to quit smoking. The treatments compared
were those included in the NMA on sustained abstinence (see Chapter 5). The NMA showed that it
was important to distinguish between doses of the treatments (see Table 1), but that the mode of
administration of NRT was not an effect modifier (based on model fit; see Appendix 5). We did not
include treatments when the dose was not specified. The following treatments were included in the
economic evaluation:
l NRT at low, standard and high dose
l bupropion at low and standard dose
l varenicline at low and standard dose
l e-cigarette at low and high dose
l bupropion standard dose plus NRT high dose
l varenicline low dose plus NRT standard dose
l varenicline standard dose plus NRT standard dose
l varenicline standard dose plus NRT high dose
l varenicline standard plus bupropion standard dose.
Combination treatments (varenicline or bupropion in combination with NRT at any dose) are not
currently licensed as smoking cessation treatments in the UK. We include these in the base case
but exclude them from a sensitivity analysis. Standard practice in the NHS is to offer smokers
attempting to quit NRT a dose based on their level of cigarette use, including combinations of NRT
modes of delivery (e.g. patch and gum). We use NRT standard dose as the reference treatment for
comparison in the cost-effectiveness analysis. We do not include waitlist, no treatment, or placebo in
the economic evaluation because these would not be used in standard care. Evidence from studies
including those comparators is included in the NMA and contributes indirectly to the estimates
between the active treatments that we include in our economic evaluation.
The perspective taken is that of the NHS for costs, and health effects on the individual for outcomes, in
line with NICE guidance.94 A lifetime time horizon was taken, using a cohort simulation model to predict
costs and utilities over a participant’s lifetime.
Methods
Model description
The model structure is based on the ‘Sheffield model’ used in a recent Health Technology Assessment
report58 on the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline
for smoking cessation. This in turn was based on the Benefits of Smoking Cessation on Outcomes
(BENESCO) model, which was adapted from the Health Economic Consequences of Smoking (HECOS)
model used by the World Health Organization European Partnership Project to reduce tobacco
dependence.95 The BENESCO model is an existing and widely used economic model that has previously
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been applied to model the effects of smoking cessation interventions in the UK, the USA, Germany,
France, Belgium, the Netherlands, Finland, Sweden and the Republic of Korea.96–105
A cohort simulation model is used for smokers making a one-time smoking cessation attempt. Smoking
status, morbidity and mortality are simulated over a lifetime (until the age of 100 years) to calculate
the costs and benefits of smoking cessation strategies from the perspective of the health-care payer.
The model uses an annual cycle length. UK estimates are used to determine the percentage
of the initial cohort that are male or female, their age (18–34, 35–64 or 65–100 years) and their
underlying health conditions [lung cancer, COPD, coronary heart disease (CHD) and stroke].
Every cohort member begins in the smoker state and at the end of the first year a percentage of the
cohort will have quit smoking, with this proportion dependent on the efficacy of the cessation aid
treatment they receive. No further quit attempts are modelled. It is, therefore, assumed that those
who fail to quit will remain smokers until death.
There is a possibility that quitters may relapse and start smoking again in future years. This possibility
decreases as time since cessation increases, with the risk of relapse being highest in the four model cycles
following cessation (recent quitters). After four cycles without relapse, recent quitters become long-run
quitters and the annual relapse rate is lower in the next five cycles, and lower still in subsequent cycles,
with this underlying relapse rate continuing for the duration of the model. It is assumed that the
probability of relapse at any stage is the same regardless of which treatment is used to aid cessation.
At the end of each year, the cohort is distributed into smokers, quitters and relapsed smokers (Figure 1).
Within these broad smoking states, cohort members can have no current morbidity or one of the
following smoking-related morbidities: lung cancer, COPD, CHD, stroke or an asthma exacerbation.
These health states correspond to the smoking-related diseases that cause the greatest morbidity,
mortality and cost. It is assumed that a person can be in one of these health states at a time only.
When a person dies, they are removed from the model. The probability of moving to a new health
state at the end of each cycle depends on current health state, smoking status, age and sex.
It is assumed that a restricted hierarchy exists in which subjects can enter the CHD or stroke health
state and subsequently transit to the COPD or lung cancer state. However, because of the irreversible
nature of COPD and lung cancer, once subjects enter these health states, they stay there until they
transition to death. An asthma exacerbation or exacerbations can occur from the no current morbidity
health state only and are assumed to resolve within 1 year.
Smokers
Quitters Relapsers
FIGURE 1 Transitions between smoking states. Note that death can occur from any state.
ECONOMIC EVALUATION METHODS: ASSESSMENT OF COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
16
The original BENESCO model did not consider the AEs of treatment, but we have incorporated these
as a probability of experiencing depression or fatal/non-fatal self-harm in the first year of treatment.
We included these aspects of MANEs because we were able to identify cohort data sources for these
outcomes with which to estimate the baseline probability of event on NRT standard. Depression and
non-fatal self-harm are represented by a one-off disutility and cost, whereas fatal self-harm results in
death. These are applied in the first year only because it is assumed that depression or self-harm would
lead to discontinuation of treatment. We did not include cardiovascular treatment-related AEs in our
model. This is because cardiovascular events are already included in the model as a consequence of
smoking. Any differences observed between treatment groups in the RCTs in terms of cardiovascular
events are more likely to be a result of having successfully quit or not (and subsequent reduction in
risk), which is already captured in the model, or a side effect of the treatment. It is not possible to
distinguish between these two causes from the RCT evidence, and we, therefore, could not estimate
treatment-related adverse cardiovascular events.
All other health states are associated with utility and cost values, as detailed later. Therefore, cohort
members accumulate costs and health outcomes each cycle until death. Future costs and benefits were
discounted at a rate of 3.5% per annum.94
Model inputs
In this section, we describe the evidence sources used for each parameter in the model. Evidence
sources were identified as follows. First, we looked for updates to the evidence sources used in
the Sheffield model58 by searching for studies that cited these sources and carrying out targeted
searches on PubMed and EMBASE. Where alternative or more recent evidence sources were available,
we considered these and made a decision about which evidence sources to use based on sample size
and relevance to a contemporary UK population.
When searching for data on prevalence, we concentrated on large routine data sources such as the
Health Survey for England. For incidence and relative risks (RRs), we searched for prospective cohorts
(if RCT evidence was not available/not possible). Where no preferable evidence sources could be
identified, we used the same data as used in the Sheffield model.
The assumed characteristics of the initial cohort
The distribution of the cohort across sex and age categories at the start of the model was designed to
reflect the distribution of smokers in the UK. The proportion of male and female adults, and the mortality
risk in each of the three age categories was determined from general population data.106,107 Smoking
prevalence data108 were applied to these data to calculate the distribution across age and sex groups for
a representative sample of 10,000 UK smokers (see Appendix 2, Table 18).
The prevalence of smoking-related diseases in the smoking cohort was estimated from various
literature sources on the prevalence of each disease in the general UK population and risk ratios of
these diseases in smokers (see Table 19). The most recent data source identified on the prevalence of
COPD and asthma in the UK was an online report from the British Lung Foundation109 based on data
from 12.6 million patients in The Health Improvement Network (THIN) database, a UK general practice
database that contains anonymised longitudinal patient records from over 500 practices (about 6% of
the population). It reports the number of people ever diagnosed with COPD and asthma per 100,000
people, by age group, in 2012. This is updated from the estimate used in the Sheffield model, which
was taken from a 2000 paper by Soriano et al.,110 who used the General Practice Research Database
to calculate the prevalence of COPD in the UK from January 1990 to December 1997. The British
Lung Foundation reports an increased prevalence of COPD compared with Soriano et al. (e.g. new
estimate of 7% in females aged > 65 years as opposed to 2%). This may be because of a difference in
the number of elderly people included in the studies, although the British Lung Foundation estimate
was thought to be a more representative estimate of COPD in the current population of those aged
≥ 65 years.109,110
DOI: 10.3310/hta25590 Health Technology Assessment 2021 Vol. 25 No. 59
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Thomas et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
17
The prevalence of lung cancer was taken from a paper by Maddams et al.,111 who used data from cancer
registries in the UK to provide prevalence estimates by sex and age for 2008. This was updated from a
2003 paper by Forman et al.,112 who used UK cancer registries to provide estimates for 1992. The estimates
were relatively similar (e.g. new estimate of 0.3% in females aged ≥ 65 years compared with 0.24%).
History of CHD prevalence was taken from the 2016 Health Survey for England,113 which is one in
a series of annual surveys designed to measure health and health-related behaviours in adults and
children living in private households in England. In 2016, interviews were completed with 8011 adults.
This was updated from an estimate taken from the 2005 Office for National Statistics (ONS) General
Household Survey and was, again, higher (12% in females aged ≥ 65 years compared with 5.9%).
The source for prevalence of stroke history was Bhatnagar et al.,114 who obtained 2013 prevalence
data from the Clinical Practice Research Datalink Global Initiative for Chronic Obstructive Lung
Disease (GOLD) database, which collates records from a widely used general practice software system
and covers approximately 8.8% of the UK population. This was updated from a 2004 report from
Asthma UK and was, again, higher (11% in females aged ≥ 65 years compared with 5.3%).
Relative risks for the prevalence of each disease in smokers relative to never-smokers were taken
from the Statistics on Smoking, England – 2017115 report for COPD, lung cancer, CHD and stroke (see
Table 37), and from Cassino et al.116 for asthma. These estimates were used to calculate the expected
number of cases in the cohort of smokers using the formulae shown in Appendix 3. The data are
reproduced in Appendix 2, Table 20.
Transition probabilities
The annual incidence of disease was estimated by age and sex categories for smokers, recent quitters
and long-run quitters. These values relied on estimates used in the Sheffield model58 (which, in turn,
used estimates from a previous manufacturer’s single technology assessment submission to NICE117)
as no preferable evidence could be identified for COPD, CHD, stroke or asthma. For lung cancer, the
2016 ONS release (updating the 2005 release used in the Sheffield model) was identified,118 which
reports directly age-standardised rates per 100,000 population of newly diagnosed cases of cancer in
England. These estimates showed that the incidence of lung cancer did not greatly increase between
2003 and 2016 (see Table 21). For simplicity, we, therefore, assumed that all incidence estimates were
the same as those reported in the Sheffield model.
Appendix 2, Tables 22–25 show the estimates of the annual incidences of diseases for the general
population, smokers, recent quitters and long-run quitters, respectively. These were obtained using the
same method as for prevalence (see Appendix 3), assuming that the RRs of incidence in smokers, short-run
and recent quitters relative to never-smokers were the same as the RRs of prevalence (see Table 37).115,116
In accordance with previous BENESCO models, the RRs in recent quitters relative to never-smokers
were assumed to be equal to the RRs for current smokers at year 1 for each disease. The RRs for
COPD, stroke and asthma exacerbations are reduced when the smoker has quit for at least 1 year.
The RRs in long-term quitters compared with never-smokers are assumed to be equal to the RRs in
never-smokers after the smoker has quit smoking for > 5 years. Lung cancer has been approached
differently: lung cancer risk for long-term quitters is kept equal to the risk in recent quitters. Although
there is evidence that quitting smoking does reduce the risk of developing lung cancer, the risk does
not return to that of non-smokers.119
Mortality
Annual mortality probability by condition, excluding asthma, was estimated using the British Heart
Foundation’s published total numbers of deaths in the UK in 2016 in each age group,120 which are
based on general population data. These numbers were used as the numerator, with the denominator
as the number of prevalent cases in the UK calculated using the population and prevalence estimates
for 2016 (see Tables 18 and 19).
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It was assumed that no additional mortality was associated with asthma exacerbation. Mortality for
chronic diseases, COPD and lung cancer is the probability of death from these diseases given the
disease is present. Mortality from acute events, CHD and stroke is the probability of a fatal event that
differs by smoking status, age and sex.
Appendix 2, Tables 26–29 show the disease-specific mortality estimates for the general population,
smokers, recent quitters and long-run quitters. The same RRs for smokers, short-run and recent quitters
relative to never-smokers that were used for prevalence and incidence of diseases were also used to
generate absolute probabilities of mortality. The probability of smoking-related mortality is equivalent or
lower for recent quitters compared with smokers, and for long-run quitters relative to recent quitters.
The exception is lung cancer, for which the mortality risk is the same regardless of smoking status.
Relapse rates
Hawkins et al.121 used British Household Panel Survey data to look at smokers who quit, but then
relapsed. These data were used to calculate the annual relapse probability for short-run quitters
(people for whom it had been < 5 years since they quit) and long-run quitters (people who had quit
smoking for > 5 years but < 10 years). The annual relapse probability ≥ 10 years post cessation was
based on a study by Krall et al.,122 which followed 483 men for up to 35 years.
The probabilities of relapse that were used in the model are shown in Appendix 2, Table 30. Uncertainty
around relapse rates is modelled as a beta distribution using event data from the original studies.
Costs
Costs included in the model related to health states and intervention costs. Owing to a lack of
recent or relevant UK data, the mean costs of COPD and lung cancer estimated by the Irish Health
Information and Quality Authority (HIQA) in its 2017 report on interventions for smoking cessation123
were used in the model. This report used Irish data on the total annual spending divided by the total
number of people with a diagnosis of each disease. The total direct costs to the Irish health service of
inpatient and day-case treatment were estimated from the Hospital Inpatient Enquiry database for
2015, which is based on 2014 prices. The annual primary care and medication costs of COPD were
estimated using 2014 Primary Care Reimbursement Service data from Ireland on the total costs of
adrenergic and other drugs for obstructive airway diseases. The primary care and medication costs
of lung cancer were estimated from a report on European cardiovascular disease statistics published
by the European Society of Cardiology in 2012.124 These costs were converted from euros to Great
British pounds and inflated to 2019 prices using HM Revenue & Customs monthly exchange rates for
February 2019.125
This resulted in a total annual cost of COPD of £1468, an increase from the £971 used in the Sheffield
model based on a paper by Britton.126 The annual cost of lung cancer (£5429) is lower than the estimate
used in the Sheffield model (£6524), which was based on Flack et al.127
The cost of CHD was estimated from the British Heart Foundation’s cardiovascular disease statistics
reported in 2014.128 These data are taken from analysis of commissioning expenditure in the UK (the
programme budgeting data return). These estimates are based on the price paid for specific activities
and services purchased from health-care providers for each region. The annual cost of CHD estimated
(£1460) is higher than the £1163 used in the Sheffield model based on McMurray et al.129
The source used for the cost of stroke was Xu et al.,130 who developed an individual patient simulation
model to estimate health and social care costs at 1 and 5 years after stroke. The results were estimated
using data on all patients with stroke included in Sentinel Stroke National Audit Programme (the national
stroke register of England,Wales and Northern Ireland) from April 2015 to March 2016 (n = 84,184).
DOI: 10.3310/hta25590 Health Technology Assessment 2021 Vol. 25 No. 59
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Thomas et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
19
The annual cost of stroke estimated (£1460) is lower than the £5484 used in the Sheffield model based
on Simpson et al.,131 who calculated the cost of a dependent/independent state due to stroke using NHS
reference costs for ‘non-transient stroke or cerebrovascular accident, nervous system infections of
encephalopathy’ long-stay/short-stay non-elective inpatients.
Tan et al.132 documented asthma costs over time for asthma patients who were enrolled in an asthma
care programme in Singapore, using a 10-year longitudinal data set. The study population comprised
different cohorts of 939 asthma patients entering the programme at different times during 2004–13.
Ten-year average annual asthma costs were estimated as £341 per patient. The main drivers of costs
were asthma medications and consultation fees. This is lower than the £1162 used in the Sheffield
model based on Hoskins et al.,133 which was a retrospective cohort analysis of a representative data
set of 12,203 patients with asthma in the UK over a 1-year period. The estimate from Tan et al. was
preferred as it was thought to be more reflective of mild asthma, which is what the majority of adults
will have.
The cost associated with depression (£340) was taken from a paper by Hunter et al.134 Here, a weighted
average annual cost per UK patient to treat depression was calculated by multiplying the proportion
of patients who access each type of treatment by the average annual cost of the treatment. The
cost associated with self-harm was taken from a paper by Tsiachristas et al.,135 who estimated hospital
resource use and care costs for all patients presenting with self-harm to the John Radcliffe Hospital
(Oxford, UK) between 1 April 2013 and 31 March 2014.
Uncertainty around cost estimates was incorporated into the probabilistic analysis. In the absence
of data, the SDs for COPD and lung cancer were assumed to be 10% of the mean estimate, and the
standard errors were calculated using this figure, along with the number of people on which the mean
estimate was based. As it was not possible to identify the number of people on whom the depression
and CHD cost estimates were based, the standard error in this case was assumed to be 10% of the
mean. These data were assumed to follow a gamma distribution.136 All costs have been inflated to
2019 prices using HM Revenue & Customs monthly exchange rates for February 2019.125
Appendix 2, Table 31 details the source, summary estimates and distributions used for the health state
costs employed in the model.
Intervention costs comprised the cost of the interventions alone. It was assumed that, although
counselling and other health professional support are likely to occur, the cost of these is likely to be
the same or very similar across interventions, thus not having an impact on the relative cost–utility.
These costs were, therefore, excluded from the economic analysis.
Data from the BNF on dosage and pricing are used to calculate the costs of varenicline, bupropion and
NRT.137 For varenicline, the cost of treatment is the cost of a starter pack covering the first 2 weeks of
tapered treatment (£27.30) plus the cost of 10 weeks at full dose (5 × £27.30), giving £163.80 in total.
The cost of low-dose varenicline is assumed to be the same, as the BNF states the same price for both
1 mg and 0.5 mg (500 µg) tablets.
Bupropion was costed as 150mg daily for 6 days and then 150mg twice daily for 7–9 weeks at a cost of
£83.52.137 The cost of low-dose bupropion is assumed to be £62.54 based on a dose of one tablet per day
for an average of 13 weeks.
Similarly, for NRT, standard treatment is assumed to be a high-strength patch daily for 6–8 weeks,
followed by the medium-strength patch for 2 weeks and then the low-strength patch for the final
2 weeks, at a cost of £105.65.137 The cost of NRT low is assumed to be £83.84, based on 4 weeks of
10-mg/16-hour patches and 4 weeks of 5-mg/16-hour patches. The cost of NRT high is estimated as
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£77.46, based on a 4-week supply of 21 mg NicoDerm CQ (GlaxoSmithKline plc, Brentford, UK)
transdermal patches followed by 2 weeks at 14 mg and 2 weeks at 7 mg.
E-cigarettes are not medically licensed in the UK.138 The HIQA report123 costed a 12-week supply of
e-cigarettes (e-cigarette + 3.55 ml liquid per day, including a replacement atomiser in months 2 and 3)
as €93.80, based on Liber et al.139 This is equivalent to approximately £82.125
The costs of all interventions including combinations of interventions are shown in Appendix 2, Table 32.
Utilities associated with health states
Baseline utility for smokers with no current comorbidity was taken from the general population
utility profile estimated by Ara and Brazier140 using 2003 and 2006 Health Survey for England data
(see Table 33). These data are a function of age and sex and are based on random samples of the
population living in private households in England. A total of 26,679 participants were asked to
complete the EuroQol-5 Dimensions (EQ-5D) questionnaire (a commonly used questionnaire to
describe and value health), and preference-based health state utility values were estimated from the
weights obtained using time trade-off valuations. Health state utility was determined by multiplying
baseline utility by age by an estimate of the impact of the disease.
Disease-specific utility values for smoking-related diseases were estimated from the literature. For lung
cancer utility, two sources were identified. Jang et al.141 measured EQ-5D scores in 172 consecutive
outpatients with non-small-cell lung cancer attending a major Canadian cancer centre outpatient clinic
and estimated a mean utility of 0.76 (95% CI –0.7 to 0.78). A more recent paper by Bertranou et al.142
derived a similar utility value for progressed non-small-cell lung cancer from EQ-5D patient-level data
collected in two lung cancer treatment trials, AURA2 (n = 199) and IMPRESS (n = 265) (0.72, SD 0.029).
The progressed disease utility was given by the mid-point of the two studies. The source used in our
model is that estimated by Bertranou et al.142 (0.72) owing to the larger sample size. This is higher than
the estimate used in the Sheffield model (0.5), which was taken from Trippoli et al.,143 who measured
quality of life in 95 patients with non-small-cell lung cancer from 15 Italian hospitals.
For utility associated with COPD, the source was Pickard et al.,144 who synthesised the literature on
the validity and reliability of EQ-5D use in studies of asthma and COPD, and estimated EQ-5D utility
scores associated with stage of disease. The authors found eight studies that recorded EQ-5D scores
ranging from 0.52 (SD 0.16) to 0.84 (SD 0.15) for patients with COPD. Sufficient studies in COPD
were available to calculate pooled mean utility scores according to GOLD stage, which categorises
COPD severity in four stages, from very mild to very severe. The utilities estimated were 0.74 for
stage I (95% CI 0.62 to 0.87), 0.74 for stage II (95% CI 0.66 to 0.83), 0.69 for stage III (95% CI 0.60 to
0.78) and 0.61 for stage IV (95% CI 0.44 to 0.77) (most severe). The utility used was that for stage II
(moderate disease) as this should capture the mid-point of severities. This could have been estimated
by calculating a weighted average based on patient numbers in each stage, but it was assumed that the
utility for moderate disease would adequately reflect a mix of mild to severe. This is higher than the
estimate used in the Sheffield model (0.63), which was based on Spencer et al.,145 who derived utility
values from 283 patients with COPD who took part in the 1996 Health Survey for England.
The source used for utility associated with CHD was Stevanović et al.146 This estimate (0.76) was based
on a multivariate meta-analysis of preference-based quality-of-life values from 40 studies representing
over 30,575 patients with CHD. For this utility, the Sheffield model cited Hay and Sterling,147 who
sourced their utilities from the Beaver Dam Health Outcomes Study (a longitudinal cohort study of
health status and health-related quality of life in a random sample of 1356 US adults). The average
CHD utility (0.77) was a weighted average of myocardial infarction and angina utilities and was similar
to that found in Stevanović et al.
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Utility associated with stroke was estimated from Haacke et al.,148 who assessed health-related quality
of life (HRQoL) in 77 patients who had experienced an ischaemic stroke, a transient ischaemic attack
or a haemorrhagic stroke. The mean EQ-5D value was 0.73 (SD 0.32). This replaces the estimate used
in the Sheffield model (0.62), which was taken from Tengs and Lin,149 who carried out a systematic
search to identify 20 articles reporting 53 unique quality-of-life weights for stroke and pooled these
using a hierarchical linear model. The estimate from Haacke et al.148 was preferred as it was from
a more recent study and was thought to more accurately reflect the specific disutility associated
with stroke.148
For utility associated with second stroke, an estimate (0.48) was sourced from Ara and Brazier,140
who looked at EQ-5D data collected in Health Survey for England from individuals who reported
a history of more than one cardiovascular condition. For utility associated with second stroke, the
Sheffield model cited Gage et al.,150 who elicited preferences from 69 volunteers at the Veterans
Affairs Palo Alto Health Care System and Stanford University who had atrial fibrillation. Twenty of
the volunteers had previously had a stroke. This paper estimated a utility value of 0.12.
Lloyd et al.151 reported the impact of asthma exacerbations on health-related quality of life and health
utility in patients with moderate to severe asthma in the UK. Prospective data regarding health-related
quality of life were collected from 112 patients at four asthma centres across the UK using the EQ-5D
at two time points. The EQ-5D utility estimated was 0.57 (SD 0.27) for patients with an exacerbation
that required oral steroids. For utility associated with asthma, the Sheffield model cited Szende et al.152
In this study, 228 consecutive adult outpatients and inpatients at four sites in Hungary completed the
EQ-5D questionnaire. Patients had to have been diagnosed and already treated for asthma, and were
involved in the study at their outpatient visit or during their hospital stay. The utility value estimated
for poorly controlled asthma is 0.52.
The utility associated with depression [0.58, standard error (SE) 0.015] was taken from a paper by
Hunter et al.,134 who calculated a score for depressed patients using a weighted average from four
UK trials.153–156 The utility associated with self-harm came from a paper by Byford et al.,157 in which
baseline EQ-5D was collected in 480 patients with a history of recurrent deliberate self-harm.
Intervention effectiveness
The absolute probabilities of cessation at 1 year for interventions were generated by combining the
results of the NMA (see Chapter 5) on sustained abstinence with an estimate of response on NRT
estimated from Taylor et al.158 This was a prospective cohort study of electronic medical records
from 654 general practices in England in the UK’s Clinical Practice Research Datalink, including
287,079 patients who were prescribed smoking cessation medications during the study period.
Of these, 149,526 patients prescribed NRTwere eligible for analysis. At 1 year, 21.2% (31,695/149,526)
of those prescribed NRT had quit smoking.
The mean probability of 1-year sustained abstinence with all treatments, and 95% credible intervals (CrIs),
are shown in Appendix 2, Table 34. The results of the NMA suggested that varenicline low plus NRT
standard and varenicline standard plus NRT standard have the highest absolute probability of sustained
abstinence, followed by e-cigarette low/varenicline plus bupropion standard/e-cigarette high. Note that
the absolute probabilities are derived from the NMA estimates, which are correlated because they are
jointly estimated from a single model.
The absolute probabilities of depression at 1 year for interventions were generated by combining
the results of the NMA on MANE (see Chapter 6) with an estimate of depression on NRT standard
estimated from Kotz et al.57 This was a retrospective cohort study using data from patients included
in the validated QResearch database (www.qresearch.org), which holds data from 753 NHS general
practices across England. Patients who were prescribed smoking cessation medications during the
study period were identified and followed for 6 months. Of these, 106,759 patients prescribed NRT
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were eligible for analysis and 8274 reported suffering from depression. This gave a probability of 7%.
The mean probabilities of depression for all treatments and 95% CrIs are shown in Appendix 2, Table 35.
As no data were available on the other interventions, assumptions had to be made about their relative
level of harm. It was, therefore, assumed that NRT low and e-cigarette low have the same level of harm
as NRT standard, e-cigarette high has the same level of harm as NRT high, bupropion low has the same
level of harm as bupropion standard, and varenicline low plus NRT standard has the same level of harm
as varenicline standard plus NRT standard.
The absolute probabilities of self-harm at 1 year for interventions were also generated by combining
the results of the NMA on MANE with an estimate of self-harm on NRT estimated from Kotz et al.57
A total of 540 of the patients in this study reported self-harm, giving a probability of 0.5%. The mean
probability of self-harm for all treatments for which data were available is shown in Appendix 2, Table 36.
Cost-effectiveness analysis methods
We conduct a probabilistic analysis in which uncertainty in the model inputs is captured by simulating
5000 times from the assumed distributions described in the previous section, using Monte Carlo
simulation performed in Microsoft Excel® version 1908 (Microsoft Corporation, Redmond,WA, USA). The
absolute probabilities of abstinence, depression and self-harm were estimated using Bayesian inference,
computed using Markov chain Monte Carlo simulation in OpenBUGS (URL: www.openbugs.net). Simulated
samples for the model were drawn from 60,000 Markov chain Monte Carlo samples from the posterior
distributions, taken from OpenBUGS and read into Microsoft Excel. Care was taken to preserve
correlations from the Markov chain Monte Carlo.
We report mean lifetime costs and quality-adjusted life-years (QALYs) for each treatment option.
Incremental cost-effectiveness ratios (ICERs), interpreted as the additional expected cost per additional
unit gain in QALY for one treatment compared with another, are computed by first ordering treatments
by increasing expected cost and then removing treatments that are dominated or extendedly dominated
(i.e. have a higher expected cost and lower expected utility than another intervention). ICERs are
then calculated for each non-dominated treatment relative to the previous (lower expected cost)
non-dominated treatment, where:
ICER = additional expected cost/additional expected utility. (1)
For each treatment we also computed net benefit for a given willingness to pay per additional QALY,
λ (cost per QALY gained ratio), where net benefit is defined as:
net benefit = utility × λ– cost. (2)
‘Net benefit’ represents the value of a treatment in monetary terms by scaling both QALYs and use
of resources to costs.159 Averaging the net benefit over the probabilistic simulation samples gives the
expected net benefit. The intervention with the highest expected net benefit (the optimal intervention)
at any willingness-to-pay threshold, λ, can be calculated. We present the expected net benefit for
λ = £20,000.
We also plot cost-effectiveness acceptability curves (CEACs), which present the uncertainty in the
optimal treatment by plotting the probability that each treatment is the most cost-effective (has the
highest net benefit) against the willingness to pay per QALY.
We also present uncertainty between these interventions using rank-o-grams that show the distribution
of the probabilities that each treatment is optimal, second, third and so on for each of the 14 treatments,
at a willingness-to-pay threshold of £20,000 per QALY. The x-axis reports each of the possible ranks,
for which position 1 means that the intervention is optimal. The y-axis shows the probability that each
treatment has been ranked at each of the possible positions and, therefore, fully encapsulates the
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uncertainty in the intervention rankings. The peaks in the rank-o-gram plots show the most likely rank of
a given treatment. Flat lines indicate a high degree of uncertainty for the ranking of that treatment type.
We also explore how uncertainty in the model inputs impacts on the treatment considered to be optimal
using value-of-information methods.160 This method is also useful in guiding research recommendations
as it can estimate the value of a future trial. The expected value of perfect information (EVPI) measures
the value (in terms of net benefit) of eliminating all uncertainty in model inputs. The expected value of
partial perfect information (EVPPI) measures the value (in terms of net benefit) of eliminating uncertainty
in some of the model inputs. This allows us to identify which model inputs are the key drivers of decision
uncertainty. Therefore, it follows that it is these areas in which further research might be most beneficial.
EVPI and EVPPI are computed per person for the threshold of willingness to pay per QALY of £20,000.
Population-level EVPI and EVPPI are also calculated, given an estimated number of smokers attempting
to quit in England of 274,021.3 The lifetime of a treatment represents the time until it becomes obsolete
or goes out of use, for example by being superseded by a new intervention. We assume a lifetime of
T = 1 year and 5 years, respectively, discounted at 3.5%. The Sheffield Accelerated Value of Information
web application161 was used to compute EVPPI for subsets of parameters.162
We also a present one sensitivity analysis in which the impact of depression and self-harm in the model
is removed, so the results are driven by abstinence from smoking alone, and another limiting the analysis
to UK-licensed treatments.
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Chapter 5 Clinical results: effectiveness
Included studies
Study selection
The results of our search strategy are summarised in the PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) flow diagram in Figure 2. Our original searches identified
345 studies for inclusion and our update searches identified an additional 18 studies for inclusion,
resulting in a total of 363 studies reported on one or more effectiveness outcomes that are described
below.19,33,69,70,163–511 For the purpose of our analyses, the EAGLES study33 was treated as two studies,
where Anthenelli 2016a33 included the four study arms from the non-psychiatric cohort and Athenelli
2016b33 included the four arms from the psychiatric cohort. A list of records excluded at full-text
screening (those that did not meet randomised or non-randomised inclusion criteria for effectiveness
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FIGURE 2 The PRISMA flow diagram for effectiveness study records. This figure has been adapted with permission
from Thomas et al.67 This is an Open Access article distributed in accordance with the terms of the Creative Commons
Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial
use, provided the original work is properly cited. See: https://creativecommons.org/licenses/by/4.0/. The figure includes
minor additions and formatting changes to the original figure.
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Study characteristics
The number of participants randomised across the 363 trials ranged from 15 to 7354, with a total of
201,045 participants. Trials were conducted across six continents, with 208 trials in the USA, 29 trials
in the UK, and 27 multicountry trials. Trials were conducted in several settings, including medical
centres and facilities, academic and research centres, universities, community centres, low-income
or subsidised housing neighbourhoods, hospitals, pharmacies, clinics (e.g. smoking cessation, dental,
urology, methadone, surgical), primary care (general, family and private practices), over the counter,
dispensaries, schools, companies and workplaces, Navy ships and over the telephone, by mail or online.
Study duration ranged from 24 to 754 weeks, with the duration of drug treatment ranging from 2 to
104 weeks. One hundred and twenty-one trials were industry sponsored and 122 trials were publicly
registered online. We included 24 trials in which smokers were unwilling or not necessarily motivated
to quit and 15 trials of smokeless-tobacco users. Twenty-six trials recruited smokers with comorbidities
as specified by the Charlson Comorbidity Index,90 16 trials recruited smokers with current or a history
of psychiatric conditions and 17 trials recruited smokers with current or a history of drug- or alcohol-
related conditions.
The mean age of trial participants ranged from 27.1 to 62 years and the percentage of female
participants (in studies that did not exclusively recruit male or female participants) ranged from
0.3% to 81%. Study populations ranged between ethnicities (e.g. white/Caucasian, African American,
Latino/Hispanic, Asian, Indigenous Maori), types of tobacco use (e.g. smokeless tobacco, spit tobacco,
cigars, waterpipes) and heaviness of smoking. Studies included smokers who were hospital inpatients
or outpatients (including smokers scheduled for surgery), smokers with human immunodeficiency
virus (HIV), smokers under criminal justice supervision, smokers with substance misuse, smokers
with psychiatric conditions, smokers who were health-care professionals, smokers who were active
or former armed forces and their family members (e.g. veterans, Navy, National Guard), smokers with
prior quit attempts or who had recently relapsed, smokers who were cancer patients or prone to
cancer or cancer survivors, female smokers concerned about weight, smokers from low-income or
subsidised housing neighbourhoods, smokers with tuberculosis and smokers with asthma. Study-level
characteristics of included trials can be found in tables in Report Supplementary Material 2.
Risk of bias in included studies
Ratings ranged from low to high risk of bias and an overall risk-of-bias domain was rated by selecting
the highest rating of bias across domains, with the exception of selective outcome reporting (as this
domain was usually rated as unclear as a result of inaccessibility of trial protocols and limited trial
registration). Risk-of-bias ratings by trial and summarised across studies are presented in Report
Supplementary Material 3 and Appendix 4, Figure 34, respectively.
Random sequence generation
Few trials were rated as high risk of bias for random sequence generation, with 45% rated as being at
low risk of bias, 53% rated as being at unclear risk of bias and only 2% rated as being at high risk of bias.
Allocation concealment
As was the case for random sequence generation, very few trials (3%) were rated as being at high risk
of bias for allocation concealment; 38% of trials were rated as being at low risk of bias and 59% were
rated as being at unclear risk of bias.
Blinding of participants and personnel
Blinding of participants and personnel saw nearly one-third of studies rated at each level; 31% of trials
were rated as being at low risk of bias, 39% were rated as being at unclear risk of bias and 30% were
rated as being at high risk of bias. This was because of a number of trials in which drugs were delivered
open label without any blinding.
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Blinding of outcome assessment
Nearly half of trials (48%) were rated as being at unclear risk of bias for blinding of outcome
assessment domains, with 37% of the remaining trials rated as being at low risk of bias and 15% rated
as being at high risk of bias.
Incomplete outcome data
More than half (62%) of trials were rated as being at low risk of bias for incomplete outcome data
domain, as many studies used intention-to-treat analyses, and loss to follow-up was either low and/or
similar among trial arms. Twenty-nine per cent of trials were rated as being at unclear risk of bias and
only 9% were rated as being at high risk of bias.
Selective reporting
As previously mentioned, most (76%) trials were rated as being at unclear risk of bias for selective
reporting due to a lack of study protocols or public trial registrations. Of the remaining 24%, 23% of
trials were rated as being at low risk of bias and only 1% were rated as being at high risk of bias.
Other bias
Most trials (93%) were rated as being at low risk of bias for the other bias domain, with 4% rated as
being at unclear risk of bias and 3% rated as being at high risk of bias.
Overall bias
Finally, ratings for our overall risk of bias domain indicated that 13% of trials were rated as being at
low risk of bias, 47% of trials were rated as being at unclear risk of bias and 40% of trials as being
at high risk of bias.
Results on clinical effectiveness
We performed NMA on four bioverified effectiveness outcomes: sustained (or continuous) abstinence,
prolonged abstinence, any abstinence at 6 months, and 7-day PPA. We fitted a standard (full interaction)
NMA model as well as fixed- and random-class NMA models for each outcome. Based on the model fit
indices (see Appendix 5), we focused on fixed-class NMA models. A list of treatments delivered in the
trials included in effectiveness analyses and their frequency is reported in Appendix 3, Table 38. In this
chapter, we present results for each outcome based on a fixed-class NMA model, with additional results
for other models provided in Appendix 5. The results are presented as median odds ratios (ORs) alongside
95% CrIs. A summary of results across outcomes is provided at the end of the effectiveness results in
the form of a rank-o-gram.
Sustained abstinence
Our primary effectiveness outcome, sustained abstinence at a follow-up of at least 24 weeks, was reported
in 171 studies with a total of 90,443 patients, of which 161 (86,884 patients) studies compared two or
more of the treatment classes of interest. The network of treatments for this outcome is displayed in
Figure 3, where thicker edges represent comparisons with a larger number of randomised patients.
Similarly, interventions with a larger number of randomised patients have larger circles. Most interventions
were compared with placebo in the primary studies, although arms with no drug treatment or with usual
care were also used as comparators in some studies, and some direct comparisons between different drug
types are also available. One study comparing varenicline standard plus NRT gum standard (114/245
patients quit) with varenicline low plus NRT gum standard (111/240 patients quit) was disconnected from
the network at the treatment level (see Figure 37) but not at the class level (see Figure 3); hence, we
excluded that study when comparing the different models (see Table 39) but were able to include it in the
analyses discussed in this section (which report results at the class level).
Figure 4 displays the results for the fixed-class NMA model based on 161 studies with placebo as a
comparator. There was evidence that smokers randomised to usual care were less likely to quit than
DOI: 10.3310/hta25590 Health Technology Assessment 2021 Vol. 25 No. 59
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Thomas et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
27
Varenicline + bupropion std
Varenicline std + NRT high
Varenicline std + NRT std
Varenicline low + NRT std
Bupropion std + NRT high
Bupropion std + NRT ns
Bupropion ns + NRT ns
E-cigarette high
E-cigarette low












FIGURE 3 Network plot for sustained abstinence at class level. Ns, not specified; std, standard. This figure has been
adapted with permission from Thomas et al.67 This is an Open Access article distributed in accordance with the terms of
the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this
work, for commercial use, provided the original work is properly cited. See: https://creativecommons.org/licenses/by/4.0/.
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FIGURE 4 Forest plot with results of the fixed-class NMA model for sustained abstinence. Ns, not specified; std, standard.
This figure has been adapted with permission from Thomas et al.67 This is an Open Access article distributed in accordance
with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt
and build upon this work, for commercial use, provided the original work is properly cited. See: https://creativecommons.org/
licenses/by/4.0/. The figure includes minor additions and formatting changes to the original figure.
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those who received placebo (OR 0.49, 95% CrI 0.33 to 0.71), whereas smokers randomised to no drug
treatment were more likely to quit than those who received placebo (OR 1.28, 95% CrI 1.01 to 1.83).
Moreover, there was evidence that smokers receiving NRT standard (OR 2.01, 95% CrI 1.68 to 2.41)
and NRT high (OR 2.32, 95% CrI 1.88 to 2.86) were more likely to quit than those randomised to
placebo. Most interventions were more effective than placebo, including bupropion low (OR 1.75, 95% CrI
1.03 to 3.00), bupropion standard (OR 1.73, 95% CrI 1.43 to 2.10), varenicline low (OR 1.79, 95% CrI
1.07 to 2.97), varenicline standard (OR 2.83, 95% CrI 2.34 to 3.39), e-cigarette high (OR 3.22,
95% CrI 1.63 to 6.36), varenicline low plus NRT standard (OR 5.70, 95% CrI 1.57 to 21.12), varenicline
standard plus NRT standard (OR 5.75, 95% CrI 2.27 to 14.88), varenicline standard plus NRT high (OR 2.34,
95% CrI 1.12 to 4.90) and varenicline standard plus bupropion standard (OR 3.25, 95% CrI 1.35 to 7.92).
There was weak evidence for the effectiveness of e-cigarette low compared with placebo (OR 3.22,
95% CrI 0.97 to 12.55).
Table 2 presents the class effect estimates with placebo as comparator obtained from the NMA
(last column) alongside the estimates obtained from direct and indirect evidence. Direct evidence
was available for most monotherapies, whereas comparisons of combinations of interventions with
placebo largely relied on indirect evidence only. Most effect estimates are above 1, suggesting that
the interventions helped smokers to reach sustained abstinence more frequently than placebo. Where
there was enough information to back-calculate indirect evidence and compare it with direct evidence,




OR (95% CrI) NMA, OR (95% CrI)
No drug treatment 0.70 (0.08 to 4.01) 1.30 (1.02 to 1.64) 1.28 (1.01 to 1.63)
Usual care 0.81 (0.38 to 1.72) 0.41 (0.27 to 0.63) 0.49 (0.33 to 0.71)
NRT not specified 1.86 (1.55 to 2.25) – 1.86 (1.55 to 2.25)
NRT low – 0.58 (0.10 to 2.36) 0.58 (0.10 to 2.36)
NRT standard 2.01 (1.68 to 2.41) – 2.01 (1.68 to 2.41)
NRT high 2.32 (1.88 to 2.86) – 2.32 (1.88 to 2.86)
Bupropion not specified – 0.17 (0.01 to 1.27) 0.17 (0.01 to 1.27)
Bupropion low 0.96 (0.44 to 2.05) 3.04 (1.46 to 6.33) 1.75 (1.03 to 3.00)
Bupropion standard 1.73 (1.43 to 2.10) – 1.73 (1.43 to 2.10)
Varenicline not specified 3.56 (1.22 to 10.7) – 3.56 (1.22 to 10.7)
Varenicline low 1.79 (1.07 to 2.97) – 1.79 (1.07 to 2.97)
Varenicline standard 2.83 (2.34 to 3.39) – 2.83 (2.34 to 3.39)
E-cigarette low 3.22 (0.97 to 12.6) – 3.22 (0.97 to 12.6)
E-cigarette high 2.46 (0.86 to 7.03) 3.89 (1.63 to 9.28) 3.22 (1.63 to 6.36)
Bupropion not specified plus NRT not specified – 1.04 (0.22 to 4.10) 1.04 (0.22 to 4.10)
Bupropion standard plus NRT not specified – 1.62 (0.73 to 3.56) 1.62 (0.73 to 3.56)
Bupropion standard plus NRT high – 1.99 (0.70 to 5.47) 1.99 (0.70 to 5.47)
Varenicline low plus NRT standard – 5.70 (1.57 to 21.1) 5.70 (1.57 to 21.1)
Varenicline standard plus NRT standard – 5.75 (2.27 to 14.9) 5.75 (2.27 to 14.9)
Varenicline standard plus NRT high – 2.34 (1.12 to 4.90) 2.34 (1.12 to 4.90)
Varenicline standard plus bupropion standard 3.42 (1.39 to 8.67) 1.88 (0.09 to 39.9) 3.25 (1.35 to 7.92)
This table is reproduced with permission from Thomas et al.67 This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and
build upon this work, for commercial use, provided the original work is properly cited. See: https://creativecommons.org/
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the results show some potentially inconsistent results, with examples where direct evidence shows a
less beneficial effect for the experimental drug than the indirect evidence (e.g. bupropion low vs.
placebo) and also the opposite (e.g. varenicline standard plus bupropion standard vs. placebo).
There was no statistical evidence of inconsistency based on model fit statistics (see Appendix 5, Table 39).
The pairwise comparisons between interventions for this outcome are presented in Table 3. Most of the
effect estimates were informed by indirect evidence only, and the results were consistent when both
direct and indirect evidence were available. There was evidence that smokers randomised to varenicline
standard plus NRT standard were more likely to achieve sustained abstinence than those receiving
NRT standard (OR 2.87, 95% CrI 1.11 to 7.49) or bupropion standard (OR 3.34, 95% CrI 1.28 to 8.65).
The results also suggest higher odds of abstinence with varenicline standard compared with NRT




OR (95% CrI) NMA, OR (95% CrI)
Bupropion standard vs. NRT standard 0.70 (0.17 to 2.83) 0.87 (0.67 to 1.12) 0.86 (0.67 to 1.11)
Varenicline standard vs. NRT standard – 1.40 (1.10 to 1.78) 1.40 (1.10 to 1.78)
E-cigarette low vs. NRT standard – 1.60 (0.48 to 6.30) 1.60 (0.48 to 6.30)
E-cigarette high vs. NRT standard – 1.60 (0.80 to 3.20) 1.60 (0.80 to 3.20)
Varenicline standard plus NRT standard vs.
NRT standard
– 2.87 (1.11 to 7.49) 2.87 (1.11 to 7.49)
Varenicline standard plus bupropion standard vs.
NRT standard
– 1.61 (0.66 to 3.98) 1.61 (0.66 to 3.98)
Varenicline standard vs. bupropion standard – 1.63 (1.27 to 2.07) 1.63 (1.27 to 2.07)
E-cigarette low vs. bupropion standard – 1.85 (0.55 to 7.29) 1.85 (0.55 to 7.29)
E-cigarette high vs. bupropion standard – 1.86 (0.92 to 3.73) 1.86 (0.92 to 3.73)
Varenicline standard plus NRT standard vs.
bupropion standard
– 3.34 (1.28 to 8.65) 3.34 (1.28 to 8.65)
Varenicline standard plus bupropion standard vs.
bupropion standard
– 1.87 (0.76 to 4.59) 1.87 (0.76 to 4.59)
E-cigarette low vs. varenicline standard – 1.14 (0.34 to 4.47) 1.14 (0.34 to 4.47)
E-cigarette high vs. varenicline standard – 1.14 (0.57 to 2.30) 1.14 (0.57 to 2.30)
Varenicline standard plus NRT standard vs.
varenicline standard
2.05 (0.82 to 5.17) – 2.05 (0.82 to 5.17)
Varenicline standard plus bupropion standard vs.
varenicline standard
– 1.15 (0.48 to 2.76) 1.15 (0.48 to 2.76)
E-cigarette high vs. e-cigarette low – 1.00 (0.22 to 4.03) 1.00 (0.22 to 4.03)
Varenicline standard plus NRT standard vs.
e-cigarette low
– 1.80 (0.34 to 8.39) 1.80 (0.34 to 8.39)
Varenicline standard plus bupropion standard vs.
e-cigarette low
– 1.01 (0.20 to 4.41) 1.01 (0.20 to 4.41)
Varenicline standard plus NRT standard vs.
e-cigarette high
– 1.79 (0.57 to 5.71) 1.79 (0.57 to 5.71)
Varenicline standard plus bupropion standard vs.
e-cigarette high
– 1.00 (0.33 to 3.08) 1.00 (0.33 to 3.08)
Varenicline standard plus bupropion standard vs.
varenicline standard plus NRT standard
– 0.56 (0.16 to 1.98) 0.56 (0.16 to 1.98)
This table is reproduced with permission from Thomas et al.67 This is an Open Access article distributed in accordance with
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standard (OR 1.40, 95% CrI 1.10 to 1.78) or bupropion standard (OR 1.63, 95% CrI 1.27 to 2.07).
Furthermore, there was weak evidence that e-cigarette high might increase the odds of sustained
abstinence compared with bupropion standard (OR 1.86, 95% CrI 0.92 to 3.73).
Estimates of absolute probabilities of sustained abstinence for each intervention can be obtained by
applying the relative effects in Table 3 to an assumed cessation rate on NRT standard (estimates shown
in Appendix 2, Table 34).
With regard to effect modifiers, there was evidence of effect modification as a function of counselling,
with interventions that included counselling being associated with a higher proportion of smokers
achieving sustained abstinence (additional log-OR was 0.86, 95% CrI 0.45 to 1.27; see Figure 45).
We also found evidence of effect modification as a function of dependence, with higher odds of
sustained abstinence among participants with higher average dependence scores (additional log-OR
0.23, 95% CrI 0.02 to 0.43; see Figure 47). We found inconclusive evidence of effect modification
according to industry sponsorship, type of placebo, treatment duration, comorbidities, willingness to
quit, smokeless tobacco, smoking level or publication year (see Figures 42, 44, 48 and 53). A sensitivity
analysis excluding studies at high risk of bias yielded the same findings reported in this section for
active interventions, although with wider intervals for most effect estimates, and particularly for
e-cigarettes and treatment combinations (see Appendix 5, Figure 40). However, the results from this
analysis suggested no difference between usual care and placebo (OR 1.16, 95% CrI 0.64 to 2.12).
We observed the same trends in a further sensitivity analysis where we excluded studies comparing
pharmacological with non-pharmacological interventions (the estimate of the OR comparing usual
care with placebo was 1.03, 95% CrI 0.57 to 1.86; see Figure 41). Within this sensitivity analysis, we
found inconclusive evidence of effect modification when pharmacological interventions were given
with counselling, with a trend towards a synergistic effect (more effective than would be expected
based on the sum of the pharmacological and counselling effects alone) (additional log-OR of 0.16,
95% CrI –0.05 to 0.37; see Figure 46).
Threshold analysis
Varenicline standard plus NRT standard had the highest estimated odds of sustained abstinence and
was the first-ranked treatment in our analyses. Figure 5 shows the results of the threshold analysis for
sustained abstinence, focusing on a selection of the eight treatment classes considered most relevant
(and examined in the rank-o-grams presented later in this chapter). Threshold analysis determines
how much the evidence could change before the first-ranked treatment changes. Each row in Figure 5
corresponds to a single study estimate, and displays the estimate (log-OR) and 95% CI from that study,
along with the invariant interval (shaded bar). Any changes to the study estimate that lie within the
invariant interval will not affect the first-ranked treatment. Changes that pass the thresholds at either
end of the invariant interval will result in a new first-ranked treatment, which are shown as numeric
treatment codes at either side of the invariant interval.
Figure 5 also shows the risk-of-bias judgements (see Report Supplementary Material 3). The smallest
threshold is 0.44 (on the log-odds scale) for the Cinciripini et al.207 study estimate of varenicline
standard plus bupropion standard versus placebo; if the log-OR of this estimate changed from 1.63
to 2.07 (= 1.63 + 0.44) or higher in favour of varenicline standard plus bupropion standard, then
varenicline standard plus bupropion standard would become the first-ranked treatment. This study was
rated as being at low risk of bias; however, the upper end of the 95% CI for the study estimate crosses
this threshold, meaning that the first-place ranking is sensitive to the level of uncertainty in this study
estimate. The second smallest threshold is –0.47 (on the log-odds scale) for the Koegelenberg et al.351
estimate of varenicline standard plus NRT standard versus varenicline standard; if the log-OR of
this estimate changes from 0.71 to 0.24 (= 0.71 – 0.47) or lower, in favour of varenicline standard,
then e-cigarette low would become the first-ranked treatment. This study was rated as being at
unclear risk of bias, and it may be judged whether or not any bias due to inadequate random sequence
generation or allocation concealment would lead to such an overestimation of treatment effects.
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Study (contrast) Log-OR 95% CI Invariant interval
Cinciripini207 2018 (28 vs. 1)
Cinciripini207 2018 (14 vs. 1)
Caponnetto202 2013 (17 vs. 1)
Hajek19 2019 (18 vs. 5)
Bullen192 2013 (18 vs. 1)
Bullen192 2013 (8 vs. 1)
Halpern294 2018 (17 vs. 4)
Anthenelli33 2016b (14 vs. 1)
Ortega392 2011 (5 vs. 2)
Aubin173 2008 (14 vs. 8)
Tonstad476 2006 (14 vs. 1)
Tønnesen473 1999 (5 vs. 1)
Anthenelli33 2016a (14 vs. 1)
Anthenelli33 2016b (5 vs. 1)
Anthenelli33 2016b (11 vs. 1)
Nakamura69 2007 (14 vs. 1)
Ebbert239 2015 (14 vs. 1)
Campbell198 1983 (4 vs. 1)
Anthenelli33 2016a (5 vs. 1)
Anthenelli33 2016a (11 vs. 1)
Aryanpur172 2016 (11 vs. 4)
Stapleton454 2013 (11 vs. 5)
Fagerström252 2010 (14 vs. 1)
Koegelenberg351 2014 (26 vs. 14)
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FIGURE 5 Threshold analysis results for sustained abstinence, sorted by size of threshold (smallest to largest). Only studies with thresholds of < 10 log-OR are shown, for brevity.
Treatment codes are (1) placebo, (7) NRT standard, (11) bupropion standard, (14) varenicline standard, (17) e-cigarette low, (18) e-cigarette high, (26) varenicline standard plus NRT
Standard and (28) varenicline plus bupropion standard. For a full list, see Appendix 6. Bold study labels and red shaded invariant intervals show where a 95% CI crosses the corresponding
threshold, indicating sensitivity to the level of uncertainty in this estimate. AC, allocation concealment; BOA, blinding of outcome assessment; BPP, blinding of participants and personnel;
IOD, incomplete outcome data; NT, no threshold; OB, other bias; RSG, random sequence generation; SR, selective reporting. ‘+’, low risk of bias; ‘?’, unclear risk of bias; ‘–’, high risk of
bias.19,33,69,172,173,192,198,202,207,239,252,294,306,351,392,454,473,476 This figure is reproduced with permission from Thomas et al.67 This is an Open Access article distributed in accordance with the terms
of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is
















































There is no threshold in the other direction for this study estimate, indicated by ‘NT’ in the invariant
interval; no amount of change to this estimate in favour of varenicline standard plus NRT would change
the first-ranked treatment. Only one other study (Caponnetto et al.;202 e-cigarette low vs. placebo) has
a threshold < 0.7 log-OR (equivalent to a factor of 2 on the OR scale); the threshold is 0.61 in the
direction favouring e-cigarette low, at which point e-cigarette low would be the first-ranked treatment.
The upper end of the 95% CI for the study estimate crosses this threshold, meaning that the first-place
ranking is sensitive to the level of uncertainty in this study estimate. Only another two studies19,192 have
thresholds < 3 log-OR (equivalent to a factor of 20 on the OR scale). Bullen et al.192 is rated as being at
low risk of bias, but Hajek et al.19 is rated as being at high or unclear risk of bias for blinding. To change
the first-ranked treatment (to e-cigarette high), the Hajek et al.19 estimate of e-cigarette high versus
NRT not specified would have to underestimate the true OR by a factor of 2.6. The remaining 212 study
estimates have even larger thresholds, and it is unlikely that any potential biases could plausibly change
these estimates by such an amount to affect the first-place ranking.
Overall, the first-place ranking of varenicline standard plus NRT standard appears relatively robust.
However, there is some sensitivity to the level of uncertainty and potential biases in the evidence,
which could lead to varenicline plus bupropion standard, e-cigarette low or e-cigarette high being
ranked first for sustained abstinence.
Prolonged abstinence
Prolonged abstinence was also restricted to measurements with a follow-up of at least 24 weeks.
It was reported in 19 studies (4434 patients), with 17 studies (3512 patients) including at least one
relevant comparison. Appendix 5, Figure 54 presents the structure of this network, sparser than the
previous one but still connected both at (a) the treatment and (b) the class level. Placebo was, again,
the main comparator across studies, although some direct comparisons between different drug types
are also available. We excluded one study comparing NRT gum standard (8/79 patients quit) with no
drug treatment (2/82 patients quit), which was disconnected from the main network both at the
treatment and at the class levels, and one study comparing bupropion low (1/9 patients quit) with
placebo (0/9 patients quit) because of small numbers that caused convergence problems in the models.
Therefore, the NMA for this outcome was based on 15 studies. Results with placebo as a comparator
are presented in Appendix 5, Figure 55. There was evidence that smokers treated with bupropion
standard (OR 2.34, 95% CrI 1.46 to 3.86), varenicline standard (OR 3.63, 95% CrI 2.23 to 6.36) and
varenicline standard plus bupropion standard (OR 4.76, 95% CrI 2.48 to 10.10) were more likely to
achieve prolonged abstinence than those who received placebo.
Appendix 5, Table 40 gives the NMA results with placebo as comparator alongside effect estimates
from direct and/or indirect evidence, where available. Most estimates are above 1, which suggests that
smokers assigned to each of the drugs examined were more likely to achieve prolonged abstinence
than those receiving placebo. As would be expected, CrIs around the NMA effect estimates are
typically narrower than those obtained using either direct or indirect evidence in isolation.
There was no statistical evidence of inconsistency based on model fit statistics (see Appendix 5, Table 42
and Figures 55 and 56). Pairwise comparisons between active interventions, mostly obtained through
indirect evidence, are displayed in Appendix 5, Table 41. There was inconclusive evidence that bupropion
standard, varenicline standard, and varenicline standard plus bupropion standard differed from each
other in the odds of achieving prolonged abstinence.
Any abstinence
Any abstinence was restricted to measurements with a follow-up of at least 22 weeks. A total of
216 studies (99,630 smokers) reported on it, with 196 (91,667 smokers) including at least one relevant
comparison. The structure of the network at the treatment level is displayed in Appendix 5, Figure 58
and at the class level in Figure 6.
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Results for the fixed-class random-effects NMA with placebo as a comparator are presented in Figure 7.
Compared with placebo, there was evidence that smokers randomised to no drug treatment were more
likely to achieve any abstinence (OR 1.48, 95% CrI 1.19 to 1.86), whereas smokers receiving usual care
were less likely to do so (OR 0.66, 95% CrI 0.46 to 0.96). With regard to active interventions, smokers
allocated to NRT not specified (OR 1.86, 95% CrI 1.57 to 2.20), NRT standard (OR 2.03, 95% CrI 1.72
to 2.44), NRT high (OR 2.46, 95% CrI 2.03 to 2.94), bupropion low (OR 2.89, 95% CrI 1.34 to 6.23),
bupropion standard (OR 1.84, 95% CrI 1.57 to 2.16), varenicline not specified (OR 4.06, 95% CrI 1.04 to
11.90), varenicline standard (OR 2.69, 95% CrI 2.27 to 3.19), e-cigarette low (OR 3.29, 95% CrI 1.13 to
10.80), e-cigarette high (OR 2.77, 95% CrI 1.01 to 7.69), bupropion low plus NRT high (OR 5.75, 95% CrI
1.79 to 19.10), bupropion standard plus NRT not specified (OR 2.10, 95% CrI 1.22 to 3.60), bupropion
standard plus NRT high (OR 2.56, 95% CrI 1.60 to 4.14), varenicline standard plus NRT standard (OR 5.53,
95% CrI 2.12 to 14.40), varenicline standard plus NRT high (OR 2.36, 95% CrI 1.12 to 4.90), and varenicline
standard plus bupropion standard (OR 3.56, 95% CrI 1.84 to 6.89) had higher odds of any abstinence than
those receiving placebo.
Appendix 5, Table 43 presents the class effect estimates with placebo as comparator obtained from the
NMA and direct and indirect evidence. Direct evidence was available for most monotherapies, whereas
comparisons of combinations of interventions compared with placebo largely relied on indirect evidence
only. Most effect estimates are above 1, suggesting that the interventions helped smokers to reach
sustained abstinence more frequently than placebo.
There was no statistical evidence of inconsistency based on model fit statistics (see Appendix 5, Table 45
and Figures 59 and 60). Where there was enough information to back-calculate indirect evidence and
compare it with direct evidence, the results were largely consistent, although there were instances
when direct evidence showed a less beneficial effect for the experimental drug than the indirect
evidence (e.g. e-cigarette low vs. placebo).
Varenicline + bupropion std
Bupropion std + NRT high
Bupropion std + NRT std
Varenicline std + NRT std
Varenicline std + NRT high
Bupropion std + NRT ns
Bupropion low + NRT high
Bupropion ns + NRT ns
E-cigarette high
E-cigarette high + NRT ns
E-cigarette low













FIGURE 6 Network plot for any abstinence at class level. Ns, not specified; std, standard. This figure has been adapted
with permission from Thomas et al.67 This is an Open Access article distributed in accordance with the terms of the
Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this
work, for commercial use, provided the original work is properly cited. See: https://creativecommons.org/licenses/by/4.0/.
The figure includes minor additions and formatting changes to the original figure.
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The pairwise comparisons between experimental interventions for this outcome are presented
in Appendix 5, Table 44. Most effect estimates were informed by indirect evidence only, and the results
were consistent when both direct and indirect evidence were available. There was evidence that
smokers randomised to varenicline standard were more likely to achieve any abstinence than those
allocated to NRT standard (OR 1.32, 95% CrI 1.05 to 1.65) and bupropion standard (OR 1.46, 95% CrI
1.18 to 1.81). Furthermore, varenicline standard plus NRT standard led to higher odds of abstinence
than NRT standard alone (OR 2.70, 95% CrI 1.02 to 7.13), bupropion standard (OR 2.99, 95% CrI 1.13
to 7.88) and standard doses of bupropion and NRT combined (OR 3.83, 95% CrI 1.05 to 14.00). Last,
there was weak evidence that the combination of varenicline standard plus bupropion standard was
more effective than bupropion standard alone (OR 1.93, 95% CrI 0.98 to 3.79).
Seven-day point prevalence abstinence
Point prevalence abstinence at 1 week was reported in 139 studies (55,724 patients), with 122 studies
(48,110 patients) including at least one relevant comparison. Appendix 5, Figure 61 presents the structure
of this network at the treatment level and Figure 8 presents the structure of this network at the class level.
The NMA for this outcome was based on 122 studies. Results with placebo as a comparator are
presented in Figure 9. There was evidence that smokers randomised to NRT not specified (OR 1.75,
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FIGURE 7 Forest plot with results of the fixed-class NMA model for any abstinence. Ns, not specified; std, standard. This
figure has been adapted with permission from Thomas et al.67 This is an Open Access article distributed in accordance
with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt
and build upon this work, for commercial use, provided the original work is properly cited. See: https://creativecommons.
org/licenses/by/4.0/. The figure includes minor additions and formatting changes to the original figure.
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FIGURE 8 Network plot for 7-day PPA at class level. Ns, not specified; std, standard. This figure has been adapted with
permission from Thomas et al.67 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: https://creativecommons.org/licenses/by/4.0/.
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FIGURE 9 Forest plot with results of the fixed-class NMA model for PPA. Ns, not specified; std, standard. This figure has
been adapted with permission from Thomas et al.67 This is an Open Access article distributed in accordance with the
terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and
build upon this work, for commercial use, provided the original work is properly cited. See: https://creativecommons.org/
licenses/by/4.0/. The figure includes minor additions and formatting changes to the original figure.
CLINICAL RESULTS: EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
36
1.67 to 2.39) were more likely to remain abstinent for a full week than those receiving placebo. Similarly,
smokers treated with bupropion standard (OR 1.67, 95% CrI 1.48 to 1.88), varenicline not specified
(OR 2.56, 95% CrI 1.21 to 5.42), varenicline standard (OR 2.14, 95% CrI 1.86 to 2.46), bupropion low
plus NRT high (OR 4.76, 95% CrI 1.82 to 12.70), bupropion standard plus NRT high (OR 2.16, 95% CrI
1.57 to 2.97), varenicline standard plus NRT standard (OR 4.01, 95% CrI 2.16 to 7.54) and varenicline
standard plus bupropion standard (OR 2.29, 95% CrI 1.48 to 3.56) reached 7-day PPA more often than
those taking placebo. There was weak evidence that varenicline low was more effective than placebo
(OR 1.75, 95% CrI 0.97 to 3.13).
Appendix 5, Table 46 presents the NMA results with placebo as comparator alongside effect estimates
from direct and/or indirect evidence, where available. Most estimates are above 1, which suggests that
smokers assigned to each of the drugs examined were more likely to remain abstinent for a full week
than those receiving placebo. Nonetheless, intervals around effect estimates obtained from direct and
indirect evidence tend to be wider than those obtained when integrating both in the NMA, which
reflects the gain in precision when using the latter approach. A comparison between direct and indirect
evidence reveals largely consistent results, although examples can be found where direct evidence
suggests a less beneficial effect of the experimental intervention (e.g. varenicline low vs. placebo)
and also the opposite (NRT high vs. placebo).
There was no statistical evidence of inconsistency based on model fit statistics (see Appendix 5, Table 48
and Figures 62 and 63). Pairwise comparisons between active interventions, mostly obtained through
indirect evidence, are displayed in Appendix 5, Table 47. Smokers allocated to varenicline standard
achieved the target more often than those treated with NRT standard (OR 1.35, 95% CrI 0.99 to 1.82)
or bupropion standard (OR 1.28, 95% CrI 1.08 to 1.53). Furthermore, there was strong evidence that
the combination of varenicline standard plus NRT standard led to higher odds of abstinence than NRT
standard alone (OR 2.54, 95% CrI 1.28 to 4.98), bupropion standard (OR 2.42, 95% CrI 1.28 to 4.57) and
varenicline standard alone (OR 1.88, 95% CrI 1.02 to 3.46).
Ranking of interventions
Table 4 presents ranks for a selection of classes according to the primary effectiveness outcome,
namely sustained abstinence. Varenicline standard plus NRT standard yielded the highest probability of
being the most effective intervention (0.61, mean rank 1.67), followed by e-cigarette low (0.19, mean
rank 3.61), varenicline standard plus bupropion standard (0.12, mean rank 3.42) and e-cigarette high
(0.08, mean rank 3.32). Conversely, there was strong evidence that placebo had the lowest rank among
the eight shortlisted interventions, with a mean rank of 7.97.
TABLE 4 Mean ranking of interventions for sustained abstinence
Intervention Pr(best) Mean rank
Placebo 0 7.97
NRT standard 0 5.64
Bupropion standard 0 6.57
Varenicline standard 0 3.80
E-cigarette low 0.19 3.61
E-cigarette high 0.08 3.32
Varenicline standard plus NRT standard 0.61 1.67
Varenicline standard plus bupropion standard 0.12 3.42
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Figure 10 is a rank-o-gram displaying the ranking of the same interventions across the four effectiveness
outcomes examined in our NMA models. Varenicline standard plus NRT standard showed a high probability
to be ranked best or second-best intervention for all of them (note that there was no information for the
effect of this drug combination on prolonged abstinence). Furthermore, varenicline standard plus bupropion
standard yielded the highest probability to be ranked as the best intervention for prolonged abstinence,
although there was higher uncertainty about its ranking for the other outcomes. Moreover, varenicline
standard showed highest probabilities of being ranked second to fourth best for the different outcomes,
whereas e-cigarettes presented a more uncertain ranking profile. Last, placebo was ranked as the least
effective intervention for all outcomes.
Rank of placebo
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FIGURE 10 Rank-o-gram of interventions across effectiveness outcomes. Rank of (a) placebo; (b) NRT standard;
(c) bupropion standard; (d) varenicline standard; (e) e-cigarette low; (f) e-cigarette high; (g) bupropion standard plus
NRT standard; (h) varenicline standard plus NRT standard; and (i) varenicline standard plus bupropion standard. Std, standard.
This figure has been adapted with permission from Thomas et al.67 This is an Open Access article distributed in accordance
with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt
and build upon this work, for commercial use, provided the original work is properly cited. See: https://creativecommons.org/
licenses/by/4.0/. The figure includes minor additions and formatting changes to the original figure.
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The results of our search strategy are summarised in Figure 11. Our original searches identified 335
studies for inclusion and our update searches identified an additional 20 studies for inclusion, resulting
in a total of 355 studies19,33,40,69,70,164–166,169–171,173–180,184–186,190,192,193,196–198,200–203,205–208,212,216–218,220,221,223–226,228–231,
233–252,255,257–259,261–263,265–268,271–275,277–279,281–283,286–288,295–297,300–303,307–311,313,315,318–331,336–340,343–345,347,349–352,354,356,357,359,
361–366,371,373–378,380,381,385–387,390,391,393,395–397,399,401,403,404,406,408,410,411,413–416,418–422,424–427,429–436,438–440,442–450,453–458,460,
463–476,478–482,484,487,488,490–495,497–506,509,511–604 that reported on one or more safety outcomes; these are
described in the following sections. For the purpose of our analyses, the EAGLES study33 was treated
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FIGURE 11 The PRISMA flow diagram for randomised safety study records. This figure has been adapted with
permission from Thomas et al.67 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: https://creativecommons.org/licenses/by/4.0/.
The figure includes minor additions and formatting changes to the original figure.
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and Anthenelli 2016b33 included the four arms from the psychiatric cohort. A list of records excluded at
full-text screening (that did not meet randomised or non-randomised inclusion criteria for effectiveness
or safety analyses) and the reasons for their exclusion are presented in Report Supplementary Material 1.
Study characteristics
The number of participants randomised across the 355 trials ranged from 5 to 5887, with a total of
159,101 participants. Trials were conducted across six continents, with 211 trials in the USA, 34 trials
in the UK, and 31 multicountry trials. Trials were conducted in several settings, including medical
centres and facilities, academic and research centres, universities, community centres, subsidised
housing neighbourhoods, hospitals, pharmacies, clinics (e.g. smoking cessation, dental, substance
misuse, HIV), primary care (general, family and private practices), over-the-counter, companies and
workplaces, over the telephone and by mail.
Trial duration ranged from 0.14 (1 day/single session) to 754 weeks and duration of drug treatment
ranged from 0.07 (half a day) to 104 weeks. One hundred and forty trials were industry sponsored
and 154 trials were publicly registered online. We included 48 trials in which smokers were unwilling
or not necessarily motivated to quit and 13 trials of smokeless-tobacco users. Twenty-three trials
recruited smokers with comorbidities as specified by the Charlson Comorbidity Index,90 29 trials
recruited smokers with current or a history of psychiatric conditions and 25 trials recruited smokers
with current or a history of drug- or alcohol-related conditions.
The mean age of trial participants ranged from 28.4 to 62.8 years and the percentage of female
participants (in studies that did not exclusively recruit male or female participants) ranged from 0.3%
to 79%. Study populations ranged between ethnicities (e.g. white/Caucasian, African American, Asian,
Indigenous Maori), types of tobacco use (e.g. smokeless tobacco, spit tobacco, cigars, waterpipes) and
heaviness of smoking. Studies included smokers who were hospital inpatients or outpatients (including
smokers scheduled for surgery), smokers with HIV, smokers with substance misuse, smokers with
psychiatric conditions, smokers who were health-care professionals, smokers who were active or
former armed forces and their family members (e.g. veterans, National Guard), smokers with previous
quit attempts or who had recently relapsed, smokers who were cancer patients or survivors, female
smokers concerned about weight, smokers from low-income or subsidised housing neighbourhoods,
smokers with tuberculosis and smokers with asthma. Study-level characteristics can be found in tables
in Report Supplementary Material 4.
Non-randomised evidence
Study selection
The results of our search strategy are summarised in Figure 12. Our original searches identified
48 studies for inclusion and our update searches identified an additional five studies for inclusion,
resulting in a total of 53 studies53–55,57,605–653 that reported on one or more safety outcomes; these are
described in the following sections. A list of records excluded at full-text screening (i.e. they did not
meet randomised or non-randomised inclusion criteria for effectiveness or safety analyses) and the
reasons for their exclusion are presented in Report Supplementary Material 1.
Study characteristics
The number of participants randomised across the 53 studies ranged from 32 to 7,917,436, with a
total of 8,783,403 participants. Study designs included case–control, population cohort, retrospective
cohort, prospective cohort and quasi-randomised. Studies were conducted across five continents, with
19 studies in the USA, seven studies in the UK, and no multicountry studies. Studies were conducted
in several settings, including hospitals, primary care (e.g. GP practices), clinics (e.g. community, smoking
cessation, tobacco dependence, surgical preoperative), academic, drug monitoring and medical centres.
Observational studies used a range of databases, including the Clinical Practice Research Datalink
(CPRD) (formerly the General Practice Research Database), New York City Fire Department, Bureau
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of Medical Services, Medicaid, Military Health System Data Repository, nationwide registries (National
Prescription Registry, National Patient Registry), and were conducted over the telephone and online.
Study duration ranged from 4 to 208 weeks and the duration of drug treatment ranged from 1.26 to
208 weeks. Three studies were industry sponsored and three studies were publicly registered online.
We included two studies in which smokers were not necessarily motivated to quit and no studies of
smokeless-tobacco users. Five studies recruited smokers with comorbidities as specified by the Charlson
Comorbidity Index,90 five studies recruited smokers with current or a history of psychiatric conditions
and two studies recruited smokers with current or a history of drug- or alcohol-related conditions.
The mean age of study participants ranged from 37.9 to 58.3 years and the percentage of female participants
(in studies that did not exclusively recruit male or female participants) ranged from 1% to 61.6%. Studies
included smokers who were hospital inpatients or outpatients (including smokers scheduled for surgery),
smokers with HIV, smokers with substance misuse, smokers with psychiatric conditions, smokers who were
veterans, New York City Fire Department employees and their household family members who smoked,
smokers with previous quit attempts, smokers who were critically ill and smokers who were Medicare
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FIGURE 12 The PRISMA flow diagram for non-randomised safety study records.
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Risk of bias in included studies
Randomised evidence
Ratings ranged from low to high risk of bias, and an overall risk of bias domain was rated by selecting
the highest rating of bias across domains, with the exception of selective outcome reporting (as this
domain was usually rated as unclear owing to inaccessibility of study protocols and limited trial
registration). Risk-of-bias ratings by study and summarised across studies are presented in Report
Supplementary Material 5 and Appendix 4, Figure 35, respectively.
Random sequence generation
Few trials were rated as being at high risk of bias for random sequence generation, with only 1% rated
as being at high risk of bias. Conversely, over half (52%) of trials were rated as being at low risk of bias
and the remaining 47% of trials were rated as being at unclear risk of bias.
Allocation concealment
As with random sequence generation, only 2% of trials were rated as being at high risk of bias for
allocation concealment, whereas 42% were rated as being at low risk of bias and over half (56%) of
trials were rated as being at unclear risk of bias.
Blinding of participants and personnel
Blinding of participants and personnel was rated as being at high risk of bias in 22% of trials, largely as
a result of trials where drugs were delivered open label without any blinding. Ratings for the remaining
trials were similarly split between low risk of bias (39%) and unclear risk of bias (39%).
Blinding of outcome assessment
Almost half (45%) of trials were rated as being at unclear risk of bias for blinding of outcome
assessment domains, with 43% of trials rated as being at low risk of bias and 12% of trials rated as
being at unclear risk of bias.
Incomplete outcome data
More than half (69%) of the trials were rated as being at low risk of bias for the incomplete outcome
data domain, as loss to follow-up was either low or similar among trial arms. The remining trials were
rated as being at unclear risk of bias (21%) or high risk of bias (10%).
Selective reporting
As previously mentioned, most (66%) of trials were rated as being at unclear risk of bias for selective
reporting owing to a lack of study protocols or public trial registrations. One-third of studies (33%)
were rated as being at low risk of bias and only 1% of trials were rated as being at high risk of bias.
Other bias
Nearly all (95%) trials were rated as being at low risk of bias for the other bias domain, with only 3%
rated as being at unclear risk of bias and 2% rated as being at high risk of bias.
Overall bias
Finally, ratings for our overall risk of bias domain indicated that 16% of trials were rated as being at
low risk of bias, 51% of trials were rated as being at unclear risk of bias and 33% of trials as being at
high risk of bias.
Non-randomised evidence
Ratings ranged from low to high risk of bias and an overall risk-of-bias domain was rated by selecting the
highest rating of bias across domains, with the exception of selective outcome reporting (as this domain
was usually rated as unclear owing to inaccessibility of study protocols and limited study registration).
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Risk-of-bias ratings by study and summarised across studies are presented in Report Supplementary
Material 7 and Appendix 4, Figure 36, respectively.
Given the non-randomised study designs, nearly all studies were rated as at high risk of bias for
random sequence generation, allocation concealment, blinding of participants and personnel, and
blinding of outcome assessment domains. This was as a result of the studies not randomising
participants and commonly not concealing the allocation to study arms, and in most studies blinding
was not used. Most studies (81%) of studies were rated as unclear for the incomplete outcome data
domain, as the number of participants followed up was either not reported or not applicable in the
study design. As previously mentioned, most (94%) of the studies were rated as unclear for selective
reporting and 92% of studies were rated as low for the other bias domain. Finally, ratings for our
overall risk of bias domain indicated that 100% of studies were rated as being at high risk as a result of
the ratings for most studies across the first four domains.
Results on safety
We performed NMA on three safety outcomes: SAEs, MACEs and MANEs. We fitted a standard
(full interaction) NMA model as well as fixed- and random-class NMA models for each outcome.
Based on the model fit indices (see Appendix 7), we focused on fixed-class NMA models. Appendix 7,
Tables 49 and 50 provide a list of the treatments delivered in the randomised trials and non-randomised
studies included in safety analyses and their frequency, respectively. In this chapter we present results
for each outcome based on a fixed-class NMA model; for additional results using other models, see
Appendix 7. Results are presented as median ORs alongside 95% CrIs. A summary of results across
outcomes is provided at the end of this chapter in the form of a rank-o-gram.
Serious adverse events
Randomised evidence only
Our primary safety outcome, SAEs, was reported in 111 studies with a total of 63,927 patients,
of which 101 studies (58,318 patients) compared two or more of the treatment classes of interest.
We excluded one study from all analyses [varenicline not specified (3/160 patients with event) vs.
placebo (0/160 patients with event)] because of small event numbers causing convergence problems.
Furthermore, two studies (bupropion standard plus NRT inhalator vs. usual care, and varenicline
standard plus NRT gum standard vs. varenicline low plus NRT gum standard) were disconnected at
the treatment level (see Figure 64), but connected to the main network at the class level (Figure 13).
We excluded both studies when comparing the different models (see Table 51), but we were able to
include them in the analyses discussed in this section (which report results at the class level).
Figure 14 displays results for the fixed-class NMA model based on 100 studies with placebo as a
comparator. There was evidence that bupropion standard (OR 1.27, 95% CrI 1.04 to 1.58) increased
the odds of SAEs compared with placebo.
Table 5 presents the class effect estimates with placebo as comparator obtained from the NMA
(final column) alongside the estimates obtained from direct and indirect evidence. Direct evidence
was available for most monotherapies, whereas comparisons of most combinations of interventions
with placebo were obtained largely through indirect evidence only. Evidence for some of the main
interventions (e.g. bupropion standard and varenicline standard) was informed by large trials that
compared these drugs against placebo, so that indirect evidence did not add anything to the NMA
results. When both direct and indirect evidence was available, results were mostly consistent, although
there were some instances in which direct evidence suggested a larger increase in the odds of a SAE
for the experimental drug (e.g. e-cigarette high vs. placebo).
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Varenicline + bupropion std
Bupropion std + NRT high
Bupropion std + NRT ns
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FIGURE 13 Network plot for SAEs at class level. Ns, not specified; std, standard. This figure has been adapted with
permission from Thomas et al.67 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: https://creativecommons.org/licenses/by/4.0/.
The figure includes minor additions and formatting changes to the original figure.
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FIGURE 14 Forest plot with results of the fixed-class NMA model for SAEs. Ns, not specified; std, standard. This figure
has been adapted with permission from Thomas et al.67 This is an Open Access article distributed in accordance with the
terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and
build upon this work, for commercial use, provided the original work is properly cited. See: https://creativecommons.org/
licenses/by/4.0/. The figure includes minor additions and formatting changes to the original figure.
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There was no statistical evidence of inconsistency based on model fit statistics (see Appendix 7, Table 51
and Figures 66 and 67). The pairwise comparisons between active interventions for this outcome are
presented in Table 6. Most effect estimates were informed by indirect evidence only. As a consequence
of this, and also the small event rates reported, effects were imprecisely estimated and all intervals
included the null.
With regard to effect modifiers, there was inconclusive evidence of effect modification according to
industry sponsorship, type of placebo, treatment duration, counselling, dependence score, comorbid
samples, studies in which patients were not required to be willing to quit, smokeless-tobacco users,
analyses restricted to samples of heavy smokers, and publication year (see Figures 69–80); sensitivity
analysis excluding studies at high risk of bias yielded the same findings reported in this section, although
with wider intervals for most effect estimates (see Figure 68; full results provided in Appendix 7). A
sensitivity analysis excluding studies that compared pharmacological interventions with psychological
interventions (that were not given on all arms of the study) was very similar to that in the main analysis
(see Appendix 7).
Threshold analysis
The results of the threshold analyses for the first- and last-ranked treatments for SAEs are shown
in Figures 15 and 16. The first-ranked treatment is placebo and the last-ranked is e-cigarette low.
Both figures also include the risk-of-bias judgements from Report Supplementary Material 5.





OR (95% CrI) NMA, OR (95% CrI)
No drug treatment – 1.11 (0.56 to 2.29) 1.11 (0.56 to 2.29)
Usual care – 0.28 (0.02 to 2.20) 0.28 (0.02 to 2.20)
NRT not specified 1.19 (0.86 to 1.62) 0.72 (0.31 to 1.68) 1.12 (0.79 to 1.49)
NRT standard 1.11 (0.74 to 1.68) 1.37 (0.38 to 4.96) 1.13 (0.76 to 1.67)
NRT high 1.11 (0.77 to 1.58) 1.40 (0.87 to 2.27) 1.21 (0.89 to 1.63)
Bupropion low 0.26 (0.03 to 1.52) 0.37 (0.01 to 9.36) 0.21 (0.01 to 1.57)
Bupropion standard 1.27 (1.04 to 1.58) – 1.27 (1.04 to 1.58)
Varenicline low 1.12 (0.54 to 2.29) 1.62 (0.15 to 17.6) 1.07 (0.40 to 2.29)
Varenicline standard 1.09 (0.91 to 1.34) – 1.09 (0.91 to 1.34)
E-cigarette low – 7.24 (0.46 to 3262) 7.24 (0.46 to 3262)
E-cigarette high 1.99 (0.90 to 4.44) 1.44 (0.61 to 3.42) 1.72 (0.77 to 2.89)
Bupropion low plus NRT high – 1.19 (0.24 to 7.46) 1.19 (0.24 to 7.46)
Bupropion standard plus NRT not specified – 0.49 (0.03 to 3.35) 0.49 (0.03 to 3.35)
Bupropion standard plus NRT high 0.73 (0.05 to 4.18) 1.57 (0.47 to 5.28) 1.31 (0.49 to 3.67)
Varenicline low plus NRT standard – 6.62 (0.09 to 4964) 6.62 (0.09 to 4964)
Varenicline standard plus NRT standard – 1.38 (0.33 to 9.78) 1.38 (0.33 to 9.78)
Varenicline standard plus NRT high – 1.11 (0.29 to 3.49) 1.11 (0.29 to 3.49)
Varenicline standard plus bupropion standard 2.51 (0.73 to 9.49) 1.48 (0.57 to 3.84) 1.79 (0.86 to 4.06)
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The first-place ranking (of placebo) is very sensitive to the level of uncertainty in the evidence, as shown
by the number of study estimates with 95% CIs that cross the corresponding threshold. At each of these
thresholds, the new first-ranked treatment is NRT standard, varenicline standard plus NRT standard,
e-cigarette high, e-cigarette low, or varenicline plus bupropion standard. Five studies351,386,415,444,468 have
thresholds < 0.7 log-OR (equivalent to a factor of 2 on the OR scale), and, of these, only one468 is rated
as being at low risk of bias.
The last-place ranking (of e-cigarette low) is sensitive to the level of uncertainty from only one study525
(e-cigarette low vs. no drug treatment). The first-place ranking is also sensitive to the level of uncertainty
in this study estimate. If the estimate were to change by –0.80 log-OR from 1.32 to 0.52 in favour





OR (95% CrI) NMA, OR (95% CrI)
Bupropion standard vs. NRT standard – 1.12 (0.72 to 1.80) 1.12 (0.72 to 1.80)
Varenicline standard vs. NRT standard – 0.98 (0.62 to 1.50) 0.98 (0.62 to 1.50)
E-cigarette low vs. NRT standard – 6.48 (0.39 to 3087) 6.48 (0.39 to 3087)
E-cigarette high vs. NRT standard – 1.54 (0.58 to 2.90) 1.54 (0.58 to 2.90)
Varenicline standard plus NRT standard vs.
NRT standard
– 1.23 (0.28 to 8.39) 1.23 (0.28 to 8.39)
Varenicline standard plus bupropion standard vs.
NRT standard
– 1.60 (0.69 to 3.82) 1.60 (0.69 to 3.82)
Varenicline standard vs. bupropion standard – 0.86 (0.67 to 1.11) 0.86 (0.67 to 1.11)
E-cigarette low vs. bupropion standard – 5.75 (0.37 to 2419) 5.75 (0.37 to 2419)
E-cigarette high vs. bupropion standard – 1.34 (0.69 to 2.28) 1.34 (0.69 to 2.28)
Varenicline standard plus NRT standard vs.
bupropion standard
– 1.10 (0.25 to 8.09) 1.10 (0.25 to 8.09)
Varenicline standard plus bupropion standard vs.
bupropion standard
– 1.39 (0.67 to 3.20) 1.39 (0.67 to 3.20)
E-cigarette low vs. varenicline standard – 6.36 (0.42 to 2879) 6.36 (0.42 to 2879)
E-cigarette high vs. varenicline standard – 1.56 (0.74 to 2.67) 1.56 (0.74 to 2.67)
Varenicline standard plus NRT standard vs.
varenicline standard
1.28 (0.30 to 7.77) – 1.28 (0.30 to 7.77)
Varenicline standard plus bupropion standard vs.
varenicline standard
1.24 (0.49 to 3.34) 2.55 (0.78 to 8.31) 1.64 (0.80 to 3.59)
E-cigarette high vs. e-cigarette low – 0.23 (0.00 to 3.47) 0.23 (0.00 to 3.47)
Varenicline standard plus NRT standard vs.
e-cigarette low
– 0.21 (0.00 to 5.40) 0.21 (0.00 to 5.40)
Varenicline standard plus bupropion standard vs.
e-cigarette low
– 0.27 (0.00 to 4.28) 0.27 (0.00 to 4.28)
Varenicline standard plus NRT standard vs.
e-cigarette high
– 0.83 (0.17 to 5.52) 0.83 (0.17 to 5.52)
Varenicline standard plus bupropion standard vs.
e-cigarette high
– 1.07 (0.42 to 3.31) 1.07 (0.42 to 3.31)
Varenicline standard plus bupropion standard vs.
varenicline standard plus NRT standard
– 1.33 (0.19 to 6.31) 1.33 (0.19 to 6.31)
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Nides386 2018 (7 vs. 1)
Koegelenberg351 2014 (26 vs. 14)
Shiffman444 2002 (7 vs. 1)
Tønnesen468 2012 (7 vs. 1)
Rennard415 2006 (7 vs. 1)
Hajek19 2019 (18 vs. 5)
Bullen192 2013 (18 vs. 1)
Shiffman444 2002 (8 vs. 1)
Anthenelli33 2016b (14 vs. 1)
Cravo525 2016 (17 vs. 2)
Ebbert239 2015 (14 vs. 1)
Rigotti418 2010 (14 vs.  1)
Bullen192 2013 (8 vs. 1)
Rigotti419 2006 (11 vs. 1)
Anthenelli33 2016b (11 vs. 1)
Cinciripini207 2018 (28 vs. 1)
Anthenelli33 2016a (14 vs. 1)
Ebbert238 2014 (28 vs. 14)
Eisenberg244 2016 (14 vs. 1)
Hajek538 2013 (26 vs. 14)
Anthenelli33 2016b (5 vs. 1)
Winhusen501 2014 (21 vs. 4)
Eisenberg243 2013  (11 vs. 1)
Joseph340 1996 (8 vs. 1)
Cinciripini207 2018 (14 vs. 1)
Anthenelli33 2016a (5 vs. 1)
Lerman362 2015 (5 vs. 1)
Mercie373 2018 (14 vs. 1)
Anthenelli33 2016a (11 vs. 1)
Lerman362 2015 (14 vs. 1)
Steinberg457 2009 (20 vs. 8)
Rose422 2013 (27 vs. 5)
Tashkin465 2011 (14 vs. 1)
Rose422 2013 (23 vs. 5)
Study (contrast) Log-OR 95% CI Invariant interval
–5 –4 –3 –2 –1 0
Log-OR
1 2 3 4 5
Base-case first-ranked treatment is 1






























































































































































































































































































































































































































































FIGURE 15 Threshold analysis results for SAEs (first-ranked treatment), sorted by size of threshold (smallest to largest). Only studies with thresholds < 3 log-OR are shown, for brevity.
Treatment codes are (1) placebo, (7) NRT standard, (11) bupropion standard, (14) varenicline standard, (17) e-cigarette low, (18) e-cigarette high, (26) varenicline standard plus NRT
standard and (28) varenicline plus bupropion standard (for a full list, see Appendix 6). Bold study labels and red shaded invariant intervals show where a 95% CI crosses the
corresponding threshold, indicating sensitivity to the level of uncertainty in this estimate. AC, allocation concealment; BOA, blinding of outcome assessment; BPP, blinding of
participants and personnel; IOD, incomplete outcome data; OB, other bias; RSG, random sequence generation; SR, selective reporting. ‘+’, low risk of bias; ‘–’, high risk of bias;
‘?’, unclear risk of bias. This figure has been adapted with permission from Thomas et al.67 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.









































































































































































































































































































































































Cravo525 2016 (17 vs. 2)
Koegelenberg351 2014 (26 vs. 14)
Carson203 2014 (14 vs. 2)
Anthenelli33 2016a (5 vs. 1)
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Lerman362 2015 (5 vs. 1)
Rose422 2013 (23 vs. 5)
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Study (contrast) Log-OR 95% CI Invariant interval
–2 –1 0
Log-OR
1 2 3 4 5
Base-case last-ranked treatment is 17




FIGURE 16 Threshold analysis results for SAEs (last-ranked treatment), sorted by size of threshold (smallest to largest). Only studies with thresholds < 3 log-OR are shown, for brevity.
Treatment codes are (1) placebo, (7) NRT standard, (11) bupropion standard, (14) varenicline standard, (17) e-cigarette low, (18) e-cigarette high, (26) varenicline standard plus NRT
standard and (28) varenicline plus bupropion standard (for a full list, see Appendix 6). Bold study labels and red shaded invariant intervals show where a 95% CI crosses the corresponding
threshold, indicating sensitivity to the level of uncertainty in this estimate. AC, allocation concealment; BOA, blinding of outcome assessment; BPP, blinding of participants and personnel;
IOD, incomplete outcome data; OB, other bias; NT, no threshold; RSG, random sequence generation; SR, selective reporting. ‘+’, low risk of bias; ‘–’, high risk of bias; ‘?’, unclear risk of bias.
This figure is reproduced with permission from Thomas et al.67 This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0)
license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: https://creativecommons.org/










































of e-cigarette low, then e-cigarette low would no longer be ranked last (replaced by varenicline plus
bupropion standard), and if the estimate were to change only a little more to 0.24, then e-cigarette low
would be ranked first for SAEs. Owing to the high level of uncertainty in this study estimate and the
resulting wide CI, both of these are plausible owing to sampling error. Cravo et al.525 has the smallest
threshold for the last-place ranking (–0.80 log-OR, equivalent to a factor of 2.2 on the OR scale) and
was judged to be at high risk of bias owing to inadequate blinding and other bias. The remaining
thresholds for the other 122 study estimates are equivalent to a factor of ≥ 8 on the OR scale, which
may be larger than any plausible biases.
Overall, the first- and last-place rankings for SAEs are not very robust: both are sensitive to the level
of uncertainty in the data, and there may be plausible biases in studies at high or unclear risk of bias
that could result in a change of first- or last-place ranking. The Cravo et al.525 study is notably influential
for both first- and last-place rankings, displays high levels of uncertainty and is rated as being at high
risk of bias. The last-place ranking is likely to be robust to plausible biases in all other studies.
Incorporating non-randomised evidence
Only one non-randomised study632 reported one or more SAEs. This was a three-arm study comparing
e-cigarette standard (14 events in 343 patients), dual smoking (10 events in 319 patients) and no drug
treatment (14 events in 693 patients). The network plots at the treatment level and at the class level,
combining randomised and non-randomised evidence for this outcome, are presented in Appendix 7,
Figure 65 and Figure 17, respectively.
The statistical integration was identical to that restricted to randomised evidence, except for the addition
of the non-randomised study. The results for the fixed-class random-effects NMA, based on 102 studies
and 59,673 smokers, are displayed in Figure 18. Comparison with Figure 14 suggests that, although only
one study was added, the effect estimates changed substantially, now suggesting that varenicline
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Bupropion std + NRT ns




Varenicline std + NRT high
Varenicline std + NRT std












FIGURE 17 Network plot for SAEs, incorporating non-randomised evidence at class level. Ns, not specified; std, standard.
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standard (OR 0.63, 95% CrI 0.45 to 0.64) and e-cigarette low (OR 0.01, 95% CrI 0.00 to 0.15) might lead
to lower odds of SAEs than placebo. The notable influence of the study added might be because of its
contribution of 38 events to a network focused on a rare outcome. Furthermore, the non-randomised
study, conducted by Manzoli et al.,632 found that no drug treatment might be the safest of the three
interventions compared. Given that no drug treatment is one of the main comparators in the network, this
finding from a single study is likely to have an impact on the effect estimates for many interventions. In
summary, this analysis illustrates the difficulties of drawing solid conclusions about the relative safety of
different smoking interventions from the currently available evidence on SAEs.
Major adverse cardiovascular events
Randomised evidence only
A total of 49 studies (38,329 patients) reported MACEs, with 44 studies (36,231 patients) including
at least one relevant comparison. The structure of this network is presented at the treatment (see
Figure 81) and at the class (Figure 19) level. We discarded three studies from all analyses owing to
small numbers causing convergence problems, namely one study comparing varenicline not specified
(1/160 patients with event) with placebo (0/160 patients with event), one study comparing bupropion
standard plus NRT inhalator not specified (0/267 patients with event) with usual care (1/271 patients
with event) and one study comparing NRT not specified (0/61 patients with event) with usual care
(5/61 patients with event). Furthermore, one further study comparing NRT gum standard (25/3923
patients with event) with usual care (12/1964 patients with event) was disconnected from the
network and, hence, was excluded from any further analyses.
Intervention OR (95% Crl)
0.41 (0.13 to 1.21)
0.73 (0.34 to 1.58)
0.72 (0.41 to 1.25)
0.24 (0.02 to 1.92)
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1.55 (0.57 to 4.44)
0.63 (0.45 to 0.84)
0.01 (0.00 to 0.15)
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2.39 (0.38 to 15.18)
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FIGURE 18 Forest plot displaying the NMA results for SAEs, combining randomised and non-randomised evidence.
Ns, not specified; std, standard.
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Therefore, the NMA for this outcome was based on 41 studies. The results with placebo as a comparator
are presented in Figure 20. Owing to the small numbers of events reported across studies, all effect
estimates show very wide intervals and, hence, it was not possible to identify differences among any
pair of interventions.
Table 7 presents the NMA results with placebo as comparator alongside effect estimates from direct
and/or indirect evidence, where available. Although intervals were wide and always included the null,
NMA estimates were generally more precise when both direct and indirect evidence were available.
There was no statistical evidence of inconsistency based on model fit statistics (see Appendix 7, Table 52
and Figures 83 and 84). The pairwise comparisons between active interventions presented in Table 8 were
almost entirely obtained through indirect evidence only. All effect estimates had wide intervals including
the null, and some effects were very imprecisely estimated. There was inconclusive evidence of effect
modification based on comorbidities (see Figure 85) and smoking level (see Figure 86).
Incorporating non-randomised evidence
A total of 10 non-randomised studies reported at least one major adverse cardiovascular event.
The treatments examined in these studies, alongside the arm sizes and events per arm, are listed in
Table 9. Furthermore, the network plots resulting from combining randomised and non-randomised
evidence for this outcome are displayed in Appendix 7, Figure 82 (treatment level) and Figure 21
(class level). The disparity between sizes of the nodes for different treatments and classes stems
from the very large numbers of smokers enrolled in some non-randomised studies (see Table 9).
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FIGURE 19 Network plot for major adverse cardiovascular events at class level. Ns, not specified; std, standard. This figure
has been adapted with permission from Thomas et al.67 This is an Open Access article distributed in accordance with the
terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and
build upon this work, for commercial use, provided the original work is properly cited. See: https://creativecommons.org/
licenses/by/4.0/. The figure includes minor additions and formatting changes to the original figure.
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Intervention OR (95% Crl)
1.08 (0.24 to 5.26)
1.12 (0.42 to 3.03)
0.15 (0.00 to 3.25)
1.28 (0.71 to 2.38)
0.76 (0.41 to 1.25)
4.01 (0.79 to 29.67)
0.33 (0.00 to 7.24)
0.08 (0.00 to 1.73)
0.47 (0.04 to 3.82)
0.08 (0.00 to 1.34)
0.2 0.5 1.0
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FIGURE 20 Forest plot with results of the fixed-class NMA model for MACEs. Ns, not specified; std, standard. This figure
has been adapted with permission from Thomas et al.67 This is an Open Access article distributed in accordance with the
terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and
build upon this work, for commercial use, provided the original work is properly cited. See: https://creativecommons.org/
licenses/by/4.0/. The figure includes minor additions and formatting changes to the original figure.





OR (95% CrI) NMA, OR (95% CrI)
No drug treatment – 1.08 (0.24 to 5.26) 1.08 (0.24 to 5.26)
NRT not specified 0.82 (0.30 to 2.03) 0.61 (0.15 to 2.52) 0.75 (0.31 to 1.57)
NRT standard 1.28 (0.21 to 8.67) 0.57 (0.03 to 9.47) 1.01 (0.22 to 4.66)
NRT high 0.44 (0.11 to 1.75) 2.98 (0.71 to 12.5) 1.12 (0.42 to 3.03)
Bupropion low 0.15 (0.00 to 3.25) – 0.15 (0.00 to 3.25)
Bupropion standard 1.31 (0.68 to 2.48) 0.95 (0.08 to 11.0) 1.28 (0.71 to 2.36)
Varenicline standard 0.76 (0.41 to 1.25) – 0.76 (0.41 to 1.25)
E-cigarette high 2.61 (0.44 to 28.22) 26.8 (0.39 to 1860) 4.01 (0.79 to 29.7)
Bupropion standard plus NRT standard 0.33 (0.00 to 7.24) – 0.33 (0.00 to 7.24)
Bupropion standard plus NRT high – 0.08 (0.00 to 1.73) 0.08 (0.00 to 1.73)
Varenicline standard plus NRT high – 0.47 (0.04 to 3.82) 0.47 (0.04 to 3.82)
Varenicline standard plus bupropion standard 0.08 (0.00 to 1.34) – 0.08 (0.00 to 1.34)
This table is reproduced with permission from Thomas et al.67 This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and
build upon this work, for commercial use, provided the original work is properly cited. See: https://creativecommons.org/
licenses/by/4.0/. The table includes minor additions and formatting changes to the original table.
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OR (95% CrI) NMA, OR (95% CrI)
Bupropion standard vs. NRT standard – 1.26 (0.26 to 6.15) 1.26 (0.26 to 6.15)
Varenicline standard vs. NRT standard 0.99 (0.03 to 49.3) 0.68 (0.12 to 3.84) 0.73 (0.15 to 3.39)
E-cigarette high vs. NRT standard – 4.35 (0.42 to 43.1) 4.35 (0.42 to 43.1)
Bupropion standard plus NRT standard vs.
NRT standard
– 0.33 (0.00 to 9.83) 0.33 (0.00 to 9.83)
Varenicline standard plus bupropion standard vs.
NRT standard
– 0.07 (0.00 to 1.96) 0.07 (0.00 to 1.96)
Varenicline standard vs. bupropion standard – 0.58 (0.27 to 1.19) 0.58 (0.27 to 1.19)
E-cigarette high vs. bupropion standard – 3.17 (0.57 to 25.3) 3.17 (0.57 to 25.3)
Bupropion standard plus NRT standard vs.
bupropion standard
– 0.26 (0.00 to 5.50) 0.26 (0.00 to 5.50)
Varenicline standard plus bupropion standard vs.
bupropion standard
– 0.06 (0.00 to 1.14) 0.06 (0.00 to 1.14)
E-cigarette high vs. varenicline standard – 5.51 (1.05 to 40.1) 5.51 (1.05 to 40.1)
Bupropion standard plus NRT standard vs.
varenicline standard
– 0.44 (0.00 to 10.4) 0.44 (0.00 to 10.4)
Varenicline standard plus bupropion standard vs.
varenicline standard
– 0.11 (0.00 to 1.88) 0.11 (0.00 to 1.88)
Bupropion standard plus NRT standard vs.
e-cigarette high
– 0.07 (0.00 to 2.97) 0.07 (0.00 to 2.97)
Varenicline standard plus bupropion standard vs.
e-cigarette high
– 0.02 (0.00 to 0.55) 0.02 (0.00 to 0.55)
Varenicline standard plus bupropion standard vs.
bupropion standard plus NRT standard
– 0.20 (0.00 to 567) 0.20 (0.00 to 567)
This table is reproduced with permission from Thomas et al.67 This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and
build upon this work, for commercial use, provided the original work is properly cited. See: https://creativecommons.org/
licenses/by/4.0/. The table includes minor additions and formatting changes to the original table.
TABLE 9 Non-randomised studies reporting major cardiovascular AEs
Study (first author and year) Treatment Arm size Number of events
Manzoli 2015632 Dual smoking 319 2
Manzoli 2015632 E-cigarette standard 343 4
Manzoli 2015632 No drug treatment 693 2
Davies 2015609 Varenicline not specified 41,742 531
Davies 2015609 NRT choice not specified 84,976 160
Ferketich 2013615 NRT combination high 110 1
Ferketich 2013615 Varenicline standard 118 0
Kotz 2017629 Bupropion not specified 350 155
Kotz 2017629 Varenicline not specified 3574 3
Kotz 2017629 NRT not specified 10,426 34
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TABLE 9 Non-randomised studies reporting major cardiovascular AEs (continued )
Study (first author and year) Treatment Arm size Number of events
Kotz 201557 Bupropion not specified 6557 2148
Kotz 201557 Varenicline not specified 51,450 52
Kotz 201557 NRT not specified 106,759 594
Woolf 2012651 NRT choice not specified 184 8
Woolf 2012651 No drug treatment 479 23
Svanström 2012648 Varenicline not specified 17,926 16
Svanström 2012648 Bupropion not specified 17,926 21
Graham 2014618 Bupropion standard 14,133 216
Graham 2014618 Varenicline not specified 74,824 44
Panos 2010637 No drug treatment 113 3
Panos 2010637 NRT patch (24 hours) not specified 114 6
Deniz 2016611 Bupropion not specified 47 1
Deniz 2016611 Varenicline not specified 94 0
Varenicline std
Varenicline + bupropion std
Bupropion std + NRT high
Bupropion std + NRT std
Bupropion std + NRT ns
E-cigarette high
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FIGURE 21 Network plot for major adverse cardiovascular events (including randomised and non-randomised studies) at
class level. Ns, not specified; std, standard.
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The combination of both types of evidence enabled the inclusion of 54 studies in the NMA, as the
incorporation of 10 non-randomised studies also made it possible to include some randomised trials
that had been excluded from the main analyses owing to small numbers causing convergence problems.
The results of this combined analysis, based on a fixed-class random-effects model, are presented in
Figure 22 and suggest that, even with the additional studies, substantial uncertainty remains about the
relative safety of the different treatment classes for this outcome.
Major adverse neuropsychiatric events
Randomised evidence only
Major adverse neuropsychiatric events were reported in 75 studies (42,088 patients), with 73 studies
(41,483 patients) including at least one relevant comparison. The structure of this network is presented
at the treatment (see Figure 87) and the class (Figure 23) levels, which show that placebo (main comparator),
NRT not specified, bupropion standard, and varenicline standard were the best represented interventions.
One study comparing bupropion standard plus NRT inhalator not specified (1/267 patients with event)
with usual care (1/271 patients with event) was disconnected from the treatment network and, hence, we
excluded it from the model comparisons (see Table 53), although we were able to include it in the analyses
reported in this section. Moreover, we excluded two studies from all analyses owing to small numbers
causing convergence problems. One of these excluded studies compared NRT nasal spray standard
(1/506 patients with event) with placebo (0/255 patients with event), while the other one compared
e-cigarette high (2/440 patients with event) with NRT choice not specified (0/448 patients with event).
Intervention OR (95% Crl)
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FIGURE 22 Forest plot with results for major adverse cardiovascular events (combining randomised and non-randomised
evidence). Ns, not specified; std, standard.
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The NMA for this outcome was based on 71 studies. The results with placebo as a comparator are
presented in Figure 24 and show wide intervals around the effect estimates owing to small numbers.
There was weak evidence that patients randomised to no drug treatment (OR 0.27, 95% CrI 0.05 to
1.05) and strong evidence that those randomised to waitlist (OR 0.03, 95% CrI 0.00 to 0.44) were
less likely to report MANEs than those allocated to placebo. Regarding active treatments, there was
evidence that patients who received NRT not specified (OR 0.60, 95% CrI 0.36 to 0.89), bupropion
standard (OR 0.67, 95% CrI 0.47 to 0.91), bupropion standard plus NRT high (OR 0.21, 95% CrI 0.03 to
0.92) were less likely to report MANEs than those treated with placebo. There was weak evidence for
patients randomised to varenicline standard plus bupropion standard (OR 0.15, 95% CrI 0.01 to 1.12)
compared with placebo.
Table 10 presents the NMA results with placebo as comparator alongside effect estimates from direct
and/or indirect evidence where available. Most comparisons were informed by direct or indirect
evidence only, and, where back-calculation of indirect evidence was possible, this led to very imprecise
and uninformative estimates.
There was no statistical evidence of inconsistency based on model fit statistics (see Appendix 7, Table 53
and Figures 89 and 90). Pairwise comparisons between active interventions are displayed in Table 11.
Although most effect estimates were imprecisely estimated owing to small numbers, there was evidence
of increased odds of MANEs for smokers randomised to varenicline standard compared with those
allocated to bupropion standard (OR 1.43, 95% CrI 1.02 to 2.09). There was inconclusive evidence of
effect modification based on psychiatric comorbidities (see Figure 91).
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FIGURE 23 Network plot for major adverse neuropsychiatric events at class level. Ns, not specified; std, standard. This
figure has been adapted with permission from Thomas et al.67 This is an Open Access article distributed in accordance
with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt
and build upon this work, for commercial use, provided the original work is properly cited. See: https://creativecommons.
org/licenses/by/4.0/. The figure includes minor additions and formatting changes to the original figure.
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Intervention OR (95% Crl)
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FIGURE 24 Forest plot with results of the fixed-class NMA model for major adverse neuropsychiatric events. Ns, not
specified; std, standard. This figure has been adapted with permission from Thomas et al.67 This is an Open Access article
distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others
to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See:
https://creativecommons.org/licenses/by/4.0/. The figure includes minor additions and formatting changes to the original figure.





OR (95% CrI) NMA, OR (95% CrI)
No drug treatment – 0.27 (0.05 to 1.05) 0.27 (0.05 to 1.05)
Waitlist 0.03 (0.00 to 0.42) – 0.03 (0.00 to 0.42)
Usual care – 0.48 (0.04 to 4.18) 0.48 (0.04 to 4.18)
NRT not specified 0.73 (0.49 to 1.09) 5.16 (1.43 to 18.7) 0.60 (0.38 to 0.89)
NRT standard 0.12 (0.00 to 1.93) 0.04 (0.00 to 5506) 0.10 (0.00 to 2.20)
NRT high 0.73 (0.38 to 1.38) 0.80 (0.14 to 4.70) 0.74 (0.40 to 1.35)
Bupropion standard 0.62 (0.44 to 0.82) 0.47 (0.25 to 0.87) 0.67 (0.47 to 0.91)
Varenicline not specified 1.60 (0.21 to 15.2) – 1.60 (0.21 to 15.2)
Varenicline low 0.99 (0.06 to 11.1) – 0.99 (0.06 to 11.1)
Varenicline standard 0.96 (0.76 to 1.21) – 0.96 (0.76 to 1.21)
Bupropion standard plus NRT not specified 2.39 (0.17 to 22.7) 0.94 (0.31 to 2.83) 1.11 (0.39 to 2.97)
Bupropion standard plus NRT high – 0.21 (0.03 to 0.92) 0.21 (0.03 to 0.92)
Varenicline standard plus NRT standard – 1.72 (0.34 to 10.9) 1.72 (0.34 to 10.9)
Varenicline standard plus NRT high – 0.64 (0.17 to 2.10) 0.64 (0.17 to 2.10)
Varenicline standard plus bupropion standard 0.06 (0.00 to 1.05) 0.23 (0.01 to 5.97) 0.15 (0.01 to 1.12)
This table is reproduced with permission from Thomas et al.67 This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and
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Incorporating non-randomised evidence
A total of 16 non-randomised studies reported one or more major adverse neuropsychiatric events.
The treatments compared in those studies, the arm sizes and the event counts are presented in Table 12,
whereas the network plots combining both types of evidence at the treatment level and class level are
displayed in Appendix 7, Figure 88 and Figure 25, respectively.
TABLE 11 Results for major adverse neuropsychiatric events: pairwise comparisons of interventions
Comparison
Direct evidence, Indirect evidence,
OR (95% CrI) NMA, OR (95% CrI)
Bupropion standard vs. NRT standard – 6.55 (0.29 to 3523) 6.55 (0.29 to 3523)
Varenicline standard vs. NRT standard – 9.43 (0.43 to 4989) 9.43 (0.43 to 4989)
Varenicline standard plus NRT standard vs.
NRT standard
– 18.52 (0.49 to 10,312) 18.52 (0.49 to 10,312)
Varenicline standard plus bupropion standard vs.
NRT standard
– 1.45 (0.02 to 950) 1.45 (0.02 to 950)
Varenicline standard vs. bupropion standard – 1.43 (1.02 to 2.09) 1.43 (1.02 to 2.09)
Varenicline standard plus NRT standard vs.
bupropion standard
– 2.58 (0.49 to 16.6) 2.58 (0.49 to 16.6)
Varenicline standard plus bupropion standard vs.
bupropion standard
– 0.22 (0.01 to 1.73) 0.22 (0.01 to 1.73)
Varenicline standard plus NRT standard vs.
varenicline standard
1.80 (0.35 to 11.2) – 1.80 (0.35 to 11.2)
Varenicline standard plus bupropion standard vs.
varenicline standard
0.22 (0.00 to 5.43) 0.12 (0.00 to 3.20) 0.15 (0.01 to 1.16)
Varenicline standard plus bupropion standard vs.
varenicline standard plus NRT standard
– 0.08 (0.00 to 1.19) 0.08 (0.00 to 1.19)
This table is reproduced with permission from Thomas et al.67 This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and
build upon this work, for commercial use, provided the original work is properly cited. See: https://creativecommons.org/
licenses/by/4.0/. The table includes minor additions and formatting changes to the original table.
TABLE 12 Non-randomised studies reporting major adverse neuropsychiatric events
Study (first author and year) Treatment Arm size
Number
of events
Cunningham 2016608 Varenicline not specified 11,774 6
Cunningham 2016608 NRT patch (24 hours) not specified 23,548 12
Dhelaria 2012612 Varenicline not specified 171 2
Dhelaria 2012612 NRT not specified 200 0
Ferketich 2013615 NRT combination high 110 0
Ferketich 2013615 Varenicline standard 118 1
Kotz 2017629 NRT not specified 10,426 722
Kotz 2017629 Bupropion not specified 350 18
Kotz 2017629 Varenicline not specified 3574 176
Jiménez-Ruiz 2017624 NRT combination high 215 0
Jiménez-Ruiz 2017624 Varenicline standard 134 1
Hodgkin 2013619 NRT choice not specified 236 0
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OR (95% CrI)
We fitted a fixed-class random-effects NMA model combining randomised and non-randomised
evidence for this outcome, which led to the inclusion of 89 studies in total. The results displayed
in Figure 26 suggest that bupropion standard (OR 0.68, 95% CrI 0.50 to 0.91), bupropion standard
plus NRT high (OR 0.23, 95% CrI 0.04 to 0.93) and varenicline standard plus bupropion standard
(OR 0.36, 95% CrI 0.15 to 0.89) are associated with lower odds of events than placebo. Some of the
effect estimates were imprecisely estimated (e.g. e-cigarette high vs. placebo), and there was also
one extreme result for varenicline not specified plus NRT not specified, stemming from a single small
study in which 2 out of 16 smokers treated with this combination reported an event (see Table 12).
TABLE 12 Non-randomised studies reporting major adverse neuropsychiatric events (continued )
Study (first author and year) Treatment Arm size
Number
of events
Hodgkin 2013619 Bupropion not specified plus NRT choice not specified 162 3
Hodgkin 2013619 Varenicline not specified plus NRT choice not specified 16 2
Jiménez Ruiz 2012623 NRT choice not specified 233 5
Jiménez Ruiz 2012623 Bupropion standard plus NRT choice not specified 45 1
Jiménez Ruiz 2012623 Varenicline standard plus NRT choice not specified 190 6
Kaduri 2015625 Varenicline not specified 98 10
Kaduri 2015625 NRT choice not specified 98 8
Kotz 201557 NRT not specified 106,759 8814
Kotz 201557 Bupropion not specified 6557 377
Kotz 201557 Varenicline not specified 51,450 2514
Thomas 201353 NRT not specified 81,545 874
Thomas 201353 Bupropion not specified 6741 44
Thomas 201353 Varenicline not specified 31,260 276
Gunnell 200954 NRT choice not specified 63,265 1824
Gunnell 200954 Bupropion not specified 6422 162
Gunnell 200954 Varenicline not specified 10,973 297
Garcia-Portilla 2016616 NRT patch (24 hours) not specified 36 0
Garcia-Portilla 2016616 Varenicline standard 39 1
Koçak 2015627 Varenicline not specified 206 4
Koçak 2015627 Bupropion not specified 137 2
Koçak 2015627 NRT patch (24 hours) not specified 112 0
Stapleton 2008646 NRT choice not specified 204 2
Stapleton 2008646 Varenicline not specified 208 10
Pasternak 2013638 Varenicline not specified 59,790 4
Pasternak 2013638 Bupropion not specified 17,936 1
Shiltz 2012645 Bupropion standard plus NRT patch (24 hours) standard 121 18
Shiltz 2012645 Varenicline standard plus bupropion standard 204 12
Shiltz 2012645 Varenicline standard 164 19
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Varenicline std Varenicline low
Varenicline ns
Varenicline + bupropion std
Bupropion std + NRT high
Bupropion std + NRT std
Bupropion std + NRT ns
Bupropion ns + NRT ns
E-cigarette high
Varenicline std + NRT high
Varenicline std + NRT std
Varenicline std + NRT ns










FIGURE 25 Network plot for major adverse neuropsychiatric events (combining randomised and non-randomised
evidence) at class level. Ns, not specified; std, standard.
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FIGURE 26 Forest plot of NMA results for major adverse neuropsychiatric events (combining randomised and
non-randomised evidence). Ns, not specified; std, standard.
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Ranking of interventions
Table 13 presents ranks for a selection of classes according to the primary safety outcome, SAEs.
Placebo yielded the largest probability of being ranked as the best intervention for reducing the odds
of SAEs (0.33) and also showed the lowest mean rank (1.97). Varenicline standard plus NRT standard
showed the next largest probability to be ranked best (0.31), but the mean rank for this intervention
(4.41) suggests substantial uncertainty about its ranking. On the other hand, the highest mean ranks
were obtained by e-cigarette low (6.97), varenicline standard plus bupropion standard (5.94), and
e-cigarette high (5.73), suggesting that these interventions were least likely to be ranked highly for
reducing the occurrence of SAEs.
Figure 27 is a rank-o-gram displaying the ranking of eight selected intervention classes across the three
safety outcomes examined in our NMA models. Placebo was most likely to be ranked best or second
best out of eight interventions for SAEs, with lower rankings for MACEs (4/7) and MANEs (5/7). NRT
standard was also most likely to be ranked among the best two interventions to reduce the odds of
SAEs, with uncertain rankings for the other adverse outcomes. However, these findings may not be
robust because of the uncertainty associated with SAE estimates. The rankings for MACEs suggest
that bupropion standard plus NRT standard, and varenicline standard plus bupropion standard might
be the safest interventions, although we note that these rankings are based on rather imprecise effect
estimates (see Figure 20). The latter statement also applies to MANEs (see Figure 24).
Tertiary and other outcomes
We now present the results for tertiary and other outcomes. The results of NMAs for nausea,
headache, dry mouth and skin rash are presented using RCTs identified in the original search. Tables
for all other AEs of interest are presented in Report Supplementary Material 8 for events reported in
RCTs and in Report Supplementary Material 9 for events reported in non-randomised studies.
Nausea
The data set for nausea comprised 168 studies, with a total of 398 arms and 72,875 patients.
Appendix 8, Figure 92, shows the structure of this network at the treatment level. The graph shows a
large number of interventions that were mostly connected and had placebo as the main comparator.
One study comparing varenicline standard plus NRT gum standard (17/245 patients with event)
with varenicline low plus NRT gum standard (13/240 patients with event) was disconnected from
the network and, therefore, was excluded from the analyses. Furthermore, to avoid convergence
problems, we excluded one study comparing bupropion low (9/169 patients with event) with no
TABLE 13 Mean ranking of interventions for SAEs
Intervention Pr(best) Mean rank
Placebo 0.33 1.97
NRT standard 0.17 3.4
Bupropion standard 0 4.5
Varenicline standard 0.06 3.08
E-cigarette low 0.07 6.97
E-cigarette high 0.04 5.73
Varenicline standard plus NRT standard 0.31 4.41
Varenicline standard plus bupropion standard 0.03 5.94
Pr, probability.
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treatment (0/36 patients with event) and another study comparing e-cigarette high plus NRT patch
(24 hours) not specified (2/20 patients with event) with NRT not specified (0/20 patients with event).
Last, to avoid computational problems, we excluded the varenicline standard arm (24 events in
16 patients) from a three-arm trial that also examined no treatment (0 events in 16 patients)
and NRT combined not specified (11 events in 16 patients).
The NMA results are presented in Appendix 8, Figure 93 (standard NMA results are presented in Appendix 8,
Figure 94). There was evidence that patients randomised to no treatment were less likely to report nausea
than those receiving placebo (OR 0.18, 95% CrI 0.08 to 0.39). Conversely, those allocated to bupropion
standard (OR 1.62, 95% CrI 1.30 to 2.05), varenicline standard (OR 3.86, 95% CrI 3.25 to 4.62), varenicline
high (OR 19.11, 95% CrI 5.75 to 64.07), varenicline standard plus NRT standard (OR 5.21, 95% CrI 2.32 to
11.7), varenicline plus bupropion standard (OR 2.92, 95% CrI 1.49 to 5.64), and NRT high (OR 1.82, 95% CrI
1.01 to 3.46) were more likely to report nausea than those in the placebo group. There was weak evidence
for those allocated to varenicline low (OR 1.43, 95% CrI 0.95 to 2.18), bupropion standard plus NRT high
(OR 1.95, 95% CrI 0.95 to 4.01), varenicline standard plus NRT high (OR 2.01, 95% CrI 0.91 to 4.44), NRT
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FIGURE 27 Rank-o-gram of interventions across safety outcomes. Std, standard. This figure has been adapted with
permission from Thomas et al.67 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: https://creativecommons.org/licenses/by/4.0/.
The figure includes minor additions and formatting changes to the original figure.
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Headache
The data set for headache comprised 152 studies, with a total of 356 arms and 67,956 patients.
Appendix 8, Figure 95 presents the structure of the network for headache. Two studies were
disconnected from the network and, therefore, were excluded from the analyses: one study comparing
varenicline standard plus NRT gum standard (5/245 patients with event) with varenicline low plus NRT
gum standard (2/240 patients with event), and another study comparing bupropion standard plus NRT
Inhalator not specified (34/267 patients with event) with usual care (13/271 patients with event).
Furthermore, we excluded three studies owing to small numbers causing convergence problems: one
study comparing e-cigarette high plus NRT patch (24 hours) not specified (1/20 patients with event)
with NRT not specified (0/20 patients with event), one study comparing NRT inhalator standard (1/145
patients with event) with placebo (0/141 patients with event), and another study comparing NRT patch
(24 hours) standard (1/40 patients with event) with placebo (0/40 patients with event).
The NMA results for this outcome are presented in Appendix 8, Figure 96 (standard NMA results are
presented in Appendix 8, Figure 97). There was evidence that patients randomised to no treatment
reported headache less frequently than those receiving placebo (OR 0.26, 95% CrI 0.13 to 0.48),
Furthermore, there was inconclusive evidence of any differences between patients randomised to any
of the experimental drugs and those in the placebo group.
Dry mouth
The data set for dry mouth comprised 88 studies, with a total of 216 arms and 40,721 patients.
Appendix 8, Figure 98 shows the structure of this network, which is smaller than the ones presented
before for other tertiary outcomes. One study comparing bupropion standard plus NRT inhalator not
specified (14/267 patients with event) with usual care (0/272 patients with event) was disconnected
from the main network and, therefore, was excluded from the analyses. Moreover, to avoid convergence
problems, we also excluded one study comparing e-cigarette low (8/306 patients with event) with
no treatment (0/102 patients with event). Last, to avoid computational problems we excluded the
varenicline standard arm (36 events in 16 patients) from a three-arm trial that also examined no
treatment (0 events in 16 patients) and NRT combined not specified (5 events in 16 patients).
The NMA results for dry mouth are displayed in Appendix 8, Figure 99 (standard NMA results are
presented in Appendix 8, Figure 100). We found strong evidence that smokers allocated to the no
treatment group (OR 0.05, 95% CrI 0.00 to 0.36) and weak evidence that those allocated to waitlist
(OR 0.23, 95% CrI 0.03 to 1.12) were less likely to report dry mouth problems than those receiving
placebo. Conversely, there was evidence that smokers randomised to bupropion standard (OR 1.92,
95% CrI 1.58 to 2.34), bupropion standard plus NRT high (OR 1.99, 95% CrI 1.20 to 3.42), and
varenicline plus bupropion standard (OR 2.44, 95% CrI 1.28 to 4.66) were more prone to dry mouth
than those receiving placebo. There was weak evidence that smokers randomised to bupropion low
were more likely to experience dry mouth than those randomised to placebo (OR 1.65, 95% CrI
0.90 to 3.03).
Skin rash
The data set for skin rash comprised 43 studies, with a total of 103 arms and 16,147 patients. Appendix 8,
Figure 101 shows that this outcome was reported less often than the previous outcomes. To avoid
convergence problems, we excluded one study comparing NRT gum high (2/54 patients with event) with
NRT gum standard (0/162 patients with event) and another study comparing e-cigarette low (6/306 patients
with event) with no treatment (0/102 patients with event).
The NMA results for this outcome are presented in Appendix 8, Figure 102 (standard NMA results are
presented in Appendix 8, Figure 103). We found evidence that patients receiving no drug treatment
were less likely to suffer from skin rash than those allocated to placebo (OR 0.03, 95% CrI 0.00 to 0.65).
Conversely, patients randomised to bupropion standard were more likely to report skin rash problems
than those in the placebo group (OR 2.23, 95% CrI 1.06 to 4.76).
DOI: 10.3310/hta25590 Health Technology Assessment 2021 Vol. 25 No. 59
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Thomas et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
63

Chapter 7 Results: cost-effectiveness
T able 14 shows the primary results of the probabilistic analysis. The expected (average) totaldiscounted costs and QALYs for all interventions are reported, which represent the estimated
average costs and benefits (allowing for length and quality of life) per smoker, having accounted for
uncertainty in the inputs to the economic model. This analysis includes disutilities and costs related
to depression and self-harm. Interventions are ordered by increasing expected total cost, with NRT
low having the lowest expected total cost and varenicline standard plus NRT standard having the
highest expected total cost. E-cigarette low has the highest expected QALYs, followed by varenicline
standard plus bupropion standard, and varenicline standard plus NRT standard. NRT low has the lowest
expected QALYs.
We prefer interventions with lower costs and higher QALYs. Any intervention that has a higher expected
cost and lower expected QALYs than another intervention is said to be dominated. As can be seen in
Table 14, all treatments apart from NRT low are dominated by e-cigarette low, which is more effective,
in terms of increased utility, and less expensive than the other interventions. If the funder is not willing
to pay £56 per QALY, then NRT low is estimated to be most cost-effective. If the funder is willing to pay
≥ £56 per QALY, then e-cigarette low is estimated to be most cost-effective.
If the payer is willing to pay up to £20,000 per QALY, e-cigarette low has the highest expected net
benefit (£7085), followed by varenicline standard plus bupropion standard (£6756), and varenicline
standard plus NRT standard (£6591).
We present the uncertainty surrounding the cost-effectiveness of the various interventions using a
CEAC (Figure 28), which plots the probability that each intervention is the most cost-effective at a given
willingness-to-pay threshold. Only interventions with a probability of being the optimal treatment of
> 10% at any willingness-to-pay value are plotted.
TABLE 14 Expected total costs, expected total utilities, ICERs and expected net benefit at a £20,000 willingness-to-pay
threshold
Treatment Total costs (£) Total QALYs ICER (£) ENB (£)
NRT low 10,259 10.934 0
E-cigarette low 10,279 11.290 56 7085
Bupropion low 10,283 11.038 Dominated 2056
NRT standard 10,292 11.119 Dominated 3663
Bupropion standard 10,304 11.033 Dominated 1937
NRT high 10,309 11.092 Dominated 3092
E-cigarette high 10,319 11.189 Dominated 5036
Bupropion standard plus NRT high 10,346 11.128 Dominated 3786
Varenicline standard 10,413 11.127 Dominated 3697
Varenicline standard plus bupropion standard 10,437 11.281 Dominated 6756
Varenicline low 10,440 10.959 Dominated 308
Varenicline standard plus NRT high 10,467 11.117 Dominated 3440
Varenicline low plus NRT standard 10,587 11.273 Dominated 6454
Varenicline standard plus NRT standard 10,587 11.280 Dominated 6591
ENB, expected net benefit.
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Figure 28 shows that, at any willingness-to-pay value, e-cigarette low has the highest probability of
being cost-effective, followed by varenicline low plus NRT standard. At any threshold above £20,000,
the probability of e-cigarette low being the most cost-effective intervention is never > 30%, indicating
a high degree of uncertainty about the optimal intervention.
The rank-o-grams presented in Figure 29 further demonstrate the uncertainty in the results. The lines
are relatively flat for most interventions, showing that there is no strong probability that they will be
the most or least cost-effective at a willingness-to-pay threshold of £20,000 per QALY. The exception is
NRT low, which shows a clear probability that it is among the least cost-effective interventions if the
payer is willing to pay £20,000 per QALY. There is a similar trend for bupropion low, bupropion standard
and varenicline low, which have higher probabilities of being among the worst interventions than being
among the best. The reverse trend is seen for e-cigarette low, e-cigarette high, varenicline low plus NRT
standard, varenicline standard plus NRT standard and varenicline plus bupropion standard.
Value-of-information analysis
Table 15 shows the results of the value-of-information analyses for the base-case model at a willingness
to-pay per QALY threshold of £20,000. EVPI estimates the most the funder would be prepared to pay
to eliminate uncertainty in the model input parameters. EVPI is helpful for understanding whether
or not future research may potentially be of value. The per-quitter EVPI is £3645 and the population
EVPI, representing all of the smokers attempting to quit in England, is £999M over a 1-year time
horizon and £4994M over a 5-year time horizon. These values are substantial and suggest that future
research studies to reduce parameter uncertainty in the model would be valuable, as the decision is
clearly sensitive to uncertainty in the model inputs.
Expected value of partial perfect information (EVPPI) estimates the most that the funder would be
prepared to pay to eliminate uncertainty in a specific subset of model input parameters. Comparing
EVPPI for different parameters allows us to identify the subsets of model inputs to which the decision
is most sensitive. This can indicate where future research efforts may be invested most effectively.
There is a high value per smoker in reducing uncertainty in all of the abstinence probabilities (£3053)
but less of a value in reducing uncertainty in all of the AEs probabilities (£1654). EVPPI is marginally
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FIGURE 28 Cost-effectiveness acceptability curve. Probability that treatment is optimal plotted against different
willingness-to-pay per unit increase in utility (ceiling ratio). Based on 5000 Monte Carlo simulations. Std, standard.
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We explored the potential value of a new trial comparing the two interventions with the highest
expected net benefit, e-cigarette low and varenicline standard plus bupropion standard, which
would provide information on the effectiveness of the interventions, costs and utilities. This gives
a per-quitter EVPPI of £2342 and a population EVPPI of £642M over a 1-year time horizon and
£3869M over a 5-year time horizon. Restricting to the collection of intervention effects only would
reduce this value marginally to £1676, suggesting that a large trial, conducted well and adequately
powered, may be a cost-effective area of future research, but that it may be most important to collect
information on probabilities of abstinence and AEs. In particular, a trial comparing e-cigarettes with
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FIGURE 29 Rank-o-grams showing the probability that each intervention is ranked first, second, etc. based on net
benefit at a willingness-to-pay threshold of £20,000 per QALY. Std, standard.
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Sensitivity analysis with results based on abstinence alone
Table 16 shows the primary results of the sensitivity analysis when the impact of depression and
self-harm is removed from the model. In this case, bupropion low has the lowest expected total cost.
Varenicline standard plus NRT standard, again, has the highest expected total cost. Varenicline
standard plus NRT standard has the highest expected QALYs, followed by varenicline low plus NRT
standard. NRT low has the lowest expected QALYs.
TABLE 15 Expected value of perfect information and EVPPI for various subsets of model parameters, at a £20,000
willingness-to-pay value per QALY
Model parameter subsets
EVPPI per smoker







All (EVPI) 3645 998.8 4994.0
All costs 1216 333.3 1666.7
All utilities 947 259.4 1297.1
All costs and utilities 1415 387.9 1939.2
All abstinence probabilities 3053 836.7 4182.4
All depression and self-harm probabilities 1654 453.1 2265.7
E-cigarette low vs. varenicline standard plus NRT
standard (probabilities, costs and utilities)
2342 641.8 3209.0
E-cigarette low vs. varenicline standard plus NRT
standard (probabilities only)
1676 459.3 2296.7
TABLE 16 Expected total costs, expected total utilities, ICERs and expected net benefit at a £20,000 willingness-to-pay
threshold, based on abstinence alone
Treatment Total costs (£) Total QALYs ICER (£) ENB (£)
Bupropion low 10,219 11.135 3159
NRT low 10,231 10.977 Dominated 0
NRT high 10,238 11.198 Extendedly dominated 4400
Bupropion standard 10,240 11.130 Dominated 3041
E-cigarette high 10,248 11.295 Extendedly dominated 6335
E-cigarette low 10,250 11.332 159 7072
NRT standard 10,264 11.162 Dominated 3657
Bupropion standard plus NRT high 10,319 11.168 Dominated 3721
Varenicline low 10,320 11.138 Dominated 3120
Varenicline standard 10,327 11.254 Dominated 5434
Varenicline standard plus NRT high 10,402 11.214 Dominated 4556
Varenicline plus bupropion standard 10,415 11.314 Dominated 6558
Varenicline low plus NRT standard 10,446 11.476 Extendedly dominated 9759
Varenicline standard plus NRT standard 10,447 11.483 1302 9895
ENB, expected net benefit.
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An intervention is said to be ‘extendedly dominated’ if a mix of two interventions can provide the same
QALYs at a lower cost. As can be seen in Table 16, all treatments apart from NRT high, e-cigarette
high, e-cigarette low, varenicline low plus NRT standard and varenicline standard plus NRT standard
are dominated by bupropion low, which is more effective, in terms of increased utility, and less
expensive than the other interventions.
The interventions on the efficiency frontier (i.e. those that are not dominated or extendedly dominated)
are NRT low, e-cigarette low and varenicline standard plus NRT standard. If the payer is not willing to
pay £159 per QALY, then bupropion low is estimated to be most cost-effective. If the payer is willing to
pay between £159 and £1302 per QALY, then e-cigarette low is estimated to be most cost-effective,
and if the willingness to pay per QALY is above £1302, then varenicline standard plus NRT standard is
estimated to be most cost-effective.
At a willingness-to-pay threshold of £20,000, varenicline standard plus NRT standard has the highest
expected net benefit (£9895), followed by varenicline low plus NRT standard (£9759).
We present the uncertainty surrounding the cost-effectiveness of the various interventions, using a
CEAC (Figure 30). Only those interventions with a probability of being the optimal treatment of more
than 10% at any willingness-to-pay value are plotted. Figure 30 shows that, at any willingness-to-pay
value, varenicline low plus NRT standard has the highest probability of being cost-effective, followed
by varenicline standard plus NRT standard. At any threshold above £20,000, the probability of any
intervention being the most cost-effective intervention is never > 40%, again, indicating a degree
of uncertainty in the optimal intervention.
The rank-o-grams are presented in Figure 31.
Sensitivity analysis with only UK-licensed interventions included
Table 17 shows the primary results of the sensitivity analysis including only interventions that are
licensed in the UK (NRT low, standard and high, bupropion low and standard, and varenicline low and
standard). In this case, NRT low has the lowest expected total cost and varenicline low has the highest
expected total cost. Varenicline standard has the highest expected QALYs, followed by NRT standard.
NRT low has the lowest expected QALYs.
E-cigarette low
E-cigarette high
Varenicline low + NRT std
Varenicline std + NRT std






































0 5000 10,000 15,000 20,000
Maximum willingness-to-pay threshold for an additional QALY (£)
25,000 30,000 35,000 40,000
FIGURE 30 Cost-effectiveness acceptability curve. Probability that treatment is optimal plotted against different
willingness-to-pay per unit increase in utility (ceiling ratio). Based on 5000 Monte Carlo simulations. Sensitivity analysis
based on abstinence alone. Std, standard.
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FIGURE 31 Rank-o-grams showing the probability that each intervention is ranked first, second, etc. based on net benefit
at a willingness-to-pay threshold of £20,000 per QALY. Sensitivity analysis based on abstinence alone. Std, standard.
TABLE 17 Expected total costs, expected total utilities, ICERs and expected net benefit at a £20,000 willingness-to-pay
threshold, based on licensed interventions only
Treatment Total costs (£) Total QALYs ICER (£) ENB (£)
NRT low 10,259 10.934 0
Bupropion low 10,283 11.038 Extendedly dominated 2056
NRT standard 10,292 11.119 32 3663
Bupropion standard 10,304 11.033 Dominated 1937
NRT high 10,309 11.092 Dominated 3092
Varenicline standard 10,413 11.127 15,665 3697
Varenicline low 10,440 10.959 Dominated 308
ENB, expected net benefit.
RESULTS: COST-EFFECTIVENESS
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As can be seen in Table 17, all treatments apart from NRT low, bupropion low and NRT standard are
dominated by varenicline standard, which is more effective, in terms of increased utility, and less
expensive than the other interventions. Bupropion low is extendedly dominated by NRT standard.
The interventions on the efficiency frontier are NRT low, NRT standard and varenicline standard.
If the payer is not willing to pay £32 per QALY, then NRT low is estimated to be most cost-effective.
At a willingness to pay per QALY above £32, but below £15,665, NRT standard is estimated to be most
cost-effective. At a willingness to pay per QALY above £15,665, varenicline standard is estimated to be
most cost-effective.
At a willingness-to-pay threshold of £20,000, varenicline standard has the highest expected net benefit
(£3697), followed by NRT standard (£3663).
We present the uncertainty surrounding the cost-effectiveness of the various interventions using
a CEAC (Figure 32). Only those interventions with a probability of being the optimal treatment of more
than 10% at any willingness-to-pay value are plotted. Figure 32 shows that, at any willingness-to-pay
value above £5000, NRT standard has the highest probability of being cost-effective, followed by
varenicline standard.
The rank-o-grams are presented in Figure 33. These show that, at a willingness-to-pay value of £20,000,
NRT standard and varenicline standard have the highest probabilities of being the most cost-effective
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FIGURE 32 Probability treatment is optimal plotted against different willingness-to-pay per unit increase in utility
(ceiling ratio). Based on 5000 Monte Carlo simulations. Sensitivity analysis based on licensed interventions. Std, standard.
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FIGURE 33 Rank-o-grams showing the probability that each intervention is ranked first, second, etc. based on net benefit at
a willingness-to-pay threshold of £20,000 per QALY. Sensitivity analysis based on licensed interventions only. Std, standard.
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Chapter 8 Discussion and conclusions
Key findings
The main findings for the clinical effectiveness, safety and cost-effectiveness analyses are summarised
in the following sections.
Key findings of the effectiveness network meta-analysis
We performed a systematic review and NMA to investigate the effectiveness of UK-licensed smoking
cessation medicines and e-cigarettes for smoking cessation. We included 363 trials that reported on
one or more effectiveness outcomes, involving 201,045 participants, that took place internationally
across a range of settings. We found that only 13% of trials were rated as being at low risk of bias,
with 40% rated as being at high risk of bias.
We found evidence that most monotherapies and combination treatments were more effective than
placebo at helping participants achieve sustained abstinence. The three most effective treatments
compared with placebo were varenicline standard plus NRT standard (OR 5.75, 95% CrI 2.27 to 14.88),
varenicline low plus NRT standard (OR 5.70, 95% CrI 1.57 to 21.12) and e-cigarette low (OR 3.22,
95% CrI 0.97 to 12.55). Smokers randomised to varenicline standard plus NRT standard were more likely
to achieve sustained abstinence than participants receiving NRT standard or bupropion standard. We also
found that varenicline standard resulted in higher odds of sustained abstinence than NRT standard or
bupropion standard, and weak evidence that e-cigarette high may increase the odds compared with
bupropion standard. As combination therapies are currently not licensed in the UK, when limiting our
findings to interventions that are licensed in the UK (NRT low, standard and high, bupropion low and
standard, and varenicline low and standard), varenicline standard (OR 2.83, 95% CrI 2.34 to 3.39), NRT
high (OR 2.32, 95% CrI 1.88 to 2.86), and NRT standard (OR 2.01, 95% CrI 1.68 to 2.41) were the three
most effective treatments compared with placebo at helping participants achieve sustained abstinence.
The results of our threshold analyses confirmed that varenicline standard plus NRT standard’s
first-place ranking (offering the highest estimated odds of sustained abstinence) was relatively robust.
However, uncertainty or potential biases in a small number of studies could lead to one of varenicline
standard plus bupropion standard, e-cigarette low, or e-cigarette high being ranked first. Finally,
we found evidence of effect modification, whereby interventions delivered with counselling were
associated with a higher proportion of smokers achieving sustained abstinence than those same
interventions delivered without counselling, and we also found a higher OR of sustained abstinence
among participants who had higher average dependence scores.
The results for the secondary effectiveness outcomes were largely similar to those for sustained
abstinence. Although reported in fewer studies and for fewer interventions, we found evidence that
smokers treated with NRT high, bupropion standard, varenicline standard and varenicline standard
plus bupropion standard were more likely to achieve prolonged abstinence than those using placebo.
Bioverified prolonged abstinence data at ≥ 6 months for e-cigarette or varenicline standard plus NRT
standard were not available. When considering pairwise comparisons between interventions, there
was inconclusive evidence that bupropion standard, varenicline standard and varenicline standard
plus bupropion standard differed from each other in the odds of resulting in prolonged abstinence.
For our ‘any abstinence’ outcome, as for sustained abstinence, we found that most interventions were
more effective than placebo at helping participants abstain from smoking, including e-cigarette at low
and high doses. The three most effective treatments compared with placebo were bupropion low plus
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NRT high, varenicline standard plus NRT standard and varenicline not specified. For ‘any abstinence’, our
NMA indicated that smokers randomised to varenicline standard were more likely to achieve abstinence
than those allocated to NRT standard or bupropion standard. We also found that varenicline standard plus
NRT standard led to higher odds of abstinence than NRT standard, bupropion standard, and bupropion
standard plus NRT standard, while varenicline standard plus bupropion standard led to higher odds of
abstinence than bupropion standard alone.
Finally, there was evidence that a number of interventions were more effective than placebo at
attaining 7-day PPA, including e-cigarette high. The three most effective treatments compared with
placebo, were bupropion low plus NRT high, varenicline standard plus NRT standard and varenicline
not specified. In terms of 7-day PPA, our NMA indicated that smokers allocated to varenicline standard
achieved abstinence more often than those using NRT standard or bupropion standard. We also found
that varenicline standard plus NRT standard led to higher odds of abstinence than NRT standard,
bupropion standard or varenicline standard.
Ranking the interventions based on smokers attaining sustained abstinence, varenicline standard plus NRT
standard had the highest probability of being ranked first, followed by e-cigarette low, varenicline standard
plus bupropion standard, and e-cigarette high, with placebo in last place. Based on our rank-o-grams,
ranking the interventions across primary and secondary effectiveness outcomes, varenicline standard plus
NRT standard showed a high probability of being ranked as the best or second-best intervention for all
outcomes, with the exception of prolonged abstinence, for which there were no data. Varenicline standard
plus bupropion standard had the highest probability of being ranked as best for prolonged abstinence,
but its rankings for other outcomes were less certain. Finally, varenicline standard showed high
probabilities of being ranked second- to fourth-best across outcomes, while e-cigarette rankings were
uncertain, and placebo was consistently ranked last.
Comparison with other studies
Our findings are largely comparable to those of previous NMAs.25,123 We found evidence that nearly
all identified doses of smoking cessation medicines increased the probability of sustained abstinence
compared with placebo. An exception to this is bupropion plus NRT; a health technology assessment
(HTA) report of smoking cessation interventions by the HIQA123 found evidence that this treatment
improved the likelihood of cessation (from the quit date or PPA) compared with placebo (control),
whereas we saw this result for the ‘any abstinence’ and 7-day PPA outcomes only. Similar to our
findings, previous NMAs also found evidence that varenicline increased the chance of cessation
compared with bupropion and with NRT, while not finding evidence of a difference in likelihood of
quitting between bupropion and NRT.25,123 Findings were also consistent for varenicline plus NRT,
which showed improved probability of quitting compared with bupropion and with NRT. However,
although the HIQA HTA found evidence that varenicline plus bupropion was more effective than
bupropion or NRT delivered as monotherapies, we did not.123 Nonetheless, the results of the ranking of
treatments for smoking cessation were similar across NMAs.25,123
Key findings of the safety network meta-analysis
A systematic review and NMA were performed to investigate the safety of UK-licensed smoking
cessation medicines and electronic cigarettes. We included 355 trials that reported on one or more
safety outcomes involving 159,101 participants, and 53 observational studies involving 8,783,403
participants that took place internationally across a range of settings. We found that only 16% of trials
were rated as being at low risk of bias, while one-third (33%) were rated as being at high risk of bias.
All observational studies were rated as being at high risk of bias owing to their non-randomised nature.
There was evidence that, compared with placebo, bupropion standard increased the odds of experiencing
SAEs (OR 1.27, 95% CrI 1.04 to 1.58). The results of our threshold analyses indicated that the first- and
last-place rankings were very sensitive to the level of uncertainty and risk of bias in the evidence. Unlike
our effectiveness analyses, we found inconclusive evidence of effect modification on the likelihood of
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experiencing a SAE. Placebo yielded the largest probability of being ranked the best intervention for
reducing the odds of experiencing a SAE; however, the first-place ranking could change to NRT standard,
varenicline standard plus NRT standard, e-cigarette high, e-cigarette low, or varenicline plus bupropion
standard simply owing to sampling error. NRT standard was also the most likely to be ranked among the
best two interventions for reducing the odds of SAEs. The last-place ranking is held by e-cigarette low,
but this is very sensitive to the high level of uncertainty in the single study by Cravo et al.525 Changes
to the estimate could result in e-cigarette low being replaced by varenicline standard plus bupropion
standard in last place or see e-cigarette low replace placebo in first place, both of which are plausible
owing to sampling error. Therefore, the first- and last-place rankings for SAEs are not very robust, as
they are sensitive to levels of uncertainty in the data and plausible biases in at-risk studies that could
alter the rankings. Although only one observational study632 reported one or more SAE, incorporating
this study into our analyses resulted in the effect estimates changing substantially, suggesting that
varencline standard and e-cigarette low might lead to lower odds of experiencing a SAE than placebo.
This may be a result of the observational study adding a substantial number of events to a network of
what was otherwise a rare outcome.
Regarding secondary outcomes, we could not find any differences between interventions for MACEs
owing to the rarity of events reported across studies, resulting in effect estimates with very wide CIs.
This did not change with the addition of 10 observational studies to our analyses; there is substantial
uncertainty regarding the relative cardiovascular safety of the treatments. For MANEs, there was
evidence that smokers receiving NRT not specified, bupropion standard, bupropion standard plus
NRT high or varenicline standard plus bupropion standard were less likely to report MANEs than
smokers treated with placebo. In pairwise comparisons between interventions, there was evidence
of increased odds of MANEs among smokers randomised to varenicline standard compared with
those using bupropion standard. Although 16 observational studies reported one or more MANEs,
our analyses incorporating these studies produced similar results to that of the randomised evidence.
We found that bupropion standard, bupropion standard plus NRT high and varenicline standard plus
bupropion standard were associated with lower odds of experiencing a MANE than placebo. Whereas
placebo and varenicline standard plus NRT standard yielded the largest probabilities of being ranked
the best interventions to reduce the odds of SAEs, e-cigarette low, varenicline standard plus bupropion
standard and e-cigarette high were the least likely to be ranked highly. Based on our rank-o-grams,
ranking the interventions across primary and secondary safety outcomes, placebo and NRT standard
were most likely to be ranked among the best interventions for reducing the odds of experiencing
SAEs, but were ranked lower for MACEs and MANEs. Bupropion standard plus NRT standard, and
varenicline standard plus bupropion standard may be the safest interventions in terms of MACEs
and MANEs, but these rankings were based on imprecise effect estimates.
We conducted random-effects NMAs at the class level for a number of our tertiary and other safety
outcomes based on data from studies identified from our initial searches ending in March 2017.
Compared with smokers randomised to placebo, we found evidence of increased odds of experiencing
nausea among smokers allocated to bupropion standard, varenicline standard, varenicline high,
varenicline standard plus NRT standard, varencline standard plus bupropion standard, NRT not
specified, NRT high and bupropion standard plus NRT not specified. However, we did not find any
evidence of a difference between interventions in the odds of experiencing headache. We found
evidence of increased odds of experiencing dry mouth among smokers using bupropion standard,
bupropion standard plus NRT high, varenicline standard plus bupropion standard and bupropion
standard plus NRT not specified compared with those allocated to placebo. Finally, we found that
smokers randomised to bupropion standard had higher odds of experiencing skin rash than smokers
allocated to placebo.
Comparison with other studies
The finding of our NMA of MACEs mirrors that of Mills et al.,39 as we also did not find evidence that
any smoking cessation increased the likelihood of experiencing a MACE compared with placebo or with
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each other. As pairwise comparisons between active interventions were almost entirely based on
indirect evidence only, and because MACEs were uncommon, it was very difficult to effectively
compare treatments with each other. Other NMAs25,123 only summarised safety data from previous
reviews and did not analyse them; this study is the first, to our knowledge, to conduct a NMA of
SAE, MANE and other AE data. Although the HIQA HTA123 reported that its two included trials of
e-cigarettes did not report SAEs linked to their use, we included the SAEs reported by Bullen et al.,192
as we included all events whether or not study authors attributed them to the use of the medication.
The authors of Cochrane’s review of electronic cigarettes similarly chose to consider SAEs that were
deemed related to e-cigarette use only, however, the occurrence of other AEs that we have presented
in our NMA in outcome tables were reported in Report Supplementary Materials 8 and 9.72
Key findings of the cost-effectiveness analysis
This analysis has shown that, in the base case, e-cigarette low appears to be the most cost-effective
intervention at any willingness to pay per QALY value above £56. However, these findings are
uncertain, with no intervention having more than a 40% chance of being the most cost-effective
intervention at a willingness to pay per QALY above £5000. When the impact of the safety outcomes
of depression and self-harm are excluded, varenicline standard plus NRT standard and varenicline low
plus NRT standard are the most cost-effective interventions. There is, again, considerable uncertainty
about the optimal intervention. When the analysis is limited to interventions that are licensed in the
UK, varenicline standard is the most cost-effective intervention at any willingness-to-pay value above
£15,665, followed by NRT standard. Value-of-information analyses indicated that a trial comparing
e-cigarettes with an active comparator such as varenicline standard and bupropion standard or NRT
standard is likely to be a cost-effective investment.
Comparison with other studies
No previous cost-effectiveness analysis could be identified that compared a similar range of interventions,
compared the standard licensed interventions with combination therapies and e-cigarettes, or incorporated
safety outcomes. A recent systematic review of cost-effectiveness analyses123 identified four studies98,104,654,655
published in the last 10 years that compared varenicline, bupropion or NRTwith each other or with
standard of care. All but one of these studies655 also used the BENESCO model, but did not adjust to
account for safety outcomes. The studies consistently found varenicline to be the most cost-effective
intervention. A report by Leaviss et al.58 compared the cost-effectiveness of varenicline and cytisine
in a UK setting, also using the BENESCO model. This study found cytisine to be the most cost-effective
intervention; however, cytisine was beyond the scope of this review. Our results show that, although the
varenicline combination treatments dominate the other interventions, among the treatments licenced in
the UK, NRTstandard is the most cost-effective.
One previous study61 was identified that compared the cost-effectiveness of e-cigarettes with that of
NRT in stop smoking services in England. Similar to our study, in which an ICER of £56 was calculated
for e-cigarette low compared with NRT low, this previous study found an ICER of £65 per QALY gained
by using e-cigarettes as a smoking cessation aid, in comparison with NRT. This suggests strong evidence
of the cost-effectiveness of e-cigarettes compared with NRT; however, to our knowledge, our study is
the first to assess the cost-effectiveness of e-cigarettes compared with all other interventions in the UK.
Strengths and limitations
Strengths and limitations of the effectiveness and safety network meta-analyses
Strengths
This is the first NMA of SAEs, MANEs and other AEs associated with smoking cessation medicines,
and the second to analyse MACEs. Whereas a previous NMA suffered from insufficient data for AE
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outcomes,25 our decision to include RCTs of any duration and the inclusion of observational studies
allowed us to utilise as many data as possible to create our networks (although this also brings some
limitations; see Limitations). Most NMAs25,123 failed to include RCTs of less than 6 months’ duration for
AEs, based on their inclusion criteria for analysing effectiveness outcomes. Given that AEs can occur
within a short time after treatment has started, previous reviews would have excluded several of the
studies that we included in our safety analyses. We also benefited from the publication of some large
studies since the start of our study that made important contributions to our analyses, such as the
EAGLES trial,33 and several electronic cigarette studies, including a large trial by Hajek et al.19
Therefore, these decisions allowed us to include and analyse data from more participants in more
studies reporting AEs than any previous NMA of these licensed medicines.25,39,123 A significant strength
of this study is the inclusion of combined therapies of smoking cessation medicines, as most reviews
have only included monotherapies and combination NRT. This proved to be a crucial decision, as our
study has found combined therapies, notably varenicline standard plus NRT standard, to be among
both the most effective and cost-effective treatments for smoking cessation. Although we only found
evidence of effect modification for the inclusion of counselling with smoking cessation treatment, the
size of our study allowed us to investigate the influence of several important covariates as potential
effect modifiers for our primary outcomes. Additionally, this is the first NMA to compare medicines
stratified by dosage. This allowed us to more specifically identify how dose affected a medicine’s
effectiveness and safety across outcomes, revealing differential effects by dose that would otherwise
have been lost. This includes the investigation of data for each licensed form of NRT by dose in our full
interaction models. We also reported effectiveness across multiple specific cessation outcomes rather
than using the approach in past NMAs of authors using the most rigorous definition of abstinence
available. Finally, this study was the first NMA of smoking cessation medicines to use threshold
analysis.91,92 This technique allowed us to visualise thresholds of how much the evidence could change
before our recommendation based on the ranking of our treatments would change, and helps readers
to understand the robustness of our treatment recommendations.
Limitations
Despite the large number of studies we were able to include in our review, there were still limitations
in the data available. Primary and secondary safety outcomes included rare events, which limited the
ability of analyses to draw firm conclusions. Pairwise comparisons between active interventions were
almost exclusively informed by indirect evidence and were affected by the small number of events,
resulting in imprecisely estimated effects and wide intervals, often including the null. Additionally,
there were instances of extreme results based on the findings of a single or very few studies, which
may be particularly problematic when attempting to draw conclusions about the safety of e-cigarettes
(e.g. Cravo et al.525). For the SAE, MACE, and MANE outcomes, we conducted a NMA that incorporated
both RCT and non-randomised evidence, as well as a NMA restricted to RCTs. Although including
non-randomised evidence increases the precision of the estimates, this comes with a risk of introducing
bias in the resulting estimates. Non-randomised evidence is vulnerable to bias by confounding, and
there was no attempt to adjust for this (which would have required the availability of individual
participant data). Identifying methods to combine RCT and non-randomised evidence while adjusting
for bias using individual patient data is an area for further research.
Network meta-analysis (like any pairwise meta-analysis) makes the assumption that the included
studies do not differ in the distribution of factors that might moderate the relative treatment
effects (effect modifiers). This assumption can be assessed statistically by checking for evidence of
heterogeneity (different effects across studies making the same comparison) and by checking for
evidence of inconsistency (different effects from studies providing direct and indirect estimates).
There was a moderate level of heterogeneity in all of our NMAs (as has also been found in previous
meta-analyses and NMAs in this field). We explored a range of covariates to explain the heterogeneity
in meta-regression analyses, and did not find any evidence of effect modification other than using
counselling alongside pharmacological treatments. We made an assumption that the effect of counselling
is additive when given together with a pharmacotherapy, which is a potential limitation of our findings.
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It may be that there is a synergistic (or even antagonistic) effect of counselling when it is used together
with pharmacotherapies. We explored this in a sensitivity analysis and found some evidence to support
a synergistic effect. Future research to explore this potential synergistic effect of smoking cessation
medicines being used together with counselling would be of value. There may be other important effect
modifiers that we have not included, for example changes in practice over time. However, although
absolute cessation rates are expected to change with time, this will be the case for all study arms, and
we found no evidence that year of publication was an effect modifier. We did not find any statistical
evidence of inconsistency for any of the outcomes. An inspection of direct and indirect estimates, where
both can be calculated, shows that in general there is good overlap of the credible intervals for the direct
and indirect estimates, although there are some differences in the point estimates. We conclude that,
for each outcomes, there is evidence of effect modification that manifests as heterogeneity between
estimates from studies on the same comparison, but no systematic differences between direct and
indirect estimates (over and above the heterogeneity seen across the entire network of evidence).
Unlike previous NMAs, we opted to use only bioverified cessation data, as most studies in our review
reported one or more bioverified outcomes. However, it is possible that more data would have been
included in our networks had we adopted the approaches used in previous projects and included
self-reported cessation data. Finally, despite extensive efforts, we were unable to obtain safety data
for industry-funded trials from pharmaceutical companies. Although we hoped to include as many
safety data as possible from these trials, our findings are limited to those events reported in publications.
Finally, we were unable to include and analyse craving and withdrawal data, as these were rarely
reported across included studies and the outcomes were assessed using a variety of measures and scales
that made summarising or analysing these data impossible.
Strengths and limitations of the cost-effectiveness analysis
This analysis has improved on previous analyses of smoking cessation interventions, as it has taken
into account not only effectiveness in terms of abstinence from smoking but also potential AEs of
treatment (depression and self-harm). The effects of the interventions on each of these outcomes
have been informed by NMAs that have shown that, although the combination of varenicline (low
or standard) plus NRT standard gives the highest probability of continuous abstinence at 1 year, this
is slightly offset by the association of this combination with a higher probability of depression and
self-harm than the other interventions. This has led to e-cigarette low being slightly more cost-effective
(the intervention with the highest expected net benefit) than varenicline (low or standard) plus NRT
standard, although these results are very uncertain.
In terms of limitations, no comparative evidence on subsequent quit attempts in these treatments
could be identified in the literature. The model, therefore, assumes that no further attempts to quit
are made and that those who fail to quit remain smokers until death. In reality, people often make
several quit attempts before they are successful and despite a failed attempt a person may have
moved forward towards their future successful attempt. We would expect our qualitative findings
to be robust to this as long as the likelihood of a successful subsequent quit attempt does not
depend on the treatment used for the index quit attempt.
Another data limitation is the assumption that the risk ratios of developing or dying from smoking-
related diseases in current smokers and former smokers compared with non-smokers (incidence and
mortality) are equal to the risk ratios of having smoking-related diseases (prevalence). We considered
this to be a reasonable assumption given that no alternative sources of information on the relative
incidence or mortality from these diseases within the relevant age and sex categories could be identified.
Longitudinal studies measuring these outcomes for the different smoking categories would be useful to
test this assumption.
This distribution of the cohort across sex and age categories at the start of the model was designed to
reflect the distribution of smokers in the UK. One issue is that this is not necessarily the same as the
DISCUSSION AND CONCLUSIONS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
78
distribution of smokers making a quit attempt. Another issue is that data availability meant that this
cohort needed to be grouped into quite broad age categories (18–34, 35–64 and ≥ 65 years) that were
assigned the same prevalence, incidence and probability of mortality from diseases. It is likely, therefore,
that greater variation exists in these categories than is being accounted for. A study measuring patient
characteristics of those seeking treatment to make a quit attempt would be useful to update the model
to better reflect the population of interest.
As e-cigarettes are not medically licensed in the UK, it is difficult to estimate a prescribing cost if they
were to be prescribed on the NHS. The best evidence we could find on this was from the HIQA HTA,123
which costed a 12-week supply of e-cigarettes at €93.80. Current high-street/internet prices may be
considerably lower than this. However, it is unclear whether the NHS would be able to access these
lower prices if e-cigarettes were made available on the NHS. If a lower price could be accessed, this
could only have the impact of increasing the cost-effectiveness of e-cigarettes compared with the
other interventions.
In addition, as no data were available, assumptions had to made about the relative effectiveness of
several interventions for the outcomes of depression and self-harm. It was assumed that (1) NRT low
and e-cigarette low have the same effect as NRT standard, (2) e-cigarette high has the same effect
as NRT high, (3) bupropion low has the same effect as bupropion standard, and (4) varenicline low plus
NRT standard has the same effect as varenicline standard plus NRT standard. The assumption that
NRT and e-cigarettes have the same impact on psychological outcomes is reasonable as the active
ingredient is the same in both (nicotine). Although a higher dose of bupropion or varenicline may
increase the probability of depression or self-harm, no evidence was available to inform this. A study
comparing the impact of different doses of these interventions on psychological outcomes would be
useful to inform the model.
We did not explicitly model treatment discontinuation, although it should be noted that the RCTs
included in the NMA will have included outcomes for patients who did not adhere to treatment, and
the treatment costs are likely to be incurred regardless of discontinuation. A final limitation was a lack
of available data to explore the cost-effectiveness of these interventions in subgroups such as those
with psychiatric illness, heavy smokers or smokers not willing to quit.
Conclusions
Implications for practice
Our findings suggest that combined therapies of smoking cessation medicines are among the most
effective, safe and cost-effective treatment options for smokers. Although combination NRT is commonly
prescribed, combined therapy of NRT delivered alongside varenicline at standard doses (currently
unlicensed) was shown to be the most effective treatment for most cessation outcomes. Using combined
therapies instead of monotherapy treatments may offer smokers a better chance of successfully quitting
smoking over both short and long periods of time. We also found that interventions that included
counselling were more effective at helping smokers to quit and should be considered when planning a
cessation attempt. Although the use of bupropion standard may increase the odds of SAEs compared
with placebo, we did not find strong evidence of any other negative associations between medicines
and SAEs, MACEs or MANEs relative to placebo. Although electronic cigarettes showed promise as
cessation tools, their safety profile remains uncertain and no existing model of the devices has been
licensed as a medicine. This study has used the most up-to-date information to give an estimate of the
most cost-effective intervention for smoking cessation in the UK today. This analysis has shown that,
in the base case, e-cigarette low, varenicline standard plus NRT standard, and varenicline standard
plus bupropion standard appear to be the most cost-effective interventions. When the impact of the
safety outcomes of depression and self-harm is excluded, varenicline standard plus NRT standard and
varenicline low plus NRT standard are the most cost-effective interventions. These results should be
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taken with the caveat of substantial uncertainty, however, with no intervention having a probability of
being the most cost-effective of > 30% at any willingness-to-pay per QALY threshold above £20,000.
Recommendations for research
Based on the findings of this study, we propose several recommendations.
First, given the relatively small number of studies rated as being at low risk of bias overall (including
recent publications), we recommend that study authors ensure complete and accurate reporting of
their study methodology. Most domains were predominantly rated as unclear risk of bias owing to a
lack of detailed description of study procedures. Although some of these ambiguities were resolved
following contact with corresponding authors, details pertinent to assessments of bias should be
reported in the main body or supplemental material of publications. We also urge those designing
future studies to think carefully about potential biases when designing their studies.
Second, there were also large discrepancies in the completeness of safety reporting. A significant
number of trials did not report any safety data at all, while those that did varied substantially in their
reporting. This included not providing definitions of what they considered to be a SAE, not providing
details about SAEs, not reporting AEs by study arm, and a wide array of reported events with seemingly
no consistency across studies (e.g. a study recording events of nausea or headache vs. another study
recording events of dry mouth, headache and abnormal dreams). There may be scope for the creation of
a core outcome set for safety outcomes for studies of smoking cessation medicines to ensure systematic
recording and reporting of AEs, as this information is of importance to patients, practitioners and
policy-makers.
Third, although we included non-randomised evidence in our safety analyses to increase the precision
of our estimates, the use of non-randomised data may introduce bias. Further research should explore
methods for combining randomised and non-randomised data to most effectively incorporate all of the
available safety evidence.
Fourth, there have been few published trials or observational studies of electronic cigarettes with control
groups. Although our findings suggest that e-cigarettes show promise for smoking cessation, the limited
amount of evidence available results in uncertainty about their safety profile and how they compare
with licensed medicines. Although e-cigarettes are regulated by The Tobacco and Related Products
Regulations 2016,656 no available e-cigarette devices are licensed as a smoking cessation medicine at
present. Medicinal e-cigarettes would need to meet the standards for consumer e-cigarettes as well
as any additional requirements needed to meet efficacy, safety and quality criteria under medicines
regulation.657 We recommend that researchers continue to investigate the use of e-cigarettes for smoking
cessation, particularly with respect to long-term effectiveness and safety outcomes, preferably in studies
with active interventions as comparators. Our value-of-information analysis suggested that a large
adequately powered and well-conducted trial comparing e-cigarettes with an active comparator such as
varenicline standard plus NRT standard or NRT standard is likely to be a cost-effective use of resources.
Finally, although it was not the focus of this report, we found in our NMA that combining counselling
and pharmacological treatments increased cessation rates compared with pharmacological treatment
alone. Further research to explore the clinical effectiveness and cost-effectiveness of combination
pharmacological and psychological interventions that account for AEs are likely to be of value.
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Chapter 9 Patient and public involvement
A lay summary of this project was reviewed by participants of the UK Centre for Tobacco andAlcohol Studies (UKCTAS) smokers’ panel and was presented to members of the Elizabeth
Blackwell Institute’s Public Advisory Group. Originally set up in 2008, the UKCTAS smokers’ panel
consists of active smokers and recent quitters who meet two or three times per year in Nottingham.
The panel meets regularly to discuss tobacco, tobacco policy, approaches to smoking cessation and
new developments in tobacco harm reduction. Panel members also serve as lay advisers on research
applications submitted from UKCTAS universities, which involves commenting on study information
sheets, consent forms and data collection instruments (literature review protocols, data management
plans and other key documents); commenting on press releases and communication plans; participating
in bespoke meetings to develop or advise on new studies; and other forms of engagement as appropriate.
The Elizabeth Blackwell Institute’s Public Advisory Group comprises key stakeholders in public engagement
and health and social care as well as representatives of patient and public involvement groups linked to
research projects at the University of Bristol. The Public Advisory Group works with the Elizabeth Blackwell
Institute to ensure excellent engagement across the research life cycle. The group meets a few times per
year, and researchers across the University of Bristol are invited to share their research with the group and
receive feedback. During the course of the project, we interviewed vapers from the UKCTAS smokers’
panel for input on our outcomes and planned analyses.We also presented preliminary findings based on
data from studies identified in our original searches to the Elizabeth Blackwell Institute’s Patient Advisory
Panel for feedback and suggestions for further analyses.
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Appendix 1 MEDLINE search strategies
MEDLINE search strategy for randomised controlled trials
1. Smoking/ (134,671)
2. Tobacco Smoking/ (397)
3. Tobacco/ (29,151)
4. Nicotine/ (24,376)
5. Tobacco Products/ (3005)
6. Smoking Cessation/ (26,370)
7. “Tobacco Use Cessation”/ (1045)
8. “Tobacco Use Disorder”/ (10,555)
9. (smoking or smoker*).ti,ab,kf. (231,897)




14. Nicotinic Agonists/ (6990)
15. (NRT or nicotine replacement).ti,ab,kf. (3901)
16. bupropion.ti,ab,kf. (4038)
17. (amfebutamone or quomen or wellbutrin or zyban or zyntabac).ti,ab,kf. (201)
18. varenicline.ti,ab,kf. (1578)
19. (champix or tabex or chantix).ti,ab,kf. (125)
20. (nicotine adj2 (patch* or gum* or nasal spray* or lozenge* or tablet* or sublingual* or inhal* or
replacement or chewing or polac* or transdermal* or product*)).ti,ab,kf. (5818)
21. (nicorette or niquitin or nicotinell).ti,ab,kf. (110)
22. (nicotinic adj3 agonist*).ti,ab,kf. (2237)
23. (benzazepine* adj2 derivative*).ti,ab,kf. (84)
24. nicotinic receptor partial agonist*.ti,ab,kf. (58)
25. or/12-24 (17,839)
26. Electronic Nicotine Delivery Systems/ (2174)
27. Vaping/ (237)
28. (electr* adj2 (cig* or nicotine or device*)).ti,ab,kf. (17,861)
29. (ecig* or e-cig*).ti,ab,kf. (2982)
30. (nicotine adj4 (electr* or ENDS or aerosol*)).ti,ab,kf. (1023)
31. (vape or vaper or vapers or vaping or vapor or vapour).ti,ab,kf. (42,208)
32. or/26-31 (60,589)
33. ((smoking or tobacco) adj5 (cessation or ceas* or quit* or stop* or giv* or prevent* or abstain* or
abstin* or control*)).ti,kf. (18,876)
34. randomized controlled trial.pt. (475,058)
35. controlled clinical trial.pt. (92,883)
36. pragmatic clinical trial.pt. (951)
37. clinical trial.pt. (514,264)
38. clinical trial/ or clinical trial, phase i/ or clinical trial, phase ii/ or clinical trial, phase iii/ or clinical
trial, phase iv/ or controlled clinical trial/ (575,942)
39. Random Allocation/ (97,344)
40. randomized controlled trial/ (475,058)
41. pragmatic clinical trial/ (951)
42. Double-Blind Method/ (149,187)
43. Single-Blind Method/ (26,163)
44. Placebos/ (34,201)
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45. ((clin* or randomi?ed) adj5 trial*).ti,ab,kf. (586,919)
46. ((singl* or doubl* or trebl* or tripl*) adj5 (blind* or mask*)).ti,ab,kf. (163,772)
47. placebo*.ti,ab,kf. (202,178)
48. control groups/ (1604)
49. randomi?ation.ti,ab,kf. (32,653)
50. randomly.ab. (304,261)
51. (random* adj3 (administ* or allocat* or assign* or class* or control* or determine* or divide* or
distribut* or expose* or fashion or number* or place* or recruit* or subsitut* or treat*)).ab. (429,094)
52. drug therapy.fs. (2,077,773)
53. trial.ti,ab,kf. (534,702)
54. groups.ab. (1,874,309)
55. (control* adj3 (trial* or study or studies)).ab,ti. (470,250)
56. ((singl* or doubl* or tripl* or trebl*) adj3 (blind* or mask* or dummy*)).mp. (222,854)
57. (quasi adj (experimental or random$)).ti,ab. (15,129)
58. ((waitlist* or wait* list* or treatment as usual or TAU) adj3 (control or group)).ab. (5264)
59. or/34-58 (4,771,652)
60. 11 and (25 or 32) and 59 (6074)
61. (animals not (humans and animals)).sh. (4,506,319)
62. 60 not 61 (5269)
63. (2017* or 2018*).yr,dp,dt,ep,ez. (2,712,640)
64. 62 and 63 (740)
65. (2018* or 2019*).yr,dp,dt,ep,ez. (1,556,937)
66. 62 and 65 (438).
MEDLINE search strategy for non-randomised studies
1. Smoking/ (134,503)
2. Tobacco Smoking/ (424)
3. Tobacco/ (29,125)
4. Nicotine/ (24,327)
5. Tobacco Products/ (3020)
6. Smoking Cessation/ (26,263)
7. “Tobacco Use Cessation”/ (1039)
8. “Tobacco Use Disorder”/ (10,482)
9. (smoking or smoker*).ti,ab,kf. (231,830)




14. Nicotinic Agonists/ (6977)
15. (NRT or nicotine replacement).ti,ab,kf. (3893)
16. bupropion.ti,ab,kf. (4026)
17. (amfebutamone or quomen or wellbutrin or zyban or zyntabac).ti,ab,kf. (200)
18. varenicline.ti,ab,kf. (1574)
19. (champix or tabex or chantix).ti,ab,kf. (125)
20. (nicotine adj2 (patch* or gum* or nasal spray* or lozenge* or tablet* or sublingual* or inhal* or
replacement or chewing or polac* or transdermal* or product*)).ti,ab,kf. (5809)
21. (nicorette or niquitin or nicotinell).ti,ab,kf. (110)
22. (nicotinic adj3 agonist*).ti,ab,kf. (2235)
23. (benzazepine* adj2 derivative*).ti,ab,kf. (84)
24. nicotinic receptor partial agonist*.ti,ab,kf. (58)
25. or/12-24 (17,812)
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26. Electronic Nicotine Delivery Systems/ (2189)
27. Vaping/ (243)
28. (electr* adj2 (cig* or nicotine or device*)).ti,ab,kf. (17,929)
29. (ecig* or e-cig*).ti,ab,kf. (3005)
30. (nicotine adj4 (electr* or ENDS or aerosol*)).ti,ab,kf. (1026)
31. (vape or vaper or vapers or vaping or vapor or vapour).ti,ab,kf. (42,034)
32. or/26-31 (60,491)
33. ((smoking or tobacco) adj5 (cessation or ceas* or quit* or stop* or giv* or prevent* or abstain* or
abstin* or control*)).ti,kf. (18,825)
34. epidemiologic studies/ or case-control studies/ or cross-sectional studies/ or cohort studies/ or follow-up
studies/ or longitudinal studies/ or prospective studies/ or retrospective studies/ (2,244,426)
35. ((epidemiologic or prospective or retrospective or cross-sectional or case control* or cohort or
longitudinal or followup or follow-up) adj3 (study or studies)).ti,ab,kf. (1,011,257)
36. (cross-sectional or follow-up or followup or longitudinal or prospective or retrospective or
observational or population).ti. (563,430)
37. cohort?.ti,ab,kf. (497,828)
38. (case control* or case series).ti,ab,kf. (179,847)
39. or/34-38 (2,928,405)
40. (dream* or nightmare? or aggression or aggressive* or anxiety or anxious or (angina or arrhythmia*
or cardiac or cardiovascular or coronary or myocardi* or heart failure? or heart attack? or isch?
emi*) or COPD or chronic obstructive pulmonary disease or death? or mortalit* or (depression or
depressive) or dry mouth or fatigue or headache? or migraine? or hospitali* or (insomnia* or sleep
disorder* or somnolence) or irritability or irritable or (nausea or vomiting) or palpitations or
pruritus or seizure* or rash or (stroke or strokes or thrombo* or thrombus or emboli* or VTE
or DVT or TIA or bleed* or h?emorrhag*) or suicid* or parasuicid* or selfharm* or self-harm* or
selfinjur* or self-injur*).mp. (5,115,897)
41. exp Hypersensitivity/ (327,542)
42. Drug Interactions/ or exp "drug-related side effects and adverse reactions"/ (187,530)
43. exp Product Surveillance, Postmarketing/ (14,019)
44. adverse effects.fs. (1,622,477)




49. chemically induced.fs. (559,975)
50. (safe* or adverse or tolerability or toxicity or toxic or adrs or adr or tolerance or tolerat* or harm
or harms or harmful or complication* or drug? interaction? or hypersensitiv* or hyper-sensitiv*).ti,kf.
(650,849)
51. ((adverse adj2 (event? or react*)) or side effect* or treatment emergent or undesirable effect*).ti,ab,kf.
(417,393)
52. ((discontinu* or withdr*) adj3 (study or treatment) adj3 due to).ti,ab,kf. (2430)
53. or/40-52 (9,947,953)
54. (11 and (25 or 32)) or 33 (31,504)
55. (2017* or 2018* or 2019*).yr,dp,dt,ep,ez. (2,836,508)
56. 39 and 53 and 54 and 55 (405).
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Appendix 2 Inputs into the economic model
TABLE 18 Data informing demographic distribution of cohort
Model parameter Source


























ONS 2016107 0.07 0.40 4.40 0.03 0.26 4.13
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TABLE 19 Prevalence of disease in general UK population
Disease Data source n













COPD British Lung Foundation 2012109 12.6 million 0.0 1.0 7.0 0.0 1.0 7.0
Lung cancer Maddams et al. 2009111 7.7 million 0.0 0.1 0.7 0.0 0.1 0.3
History of CHD Health Survey for England 2016113 8011 0.2 4.5 20.9 0.4 1.9 12.0
History of stroke Bhatnagar et al. 2015114 35 million 0.1 1.8 10.6 0.1 1.4 8.4
Asthma exacerbation British Lung Foundation 2012109 12.6 million 19.0 12.0 11.0 19.0 12.0 11.0
TABLE 20 Prevalence of disease in simulated cohort of UK smokers at beginning of modela
Disease
Age and sex category (%)







COPD 0.0 2.1 12.1 0.0 2.3 15.2
Lung cancer 0.0 0.3 2.5 0.0 0.2 1.3
History of CHD 0.2 9.1 29.0 0.4 4.6 18.6
History of stroke 0.1 4.4 17.8 0.1 4.0 14.6
Asthma exacerbation 24.8 12.1 12.1 25.2 12.2 12.1
a Calculated from the prevalence of smokers (see Table 18), prevalence of disease (see Table 19) and RRs for smokers relative to never-smokers for each disease (source: Statistics




































TABLE 21 Annual incidence of lung cancer
Original source











ONS (2005b) Registrations of Cancer Diagnosed in 2003658 0 0.05 0.4 0 0.03 0.2
Cancer Registration Statistics, England, 2016 (First Release) ONS118 0 0.04 0.4 0 0.04 0.3
TABLE 22 Annual incidence of diseases in general population by age and sex category
Disease Data source n













COPD Pfizer 2007117 UK population 0.00 0.01 0.30 0.00 0.01 0.20
Lung cancer ONS 2005658 Population of England 0.00 0.04 0.40 0.00 0.04 0.33
CHD (first non-fatal event) British Heart Foundation 2006659 151,000 0.00 0.08 0.80 0.00 0.02 0.60
CHD (any non-fatal event) Volmink et al. 1998660 568,800 0.00 0.12 1.40 0.00 0.03 0.90
Stroke (first non-fatal event) ONS 2001661 UK population 0.00 0.15 0.65 0.00 0.10 0.60
Stroke (any non-fatal event) ONS 2001661 UK population 0.00 0.20 1.00 0.00 0.14 1.00










































































































































































































































































































































































TABLE 23 Annual incidence of diseases in smokers by age and sex category
Disease













COPD 0.00 0.02 0.52 0.00 0.02 0.44
Lung cancer 0.00 0.13 1.35 0.00 0.14 1.34
CHD (first non-fatal event) 0.00 0.16 1.11 0.00 0.05 0.93
Stroke (first non-fatal event) 0.00 0.36 1.09 0.00 0.28 1.04
CHD (any non-fatal event) 0.00 0.24 1.94 0.00 0.07 1.40
Asthma 0.08 0.05 0.07 0.08 0.05 0.06
Stroke (any non-fatal event) 0.00 0.49 1.68 0.00 0.40 1.73
TABLE 24 Annual incidence of diseases in recent quitters by age and sex category
Disease













COPD 0.00 0.02 0.47 0.00 0.02 0.43
Lung cancer 0.00 0.05 0.50 0.00 0.05 0.48
CHD (first non-fatal event) 0.00 0.09 0.83 0.00 0.02 0.64
Stroke (first non-fatal event) 0.00 0.11 0.63 0.00 0.08 0.61
CHD (any non-fatal event) 0.00 0.13 1.46 0.00 0.03 0.96
Asthma 0.06 0.05 0.06 0.06 0.05 0.05
Stroke (any non-fatal event) 0.00 0.14 0.97 0.00 0.11 1.02
TABLE 25 Annual incidence of diseases in long-run quitters by age and sex category
Disease













COPD 0.000 0.001 0.030 0.000 0.002 0.036
Lung cancer 0.00 0.05 0.50 0.00 0.05 0.48
CHD (first non-fatal event) 0.000 0.048 0.693 0.000 0.012 0.533
Stroke (first non-fatal event) 0.000 0.097 0.575 0.000 0.062 0.533
CHD (any non-fatal event) 0.000 0.072 1.213 0.000 0.018 0.799
Asthma 0.055 0.050 0.059 0.056 0.050 0.050
Stroke (any non-fatal event) 0.000 0.130 0.885 0.000 0.087 0.889
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TABLE 26 Annual mortality for the general population by age and sex category
Disease Data source n













COPD BHF 2018120 UK population 0.00 1.45 4.22 0.00 1.26 3.63
Lung cancer BHF 2018120 UK population 0.00 29.30 48.80 0.00 23.80 34.30
Stroke (first non-fatal event) Assumption. The same split
between first event and all
events is assumed for first/
subsequent for mortality as
for incidence
UK population 0.41 0.51 1.78 0.14 0.58 2.74
Stroke (any non-fatal event) BHF 2018120 UK population 0.60 0.68 2.74 0.20 0.81 4.57
CHD (first non-fatal event) Assumption. The same split
between first event and all
events as used in a previous
manufacturer's STA submission117
is assumed for first/subsequent
UK population 0.53 0.92 1.71 0.06 0.88 2.23
CHD (any non-fatal event) BHF 2018120 UK population 0.70 1.37 2.90 0.08 0.88 3.05










































































































































































































































































































































































TABLE 27 Annual mortality for smokers by age and sex category
Disease













COPD 0.00 3.05 7.28 0.00 2.88 7.89
Lung cancer 0.00 29.30 48.80 0.00 23.80 34.30
CHD (first non-fatal event) 0.53 1.85 2.37 0.06 2.14 3.46
CHD (any non-fatal event) 0.70 2.76 4.02 0.08 2.14 4.74
Stroke (first non-fatal event) 0.41 1.24 3.00 0.14 1.64 4.75
Stroke (any non-fatal event) 0.60 1.65 4.61 0.20 2.29 7.92
TABLE 28 Annual mortality for recent quitters by age and sex category
Disease













COPD 0.00 2.79 6.65 0.00 2.81 7.71
Lung cancer 0.00 29.30 48.80 0.00 23.80 34.30
CHD (first non-fatal event) 0.53 0.99 1.78 0.06 0.98 2.37
Stroke (first non-fatal event) 0.41 0.36 1.73 0.14 0.47 2.80
CHD (any non-fatal event) 0.70 0.99 2.51 0.08 0.98 3.25
Stroke (any non-fatal event) 0.60 0.48 2.67 0.20 0.66 4.67
TABLE 29 Annual mortality for long-run quitters by age and sex category
Disease













COPD 0.0 0.2 0.4 0.0 0.2 0.7
Lung cancer 0.00 29.30 48.80 0.00 23.80 34.30
CHD (first non-fatal event) 0.5 0.6 1.5 0.1 0.5 2.0
Stroke (first non-fatal event) 0.4 0.3 1.6 0.1 0.4 2.4
CHD (any non-fatal event) 0.7 0.8 2.5 0.1 0.5 2.7
Stroke (any non-fatal event) 0.6 0.4 2.4 0.2 0.5 4.1








Annual relapse probability, > 1 and < 5 years
post cessation (time period 4 years)
Hawkins et al. 2010121 0.1291 0.1174 to 0.1414 Beta(395, 35)
Annual relapse probability, ≥ 5 and < 10 years
post cessation (time period 5 years)
Hawkins et al. 2010121 0.0331 0.0230 to 0.0452 Beta(33, 180)
Annual relapse probability, > 10 years post
cessation (time period 26 years)
Krall et al. 2002122 0.0009 0.0004 to 0.0015 Beta(9, 360)
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TABLE 31 Health state costs
Data Original source n
Mean cost from paper
(currency) 95% CrI (currency) Cost for model (£) Distribution
COPD Hospital Inpatient Enquiry Database 2015.663
Cost per prevalent case of inpatient and day
case treatment
73,901 868 (euros) 664 to 1097 (euros) 1468 (exchange
rate £1 = €1.14)125
Gamma (7,390,100, 0.0002)
Primary Care Reimbursement Service 2014.664
Cost per prevalent case of primary care
treatment
73,657 662 (euros) 504 to 831 (euros)
Total of inpatient and primary care 1530 (euros)
Lung cancer Hospital Inpatient Enquiry Database 2015.663
Cost per prevalent case of inpatient and
day-case treatment
4666 5107 (euros) 3915 to 6499 (euros) 5429 (exchange
rate £1 = €1.14)125
Gamma (466,600, 0.01)
Primary Care Reimbursement Service 2014.664
Cost per prevalent case of primary care
treatment
4666 555 (euros) 423 to 698 (euros)
Total of inpatient and primary care 5662 (euros)
CHD (non-fatal event) British Heart Foundation. 2014128 1323 (GBP) 1460 Gamma (100, 14.60)
Stroke (non-fatal event) Xu et al. 2018130 84,184 13,452 at 1 year (GBP) 13,788 Gamma (8,418,400, 0.002)
Asthma exacerbation Tan et al. 2016132 939 341 (GBP) SE 12.94 (GBP) 367 Gamma (805, 0.46)
Depression Hunter et al. 2014134 340.35 (GBP) 395 Gamma (100, 3.95)
Self-harm Tsiachristas et al. 2017135 1140 809 (GBP) SE 26.78 (GBP) 850 Gamma (1007, 0.84)










































































































































































































































































































































































TABLE 32 Intervention costs
Treatment
Assumed
mean cost (£) Source Assumption
NRT low 83.84 BNF137 4 weeks of 10-mg/16-hour patches and 4 weeks
of 5-mg/16-hour patches
NRT standard 105.65 BNF137 High-strength patch daily for 6–8 weeks,
followed by medium-strength patch for 2 weeks,
and low-strength patch for final 2 weeks
NRT high 77.46 BNF137 4-week supply of 21 mg NicoDerm transdermal
patches, followed by 2 weeks of 14 mg and
2 weeks of 7 mg
Bupropion low 62.64 BNF137 One 150-mg tablet a day for an average of
13 weeks
Bupropion standard 83.52 BNF137 150mg daily for 6 days, then 150mg twice daily
for a period of treatment of 7–9 weeks
Varenicline low 163.80 BNF137 0.5 mg once daily for 3 days, increased to 0.5 mg
twice daily for 4 days, then 1mg twice daily for
11 weeks
Varenicline standard 163.80 BNF137 1 mg once daily for 3 days, increased to 1 mg
twice daily for 4 days, then 1mg twice daily for
11 weeks
E-cigarette 82 Liber et al.
2017139
12-week supply of e-cigarettes (e-cigarette+
3.55 ml liquid per day including a replacement
atomiser in months 2 and 3)
Bupropion standard plus NRT high 160.98 BNF137
Varenicline low plus NRT standard 269.45 BNF137
Varenicline standard plus NRT standard 269.45 BNF137
Varenicline standard plus NRT high 241.26 BNF137
Varenicline standard plus bupropion
standard
247.32 BNF137
TABLE 33 Health state mean utility values
Health state Utility source n Mean utility SE
NCM, male, 18–34 years Ara and Brazier 2010140 26,679 0.94
NCM, male, 35–64 years Ara and Brazier 2010140 26,679 0.88
NCM, male, 65–100 years Ara and Brazier 2010140 26,679 0.72
NCM, female, 18–34 years Ara and Brazier 2010140 26,679 0.92
NCM, female, 35–64 years Ara and Brazier 2010140 26,679 0.86
NCM, female, 65–100 years Ara and Brazier 2010140 26,679 0.70
Lung cancer Bertranou et al. 2018142 464 0.72 0.001
COPD Pickard et al. 2008144 0.69 0.043
CHD Stevanović et al. 2016146 30,575 0.76 0.01
Stroke (first event) Haacke et al. 2006148 77 0.73 0.036
Stroke (second event) Ara and Brazier 2010140 18 0.48 0.087
Asthma exacerbation Lloyd et al. 2007151 112 0.57 0.026
Depression Hunter et al. 2014134 0.58 0.015
Self-harm Byford et al. 2003157 480 0.50 0.016
NCM, No comorbidity.
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TABLE 34 Absolute probability of 1-year continuous cessation based on NRT standard taken from Taylor et al.158 and
ORs estimated from the NMA (see Chapter 5)
Treatment
1-year continuous abstinence probability
Mean 2.5% 97.5%
Varenicline low plus NRT standard 0.43 0.17 0.73
Varenicline standard plus NRT standard 0.43 0.23 0.66
E-cigarette low 0.32 0.12 0.63
Varenicline plus bupropion standard 0.31 0.15 0.51
E-cigarette high 0.30 0.18 0.45
Varenicline standard 0.27 0.23 0.32
Varenicline standard plus NRT high 0.24 0.12 0.38
NRT high 0.23 0.19 0.27
NRT standard 0.21 0.21 0.21
Varenicline low 0.19 0.12 0.28
Bupropion standard plus NRT high 0.19 0.10 0.32
Bupropion low 0.19 0.12 0.28
Bupropion standard 0.18 0.15 0.22
NRT low 0.07 0.02 0.16
This table is reproduced with permission from Thomas et al.67 This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and
build upon this work, for commercial use, provided the original work is properly cited. See: https://creativecommons.org/
licenses/by/4.0/. The table includes minor additions and formatting changes to the original table.
TABLE 35 Absolute probability of depression based on NRT not specified taken from Kotz et al.57 and ORs estimated




NRT standard 0.07 0.00 0.39
Bupropion standard plus NRT high 0.08 0.01 0.22
NRT not specified 0.15 0.15 0.15
Bupropion standard 0.17 0.11 0.24
Varenicline standard plus NRT high 0.17 0.06 0.37
NRT high 0.19 0.10 0.30
Varenicline standard 0.22 0.16 0.31
Varenicline low 0.29 0.02 0.78
Varenicline standard plus NRT standard 0.36 0.09 0.77
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TABLE 36 Absolute probability of self-harm based on NRT not specified taken from Kotz et al.57 and ORs estimated from




Varenicline plus bupropion standard 0.004 0.000 0.018
Bupropion standard plus NRT high 0.005 0.001 0.016
NRT standard 0.006 0.000 0.036
NRT not specified 0.010 0.010 0.011
Bupropion standard 0.012 0.007 0.018
Varenicline standard plus NRT high 0.013 0.003 0.033
NRT high 0.013 0.006 0.024
Varenicline standard 0.016 0.011 0.025
Varenicline low 0.034 0.001 0.171
Varenicline standard plus NRT standard 0.042 0.006 0.158
TABLE 37 Relative risks of disease prevalence in smokers relative to never-smokers
Disease RR in smokers RR in former smokers RR in never-smokers
COPDa
Male aged 18–34 years 1 1 1
Male aged 35–64 years 17.1 15.64 1
Male aged ≥ 65 years 17.1b 15.64b 1
Female aged 18–34 years 1 1 1
Female aged 35–64 years 12.04 11.77 1
Female aged ≥ 65 years 12.04b 11.77b 1
Lung cancera
Male aged 18–34 years 1 1 1
Male aged 35–64 years 23.26 8.7 1
Male aged ≥ 65 years 23.26b 8.7b 1
Female aged 18–34 years 1 1 1
Female aged 35–64 years 12.69 4.53 1
Female aged ≥ 65 years 12.69b 4.53b 1
CHDc
Male aged 18–34 years 1 1 1
Male aged 35–64 years 3.35 1.80 1
Male aged ≥ 65 years 1.60 1.20 1
Female aged 18–34 years 1 1 1
Female aged 35–64 years 4.05 1.85 1
Female aged ≥ 65 years 1.75 1.20 1
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TABLE 37 Relative risks of disease prevalence in smokers relative to never-smokers (continued )
Disease RR in smokers RR in former smokers RR in never-smokers
Strokec
Male aged 18–34 years 1 1 1
Male aged 35–64 years 3.75 1.1 1
Male aged ≥ 65 years 1.9 1.1b 1
Female aged 18–34 years 1 1 1
Female aged 35–64 years 4.55 1.3 1
Female aged ≥ 65 years 1.95 1.15 1
a Health Profile for England 2007, Department of Health, Tobacco in London, The Preventable Burden, Smokefree
London & The London Health Observatory, 2004.
b Relative risk assumed to be the same as that in persons aged 35–64 years.
c Based on data from CPS-II 1982–8, which was a prospective study of smoking and death in more than 1 million
Americans aged ≥ 30 years.
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Appendix 3 Formulae to calculate the
expected number of cases of disease in the
cohort of smokers
Total disease prevalence (PT) within the overall population is the weighted sum of the prevalencewithin the three subgroups [current smokers (PCS), former smokers (PFS) and never smokers (PNS)],
with the weights being the proportion of people in each group [current smokers (πCS), former smokers
(πFS) or never smokers (1 – πCS – πFS); Equation 3].
PT = PNS × (1 – πCS– πFS) + PFS × πFS + PCS × πCS. (3)
Disease prevalence within the group of current and former smokers can be expressed in terms of the
prevalence among never smokers using the RR of the disease in current and former smokers (RRCS and
RRFS, respectively).
PFS = PNS × RRFS . (4)
PCS = PNS × RRCS . (5)
Substituting these into Equation 3 gives Equation 6, which on rearrangement allows the disease
prevalence among never-smokers (PNS) to be expressed in terms of the total population prevalence (PT),
the proportion of people who are current smokers (πCS), former smokers (πFS), and the RR associated
with being a current or former smoker (RRCS, RRFS), all of which are known (Equation 7):
PT = PNS × (1 – πFS – πCS) + PNS × RRFS × πFS + PNS × RRCS × πCS . (6)
PNS =
PT
((1 – πFS – πCS) + RRFS × πFS + RRCS × πCS)
. (7)
Solving for PNS then allows us to calculate PFS (prevalence rate in former smokers) and PCS (prevalence
rate in current smokers) using Equations 4 and 5.
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Appendix 4 Risk-of-bias summary figures
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Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
Overall bias





FIGURE 34 Risk-of-bias summary figure for RCTs reporting one or more effectiveness outcomes. This figure is reproduced with permission from Thomas et al.67 This is an Open Access
article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: https://creativecommons.org/licenses/by/4.0/. The figure includes minor additions and formatting changes to the
original figure.
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
Overall bias





FIGURE 35 Risk-of-bias summary figure for RCTs reporting one or more safety outcomes. This figure is reproduced with permission from Thomas et al.67 This is an Open Access article
distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for
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Appendix 5 Effectiveness analyses
TABLE 38 List and frequency of treatments delivered in trials included in effectiveness analyses
Treatment Frequency
Bupropion low 10
Bupropion high plus NRT combination high 1
Bupropion not specified 2
Bupropion not specified plus NRT choice not specified 1
Bupropion not specified plus NRT patch (24 hours) not specified 1
Bupropion standard 73
Bupropion standard plus NRT choice not specified 1
Bupropion standard plus NRT combination high 1
Bupropion standard plus NRT gum high 1
Bupropion standard plus NRT gum not specified 4
Bupropion standard plus NRT gum standard 1
Bupropion standard plus NRT inhalator not specified 1
Bupropion standard plus NRT lozenge not specified 2
Bupropion standard plus NRT patch (24 hours) high 8
Bupropion standard plus NRT patch (24 hours) not specified 2
E-cigarette high 2
E-cigarette high plus NRT patch (24 hours) not specified 1
E-cigarette high 4
No drug treatment 97
NRT choice high 1
NRT choice not specified 29
NRT choice standard 1
NRT combination high 8
NRT combination not specified 7
NRT combination standard 6
NRT gum high 13
NRT gum high 1
NRT gum not specified 14
NRT gum standard 79
NRT inhalator standard 10
NRT lozenge high 7
NRT lozenge high 1
NRT lozenge not specified 9
NRT lozenge standard 2
NRT mouth spray standard 3
NRT nasal spray standard 6
NRT not specified 55
continued
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Sustained abstinence
TABLE 38 List and frequency of treatments delivered in trials included in effectiveness analyses (continued )
Treatment Frequency
NRT patch (16 hours) high 3
NRT patch (16 hours) high 3
NRT patch (16 hours) standard 14
NRT patch (24 hours) high 63
NRT patch (24 hours) high 1
NRT patch (24 hours) not specified 48
NRT patch (24 hours) standard 2
NRT sublingual tablet not specified 4
Placebo 210
Usual care 30
Varenicline standard plus bupropion standard 2
Varenicline high 6
Varenicline high plus NRT gum standard 1
Varenicline not specified 4
Varenicline standard 64
Varenicline standard plus NRT gum standard 1
Varenicline standard plus NRT patch (16 hours) standard 1
Varenicline standard plus NRT patch (24 hours) high 3
Waitlist 4
Bupropion std + NRT combo high
Bupropion std + NRT patch (24 hours) high
[Varenicline low + NRT gum std]
[Varenicline std + NRT gum std]
Varenicline std + NRT patch (16 hours) std
Varenicline std + NRT patch (24 hours) high





NRT patch (24 hours) ns
NRT patch (16 hours) low








NRT mouth spray std
NRT nasal spray std
NRT sublingual tablet ns









NRT patch (24 hours) high
NRT patch (16 hours) high
Bupropion std + NRT choice ns
FIGURE 37 Network plot for sustained abstinence at treatment level. Square brackets denote disconnected interventions.
Ns, not specified; std, standard.
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TABLE 39 Comparison of different NMA models for sustained abstinence (349 data points)
Model Residual deviance DIC SDd (95% CrI) SDD (95% CrI)
Full interaction model, consistency 340.0 2194 0.41 (0.34 to 0.49) –
Random-class model, consistency 338.3 2187 0.40 (0.34 to 0.48) 0.12 (0.01 to 0.32)
Fixed-class model, consistency 338.5 2186 0.41 (0.34 to 0.49) –
Fixed-class model, inconsistency 353.7 2209 0.32 (0.25 to 0.40) –
SDd, standard deviation across treatment effect estimates; SDD, standard deviation across class effect estimates.
This table has been adapted with permission from Thomas et al.67 This is an Open Access article distributed in
accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: https://creativecommons.org/licenses/by/4.0/. The table includes minor additions and formatting changes to the
original table.
OR (95% Crl)
1.22 (0.94 to 1.58)
0.46 (0.31 to 0.68)
1.93 (1.46 to 2.59)
1.48 (0.82 to 2.69)
1.70 (1.08 to 2.66)
1.80 (1.16 to 2.80)
2.12 (1.14 to 3.97)
0.79 (0.13 to 3.49)
1.82 (1.43 to 2.32)
2.94 (1.55 to 5.64)
2.32 (1.36 to 3.97)
1.05 (0.41 to 2.77)
2.89 (1.31 to 6.62)
2.05 (1.20 to 3.49)
2.72 (1.65 to 4.53)
2.16 (1.01 to 4.62)
3.32 (2.16 to 5.10)
1.70 (0.62 to 4.57)
1.65 (0.92 to 2.86)
2.10 (1.55 to 2.83)
0.16 (0.01 to 1.23)
1.70 (0.99 to 2.92)
1.73 (1.42 to 2.10)
3.53 (1.23 to 10.59)
1.79 (1.07 to 2.97)
2.80 (2.34 to 3.39)
3.22 (0.98 to 12.55)
2.94 (1.45 to 6.05)
0.98 (0.21 to 4.10)
1.54 (0.68 to 3.49)
3.35 (0.38 to 35.52)
1.75 (0.50 to 5.58)
5.75 (2.25 to 14.59)
2.29 (1.07 to 4.85)
3.22 (1.34 to 7.85)
0.2 0.5 1.0





NRT gum  ns
NRT choice ns
NRT patch (24 hours) ns
NRT sublingual tablet ns
NRT patch (16 hours) low
NRT gum  std
NRT combo  std
NRT inhalator std
NRT lozenge std
NRT mouth spray std
NRT nasal spray std




NRT patch (16 hours) high









Bupropion ns + NRT patch (24 hours) ns
Bupropion std + NRT choice ns
Bupropion std + NRT combo high
Bupropion std + NRT patch (24 hours) high
Varenicline std + NRT patch (16 hours) std
Varenicline std + NRT patch (24 hours) high
Varenicline and bupropion std
Intervention
FIGURE 38 Forest plot with full interaction NMA model results for sustained abstinence. Ns, not specified; std, standard.
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OR (95% Crl)
1.27 (0.99 to 1.62)
0.63 (0.12 to 2.61)
2.10 (1.70 to 2.69)
2.29 (1.75 to 2.97)
0.17 (0.01 to 1.28)
1.73 (1.01 to 2.97)
1.73 (1.43 to 2.10)
3.56 (1.25 to 10.49)
1.79 (1.07 to 2.94)
2.80 (2.36 to 3.39)
3.25 (0.98 to 12.55)
3.16 (1.58 to 6.23)
1.03 (0.22 to 4.06)
1.58 (0.72 to 3.49)
1.99 (0.71 to 5.75)
5.75 (2.25 to 14.59)
2.34 (1.11 to 4.85)
3.22 (1.35 to 7.77)
0.2 0.5 1.0
OR (compared with placebo)
2.0 5.0
0.47 (0.32 to 0.70)














Varenicline std + NRT std
Varenicline std + NRT high
Varenicline and bupropion std
E-cigarette low
E-cigarette high
Bupropion std + NRT high
Bupropion std + NRT ns
Bupropion ns + NRT ns
FIGURE 39 Forest plot with random-class NMA model results for sustained abstinence. Ns, not specified; std, standard.
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Sensitivity analyses
Analysis excluding studies at high risk of bias
This analysis was based on 111 studies. The estimate of the SDs between class effects was 0.34













Bupropion ns + NRT ns
Bupropion std + NRT ns
Bupropion std + NRT high
Bupropion low
Bupropion std
Intervention OR (95% Crl)
1.25 (0.84 to 1.84)
1.16 (0.64 to 2.12)
1.86 (1.52 to 2.27)
0.53 (0.11 to 2.03)
1.84 (1.52 to 2.23)
2.23 (1.80 to 2.77)
0.95 (0.42 to 2.12)
1.88 (1.55 to 2.27)
3.49 (1.32 to 9.58)
1.86 (1.02 to 3.42)
2.80 (2.34 to 3.35)
3.22 (0.93 to 13.46)
2.64 (1.05 to 6.62)
1.95 (0.74 to 5.00)
5.75 (2.51 to 13.20)
2.36 (1.20 to 4.57)
3.13 (1.43 to 7.03)
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
FIGURE 40 Forest plot with fixed-class NMA model results for sustained abstinence without studies at high risk of bias.
Ns, not specified; std, standard.
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Sensitivity analysis excluding studies of pharmacological treatment plus counselling
(if counselling is not given in all study arms)
This analysis was based on 143 studies. The estimate of the SD between class effects was 0.31













Bupropion ns + NRT ns
Bupropion std + NRT ns
Bupropion std + NRT high
Varenicline std + NRT std
Varenicline std + NRT high
Varenicline and bupropion std
Bupropion low
Bupropion std
Intervention OR (95% Crl)
1.09 (0.85 to 1.40)
1.03 (0.57 to 1.86)
1.88 (1.60 to 2.20)
0.54 (0.11 to 1.97)
1.86 (1.60 to 2.20)
2.27 (1.88 to 2.75)
0.15 (0.01 to 1.05)
1.23 (0.67 to 2.29)
1.84 (1.55 to 2.18)
3.53 (1.39 to 9.30)
1.75 (1.13 to 2.72)
2.77 (2.36 to 3.25)
3.63 (1.22 to 14.01)
3.25 (1.84 to 5.75)
0.92 (0.21 to 3.39)
1.67 (0.87 to 3.19)
1.93 (0.74 to 4.85)
5.64 (1.93 to 16.44)
5.70 (2.59 to 12.55)
2.39 (1.26 to 4.48)
3.13 (1.49 to 6.55)
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
FIGURE 41 Forest plot with fixed-class NMA model results for sustained abstinence without studies that include
pharmacological treatment plus counselling (unless counselling included on all arms). Ns, not specified; std, standard.
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Meta-regressions
Industry sponsorship as covariate
This analysis was based on 145 studies. There was inconclusive evidence of effect modification based
on industry sponsorship (B = 0.42, –197.0 to 198.3). The estimate of the SD between class effects was












Bupropion std + NRT ns
Bupropion std + NRT high
Varenicline std + NRT std
Varenicline low + NRT std
Varenicline std + NRT high
Varenicline and bupropion std
Bupropion low
Bupropion std
Intervention OR (95% Crl)
1.32 (1.01 to 1.70)
1.48 (0.33 to 0.72)
1.88 (1.52 to 2.29)
0.59 (0.10 to 2.44)
2.03 (1.67 to 2.46)
2.29 (1.84 to 2.86)
1.63 (0.90 to 3.00)
1.68 (1.38 to 2.08)
3.56 (1.20 to 10.70)
1.79 (1.05 to 3.00)
2.83 (2.34 to 3.42)
3.22 (0.96 to 12.81)
3.22 (1.63 to 6.42)
1.58 (0.70 to 3.56)
1.97 (0.70 to 5.53)
5.70 (1.52 to 21.54)
5.75 (2.20 to 15.18)
2.32 (1.07 to 4.95)
3.29 (1.34 to 8.17)
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
FIGURE 42 Forest plot with fixed-class NMA model results for sustained abstinence adjusted for sponsorship. Ns, not
specified; std, standard.
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Placebo type as covariate
This analysis was based on 113 studies. There was inconclusive evidence of effect modification based
on type of placebo (B = 0.34, –196.8 to 196.2). The estimate of the SD between class effects was 0.34









Bupropion std + NRT high
Varenicline std + NRT high
Varenicline and bupropion std
Bupropion low
Bupropion std
Intervention OR (95% Crl)
0.67 (0.08 to 3.56)
1.06 (0.54 to 2.10)
1.90 (1.58 to 2.29)
1.88 (1.57 to 2.25)
2.27 (1.84 to 2.80)
0.95 (0.43 to 2.10)
1.84 (1.54 to 2.20)
3.49 (1.35 to 9.39)
1.75 (1.12 to 2.77)
2.75 (2.32 to 3.29)
1.97 (0.73 to 5.05)
2.39 (1.21 to 4.62)
3.10 (1.43 to 6.82)
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
FIGURE 43 Forest plot with fixed-class NMA model results for sustained abstinence adjusted for type of placebo. Ns, not
specified; std, standard.
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Treatment duration as covariate
This analysis was based on 150 studies. There was inconclusive evidence of effect modification as a
function of treatment duration (B = –0.01, –0.05 to 0.04). The estimate of the SD between class effects








Bupropion ns + NRT ns
Bupropion std + NRT high
Varenicline std + NRT std
Varenicline low + NRT std
Varenicline std + NRT high
Varenicline and bupropion std
Bupropion ns
Bupropion std
Intervention OR (95% Crl)
1.95 (0.90 to 4.26)
0.50 (0.12 to 1.77)
1.86 (0.90 to 3.94)
2.25 (1.08 to 4.71)
0.66 (0.02 to 9.30)
1.92 (0.89 to 4.22)
1.88 (0.82 to 4.35)
2.94 (1.40 to 6.30)
2.92 (0.86 to 9.58)
2.92 (0.42 to 23.10)
1.31 (0.32 to 5.05)
6.05 (1.52 to 23.10)
6.05 (1.97 to 18.17)
1.07 (0.25 to 4.35)
2.86 (0.92 to 8.76)
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
FIGURE 44 Forest plot with fixed-class NMA model results for sustained abstinence adjusted for treatment duration.
Ns, not specified; std, standard.
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Counselling as covariate
This analysis was based on 161 studies. There was evidence of effect modification as a function of
counselling, with interventions including counselling associated with a higher proportion of smokers
achieving sustained abstinence (B = 0.86, 0.450 to 1.27). The estimate of the SD between class effects












Bupropion std + NRT ns
Bupropion ns + NRT ns
Bupropion std + NRT high
Varenicline std + NRT std
Varenicline low + NRT std
Varenicline std + NRT high




Intervention OR (95% Crl)
1.30 (1.03 to 1.62)
1.89 (0.57 to 1.40)
1.84 (1.54 to 2.18)
0.58 (0.12 to 2.23)
1.99 (1.68 to 2.34)
2.25 (1.84 to 2.75)
0.18 (0.01 to 1.25)
1.65 (1.01 to 2.69)
1.77 (1.48 to 2.12)
3.53 (1.32 to 9.78)
1.75 (1.09 to 2.83)
2.72 (2.32 to 3.22)
3.60 (1.14 to 13.60)
3.19 (1.72 to 5.87)
1.03 (0.23 to 3.97)
1.60 (0.79 to 3.25)
1.92 (0.70 to 5.00)
5.53 (1.73 to 17.81)
5.58 (2.39 to 13.07)
2.29 (1.15 to 4.57)
3.10 (1.38 to 6.96)
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
FIGURE 45 Forest plot with fixed-class NMA model results for sustained abstinence adjusted for counselling. Ns, not
specified; std, standard.
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Counselling as covariate (excluding pharma vs. psychiatric studies)
This analysis was based on 143 studies. There was inconclusive evidence of effect modification as a
function of counselling (B = 0.16, –0.05 to 0.37). The estimate of the SD between class effects was












Bupropion std + NRT ns
Bupropion ns + NRT ns
Bupropion std + NRT high
Varenicline std + NRT std
Varenicline low + NRT std
Varenicline std + NRT high




Intervention OR (95% Crl)
1.13 (0.87 to 1.45)
0.98 (0.54 to 1.79)
1.67 (1.35 to 2.10)
0.51 (0.10 to 1.80)
1.70 (1.38 to 2.08)
2.03 (1.62 to 2.59)
0.13 (0.00 to 0.97)
1.06 (0.57 to 2.01)
1.60 (1.25 to 2.03)
3.00 (1.19 to 7.85)
1.51 (0.94 to 2.44)
2.39 (1.88 to 3.06)
3.63 (1.20 to 13.74)
2.94 (1.63 to 5.26)
1.85 (0.20 to 3.06)
1.46 (0.75 to 2.83)
1.72 (0.64 to 4.31)
4.90 (1.68 to 14.30)
4.95 (2.20 to 11.02)
2.10 (1.07 to 4.01)
2.66 (1.25 to 5.81)
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
FIGURE 46 Forest plot with fixed-class NMA model results for sustained abstinence adjusted for counselling (excluding
pharma vs. psychiatric studies). Ns, not specified; std, standard.
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Dependence as covariate
This analysis was based on 94 studies. There was evidence of effect modification as a function of
dependence, with higher odds of quitting among smokers with higher dependence scores (B = 0.23,










Bupropion ns + NRT ns
Bupropion std + NRT high
Varenicline std + NRT std
Varenicline low + NRT std
Varenicline std + NRT high




Intervention OR (95% Crl)
2.10 (1.45 to 3.00)
0.43 (0.21 to 0.88)
2.05 (1.65 to 2.56)
2.10 (1.68 to 2.66)
2.56 (1.97 to 3.32)
0.22 (0.01 to 1.70)
0.06 (0.00 to 3.29)
1.77 (1.45 to 2.16)
1.88 (1.17 to 3.00)
3.03 (2.56 to 3.63)
3.32 (0.94 to 13.74)
3.60 (1.93 to 6.69)
1.38 (0.31 to 5.21)
2.23 (0.81 to 5.87)
6.36 (1.97 to 20.29)
5.87 (2.53 to 13.87)
2.48 (1.25 to 4.85)
3.35 (1.52 to 7.54)
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
FIGURE 47 Forest plot with fixed-class NMA model results for sustained abstinence adjusted for dependence. Ns, not
specified; std, standard.
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Comorbidities as covariate
This analysis was based on 161 studies. There was inconclusive evidence of effect modification as a
function of the covariate (B = 0.18, –195.6 to 196.0). The estimate of the SD between class effects was












Bupropion std + NRT ns
Bupropion ns + NRT ns
Bupropion std + NRT high
Varenicline std + NRT std
Varenicline low + NRT std
Varenicline std + NRT high




Intervention OR (95% Crl)
1.28 (1.01 to 1.63)
1.49 (0.33 to 0.72)
1.86 (1.55 to 2.25)
0.59 (0.10 to 2.36)
2.01 (1.68 to 2.41)
2.32 (1.86 to 2.86)
0.18 (0.01 to 1.27)
1.75 (1.03 to 3.00)
1.73 (1.43 to 2.10)
3.53 (1.22 to 10.70)
1.77 (1.06 to 2.97)
2.80 (2.36 to 3.39)
3.22 (0.98 to 12.68)
3.22 (1.63 to 6.36)
1.02 (0.22 to 4.10)
1.62 (0.73 to 3.56)
1.95 (0.69 to 5.37)
5.70 (1.57 to 20.49)
5.75 (2.23 to 14.88)
2.32 (1.11 to 4.85)
3.25 (1.35 to 7.92)
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
FIGURE 48 Forest plot with fixed-class NMA model results for sustained abstinence adjusted for comorbidities. Ns, not
specified; std, standard.
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Psychiatric comorbidities as covariate
This analysis was based on 161 studies. There was inconclusive evidence of effect modification as a
function of the covariate (B = 0.18, –195.6 to –196.0). The estimate of the SD between class effects
was 0.41 (95% CrI 0.34 to 0.49).
OR (95% Crl)
1.28 (1.01 to 1.63)
0.59 (0.10 to 2.36)
2.01 (1.68 to 2.41)
2.32 (1.86 to 2.86)
0.18 (0.01 to 1.27)
1.75 (1.03 to 300)
1.73 (1.43 to 2.10)
3.53 (1.22 to 10.70)
1.77 (1.06 to 2.97)
2.80 (2.36 to 3.39)
3.22 (0.98 to 12.68)
3.22 (1.63 to 6.36)
1.02 (0.22 to 4.10)
1.62 (0.73 to 3.56)
1.95 (0.69 to 5.37)
5.70 (1.57 to 20.49)
5.75 (2.23 to 14.88)
2.32 (1.11 to 4.85)
3.25 (1.35 to 7.92)
0.2 0.5 1.0
OR (compared with placebo)
2.0 5.0
0.49 (0.33 to 0.72)














Varenicline std + NRT std
Varenicline low + NRT std
Varenicline std + NRT high
Varenicline and bupropion std
E-cigarette low
E-cigarette high
Bupropion std + NRT high
Bupropion std + NRT ns
Bupropion ns + NRT ns
FIGURE 49 Forest plot with fixed-class NMA model results for sustained abstinence adjusted for psychiatric comorbidities.
Ns, not specified; std, standard.
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
166
Requirement for patients to be willing to quit as covariate
This analysis was based on 161 studies. There was inconclusive evidence of effect modification as a
function of the covariate (B = 0.18, –195.6 to –196.0). The estimate of the SD between class effects
was 0.41 (95% CrI 0.34 to 0.49).
OR (95% Crl)
1.28 (1.01 to 1.63)
0.59 (0.10 to 2.36)
2.01 (1.68 to 2.41)
2.32 (1.86 to 2.86)
0.18 (0.01 to 1.27)
1.75 (1.03 to 300)
1.73 (1.43 to 2.10)
3.53 (1.22 to 10.70)
1.77 (1.06 to 2.97)
2.80 (2.36 to 3.39)
3.22 (0.98 to 12.68)
3.22 (1.63 to 6.36)
1.02 (0.22 to 4.10)
1.62 (0.73 to 3.56)
1.95 (0.69 to 5.37)
5.70 (1.57 to 20.49)
5.75 (2.23 to 14.88)
2.32 (1.11 to 4.85)
3.25 (1.35 to 7.92)
0.2 0.5 1.0
OR (compared with placebo)
2.0 5.0
0.49 (0.33 to 0.72)














Varenicline std + NRT std
Varenicline low + NRT std
Varenicline std + NRT high
Varenicline and bupropion std
E-cigarette low
E-cigarette high
Bupropion std + NRT high
Bupropion std + NRT ns
Bupropion ns + NRT ns
FIGURE 50 Forest plot with fixed-class NMA model results for sustained abstinence adjusted for willingness to quit.
Ns, not specified; std, standard.
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Smokeless tobacco as covariate
This analysis was based on 161 studies. There was inconclusive evidence of effect modification as a
function of the covariate (B = 0.18, –195.6 to –196.0). The estimate of the SD between class effects
was 0.41 (95% CrI 0.34 to 0.49).
OR (95% Crl)
1.28 (1.01 to 1.63)
0.59 (0.10 to 2.36)
2.01 (1.68 to 2.41)
2.32 (1.86 to 2.86)
0.18 (0.01 to 1.27)
1.75 (1.03 to 300)
1.73 (1.43 to 2.10)
3.53 (1.22 to 10.70)
1.77 (1.06 to 2.97)
2.80 (2.36 to 3.39)
3.22 (0.98 to 12.68)
3.22 (1.63 to 6.36)
1.02 (0.22 to 4.10)
1.62 (0.73 to 3.56)
1.95 (0.69 to 5.37)
5.70 (1.57 to 20.49)
5.75 (2.23 to 14.88)
2.32 (1.11 to 4.85)
3.25 (1.35 to 7.92)
0.2 0.5 1.0
OR (compared with placebo)
2.0 5.0
0.49 (0.33 to 0.72)














Varenicline std + NRT std
Varenicline low + NRT std
Varenicline std + NRT high
Varenicline and bupropion std
E-cigarette low
E-cigarette high
Bupropion std + NRT high
Bupropion std + NRT ns
Bupropion ns + NRT ns
FIGURE 51 Forest plot with fixed-class NMA model results for sustained abstinence adjusted for use of smokeless tobacco.
Ns, not specified; std, standard.
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Smoking level as covariate
This analysis was based on 108 studies. There was inconclusive evidence of effect modification as a
function of smoking level (B = –0.06, –0.21 to 0.33). The estimate of the SD between class effects was
0.29 (95% CrI 0.33 to 0.37).
OR (95% Crl)
1.27 (0.91 to 1.77)
0.58 (0.11 to 2.08)
2.05 (1.73 to 2.48)
2.53 (2.05 to 3.16)
0.17 (0.01 to 1.25)
1.22 (0.67 to 2.29)
1.77 (1.48 to 2.10)
3.53 (1.45 to 9.03)
1.73 (1.14 to 2.64)
2.80 (2.41 to 3.29)
2.94 (1.26 to 6.89)
1.04 (0.25 to 3.82)
1.58 (0.84 to 2.97)
1.97 (0.76 to 4.85)
5.75 (2.77 to 12.18)
2.46 (1.32 to 4.48)
3.13 (1.54 to 6.49)
0.2 0.5 1.0
OR (compared with placebo)
2.0 5.0
0.40 (0.25 to 0.64)














Varenicline std + NRT std
Varenicline std + NRT high
Varenicline and bupropion std
E-cigarette high
Bupropion std + NRT high
Bupropion std + NRT ns
Bupropion ns + NRT ns
FIGURE 52 Forest plot with fixed-class NMA model results for sustained abstinence adjusted for smoking level. Ns, not
specified; std, standard.
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Publication year as covariate
This analysis was based on 161 studies. There was inconclusive evidence of effect modification based
on publication year (B = 0.14, –195.6 to 196.9). The estimate of the SD between class effects was
0.40 (95% CrI 0.34 to 0.48).
OR (95% Crl)
1.16 (0.93 to 1.45)
0.50 (0.14 to 1.45)
2.03 (1.72 to 2.41)
2.20 (1.84 to 2.66)
0.38 (0.01 to 2.92)
1.68 (0.99 to 2.86)
1.67 (1.39 to 1.99)
2.16 (0.97 to 4.90)
1.75 (1.05 to 2.92)
2.77 (2.32 to 3.29)
3.22 (0.98 to 12.55)
3.13 (1.62 to 6.11)
1.63 (0.34 to 6.82)
1.55 (0.71 to 3.39)
1.72 (0.80 to 3.60)
5.58 (1.58 to 19.69)
5.64 (2.25 to 14.15)
2.23 (1.07 to 4.57)
3.19 (1.34 to 7.69)
0.2 0.5 1.0
OR (compared with placebo)
2.0 5.0
0.49 (0.34 to 0.70)














Varenicline std + NRT std
Varenicline low + NRT std
Varenicline std + NRT high
Varenicline and bupropion std
E-cigarette low
E-cigarette high
Bupropion std + NRT high
Bupropion std + NRT ns
Bupropion ns + NRT ns
FIGURE 53 Forest plot with fixed-class NMA model results for sustained abstinence adjusted for publication year.
Ns, not specified; std, standard.
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Prolonged abstinence
Varenicline + bupropion std
Varenicline std
Bupropion std +
NRT patch (24 hours) high
NRT patch (24 hours) high
NRT combo high
[NRT gum std]















Bupropion std + NRT high
[Bupropion low]
FIGURE 54 Network plots for prolonged abstinence at (a) treatment and (b) class level. Squared brackets denote
interventions that were not included in the NMA. Ns, not specified; std, standard. This figure has been adapted with
permission from Thomas et al.67 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: https://creativecommons.org/licenses/by/4.0/.
The figure includes minor additions and formatting changes to the original figure.
DOI: 10.3310/hta25590 Health Technology Assessment 2021 Vol. 25 No. 59
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Thomas et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
171




OR (95% CrI) NMA, OR (95% CrI)
Varenicline standard vs. bupropion standard – 1.57 (0.86 to 2.92) 1.57 (0.86 to 2.92)
Varenicline standard plus bupropion
standard vs. bupropion standard
– 2.03 (0.97 to 4.61) 2.03 (0.97 to 4.61)
Varenicline standard plus bupropion
standard vs. varenicline standard
1.39 (0.49 to 3.94) 1.28 (0.71 to 2.33) 1.31 (0.80 to 2.26)
This table is reproduced with permission from Thomas et al.67 This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and
build upon this work, for commercial use, provided the original work is properly cited. See: https://creativecommons.org/
licenses/by/4.0/. The table includes minor additions and formatting changes to the original table.
NRT ns
Intervention OR (95% Crl)
1.26 (0.64 to 2.53)
2.14 (1.01 to 5.42)
2.34 (1.46 to 3.86)
3.36 (2.23 to 6.36)
0.49 (0.02 to 8.08)
4.76 (2.48 to 10.07)
0.2 0.5 1.0 2.0 5.0




Varenicline and bupropion std
Bupropion std + NRT high
FIGURE 55 Forest plot with results of the fixed-class NMA model for prolonged abstinence. Ns, not specified; std, standard.
This figure has been adapted with permission from Thomas et al.67 This is an Open Access article distributed in accordance
with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and
build upon this work, for commercial use, provided the original work is properly cited. See: https://creativecommons.org/
licenses/by/4.0/. The figure includes minor additions and formatting changes to the original figure.




OR (95% CrI) NMA, OR (95% CrI)
NRT not specified 1.31 (0.53 to 3.29) 1.18 (0.38 to 3.67) 1.26 (0.64 to 2.53)
NRT high 2.18 (0.43 to 11.0) 2.12 (0.79 to 5.69) 2.14 (1.01 to 5.42)
Bupropion standard 2.39 (1.31 to 4.39) 2.26 (1.03 to 4.95) 2.34 (1.46 to 3.86)
Varenicline standard 3.67 (1.93 to 7.17) 3.56 (1.42 to 8.94) 3.63 (2.23 to 6.36)
Bupropion standard plus NRT high – 0.49 (0.02 to 8.08) 0.49 (0.02 to 8.08)
Varenicline standard plus bupropion standard 5.05 (1.75 to 24.1) 4.64 (2.00 to 10.8) 4.76 (2.48 to 10.1)
This table is reproduced with permission from Thomas et al.67 This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and
build upon this work, for commercial use, provided the original work is properly cited. See: https://creativecommons.org/
licenses/by/4.0/. The table includes minor additions and formatting changes to the original table.
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TABLE 42 Comparison of different NMA models for prolonged abstinence (32 data points)
Model Residual deviance DIC SDd (95% CrI) SDD (95% CrI)
Full interaction model, consistency 30.0 182.8 0.18 (0.01 to 0.69) –
Random-class model, consistency 29.5 182.6 0.18 (0.01 to 0.7) 1.33 (0.07 to 4.58)
Fixed-class model, consistency 32.0 182.9 0.18 (0.01 to 0.71) –
Fixed-class model, inconsistency 32.2 186.7 0.30 (0.01 to 1.05) –
SDd, standard deviation across treatment effect estimates; SDD, standard deviation across class effect estimates.
This table has been adapted with permission from Thomas et al.67 This is an Open Access article distributed in accordance
with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt
and build upon this work, for commercial use, provided the original work is properly cited. See: https://creativecommons.org/
licenses/by/4.0/. The table includes minor additions and formatting changes to the original table.
NRT ns
NRT patch (24 hours) ns
NRT patch (24 hours) high
Bupropion std + NRT patch (24 hours) high
NRT combo high
Varenicline std
Varenicline and bupropion std
Bupropion std
Intervention OR (95% Crl)
1.52 (0.62 to 3.94)
1.09 (0.40 to 3.19)
40.85 (2.53 to 21375.49)
2.18 (0.85 to 5.75)
2.32 (1.43 to 3.82)
3.60 (2.14 to 6.17)
0.63 (0.02 to 10.70)
4.71 (2.41 to 9.87)
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
FIGURE 56 Forest plot with full interaction NMA model results for prolonged abstinence. Ns, not specified; std, standard.
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NRT ns
Bupropion std + NRT high
NRT high
Varenicline std
Varenicline and bupropion std
Bupropion std
Intervention OR (95% Crl)
1.28 (0.05 to 36.23)
3.94 (0.24 to 304.90)
2.32 (1.46 to 3.82)
3.63 (2.18 to 6.30)
0.57 (0.02 to 8.50)
4.76 (2.51 to 9.97)
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
FIGURE 57 Forest plot with random-class NMA model results for prolonged abstinence. Ns, not specified; std, standard.
Bupropion std + NRT combo high
Bupropion std + NRT gum std
Bupropion std + NRT patch (24 hours) ns
Bupropion std + NRT patch (24 hours) high
E-cigarette high + NRT patch (24 hours) ns
Bupropion std + NRT gum high
Varenicline std + NRT patch (16 hours) std
Varenicline std + NRT patch (24 hours) high











NRT patch (24 hours) ns
NRT patch (16 hours) low
NRT patch (24 hours) std








NRT mouth spray std
NRT nasal spray std
NRT sublingual tablet ns
Bupropion std + NRT inhalator ns
Bupropion ns + NRT patch (24 hours) ns









NRT patch (24 hours) high
NRT patch (16 hours) high
Bupropion std + NRT lozenge ns
FIGURE 58 Network plot for any abstinence at treatment level. Ns, not specified; std, standard.
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OR (95% CrI) NMA, OR (95% CrI)
No drug treatment 1.01 (0.58 to 1.75) 1.61 (1.24 to 2.09) 1.48 (1.19 to 1.86)
Waitlist – 1.09 (0.51 to 2.29) 1.09 (0.51 to 2.29)
Usual care 0.93 (0.47 to 1.82) 0.58 (0.37 to 0.90) 0.66 (0.46 to 0.96)
NRT not specified 1.93 (1.60 to 2.36) 1.57 (1.05 to 2.35) 1.86 (1.57 to 2.20)
NRT low 1.51 (0.61 to 3.86) 1.17 (0.26 to 5.20) 1.40 (0.63 to 3.06)
NRT standard 2.03 (1.72 to 2.44) – 2.03 (1.72 to 2.44)
NRT high 2.39 (1.92 to 2.97) 2.84 (1.77 to 4.54) 2.46 (2.03 to 2.94)
Bupropion not specified – 0.19 (0.01 to 1.43) 0.19 (0.01 to 1.43)
Bupropion low 5.58 (0.15 to 3041) 2.84 (1.31 to 6.15) 2.89 (1.34 to 6.23)
Bupropion standard 1.84 (1.57 to 2.16) – 1.84 (1.57 to 2.16)
Varenicline not specified 4.06 (1.40 to 11.9) – 4.06 (1.40 to 11.9)
Varenicline low 1.52 (0.84 to 2.75) – 1.52 (0.84 to 2.75)
Varenicline standard 2.69 (2.27 to 3.19) – 2.69 (2.27 to 3.19)
E-cigarette low 2.51 (0.78 to 9.12) 11.1 (0.81 to 153) 3.29 (1.13 to 10.8)
E-cigarette high 2.64 (0.88 to 7.85) 3.79 (0.24 to 59.1) 2.77 (1.01 to 7.69)
Bupropion not specified plus NRT not specified – 1.12 (0.24 to 4.44) 1.12 (0.24 to 4.44)
Bupropion low plus NRT high – 5.75 (1.79 to 19.1) 5.75 (1.79 to 19.1)
Bupropion standard plus NRT not specified 1.88 (0.87 to 4.06) 2.36 (1.07 to 5.18) 2.10 (1.22 to 3.60)
Bupropion standard plus NRT standard 1.48 (0.61 to 3.63) 0.74 (0.01 to 51.7) 1.43 (0.60 to 3.46)
Bupropion standard plus NRT high 2.48 (1.39 to 4.48) 2.70 (1.23 to 5.91) 2.56 (1.60 to 4.14)
Varenicline standard plus NRT standard – 5.53 (2.12 to 14.4) 5.53 (2.12 to 14.4)
Varenicline standard plus NRT high – 2.36 (1.12 to 4.90) 2.36 (1.12 to 4.90)
Varenicline standard plus bupropion standard 3.32 (1.28 to 8.94) 3.78 (1.52 to 9.38) 3.56 (1.84 to 6.89)
E-cigarette high plus NRT not specified – 4.76 (0.62 to 47.8) 4.76 (0.62 to 47.8)
This table is reproduced with permission from Thomas et al.67 This is an Open Access article distributed in accordance
with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt
and build upon this work, for commercial use, provided the original work is properly cited. See: https://creativecommons.
org/licenses/by/4.0/. The table includes minor additions and formatting changes to the original table.





OR (95% CrI) NMA, OR (95% CrI)
Bupropion standard vs. NRT standard – 0.90 (0.72 to 1.13) 0.90 (0.72 to 1.13)
Varenicline standard vs. NRT standard – 1.32 (1.05 to 1.65) 1.32 (1.05 to 1.65)
E-cigarette low vs. NRT standard – 1.60 (0.55 to 5.38) 1.60 (0.55 to 5.38)
E-cigarette high vs. NRT standard – 1.35 (0.49 to 3.76) 1.35 (0.49 to 3.76)
Bupropion standard plus NRT standard vs. NRT standard – 0.71 (0.29 to 1.72) 0.71 (0.29 to 1.72)
Varenicline standard plus NRT standard vs. NRT standard – 2.70 (1.02 to 7.13) 2.70 (1.02 to 7.13)
Varenicline standard plus bupropion standard vs.
NRT standard
– 1.75 (0.88 to 3.45) 1.75 (0.88 to 3.45)
Varenicline standard vs. bupropion standard – 1.46 (1.18 to 1.81) 1.46 (1.18 to 1.81)
E-cigarette low vs. bupropion standard – 1.78 (0.61 to 5.95) 1.78 (0.61 to 5.95)
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OR (95% CrI) NMA, OR (95% CrI)
E-cigarette high vs. bupropion standard – 1.50 (0.54 to 4.19) 1.50 (0.54 to 4.19)
Bupropion standard plus NRT standard vs.
bupropion standard
– 0.78 (0.33 to 1.89) 0.78 (0.33 to 1.89)
Varenicline standard plus NRT standard vs.
bupropion standard
– 2.99 (1.13 to 7.88) 2.99 (1.13 to 7.88)
Varenicline standard plus bupropion standard vs.
bupropion standard
– 1.93 (0.98 to 3.79) 1.93 (0.98 to 3.79)
E-cigarette low vs. varenicline standard – 1.22 (0.42 to 4.07) 1.22 (0.42 to 4.07)
E-cigarette high vs. varenicline standard – 1.03 (0.37 to 2.86) 1.03 (0.37 to 2.86)
Bupropion standard plus NRT standard vs.
varenicline standard
– 0.53 (0.22 to 1.30) 0.53 (0.22 to 1.30)
Varenicline standard plus NRT standard vs.
varenicline standard
2.05 (0.80 to 5.25) – 2.05 (0.80 to 5.25)
Varenicline standard plus bupropion standard vs.
varenicline standard
1.50 (0.70 to 3.27) 0.95 (0.28 to 3.21) 1.32 (0.69 to 2.52)
E-cigarette high vs. e-cigarette low – 0.84 (0.18 to 3.69) 0.84 (0.18 to 3.69)
Bupropion standard plus NRT standard vs. e-cigarette low – 0.44 (0.10 to 1.74) 0.44 (0.10 to 1.74)
Varenicline standard plus NRT standard vs. e-cigarette low – 1.67 (0.37 to 6.99) 1.67 (0.37 to 6.99)
Varenicline standard plus bupropion standard vs.
e-cigarette low
– 1.08 (0.28 to 3.82) 1.08 (0.28 to 3.82)
Bupropion standard plus NRT standard vs. e-cigarette high – 0.52 (0.14 to 1.98) 0.52 (0.14 to 1.98)
Varenicline standard plus NRT standard vs. e-cigarette high – 2.00 (0.49 to 8.02) 2.00 (0.49 to 8.02)
Varenicline standard plus bupropion standard vs.
e-cigarette high
– 1.29 (0.38 to 4.27) 1.29 (0.38 to 4.27)
Varenicline standard plus NRT standard vs.
bupropion standard plus NRT standard
– 3.83 (1.05 to 14.0) 3.83 (1.05 to 14.0)
Varenicline standard plus bupropion standard vs.
bupropion standard plus NRT standard
– 2.48 (0.83 to 7.34) 2.48 (0.83 to 7.34)
Varenicline standard plus bupropion standard vs.
varenicline standard plus NRT standard
– 0.65 (0.21 to 2.04) 0.65 (0.21 to 2.04)
This table is reproduced with permission from Thomas et al.67 This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and
build upon this work, for commercial use, provided the original work is properly cited. See: https://creativecommons.org/
licenses/by/4.0/. The table includes minor additions and formatting changes to the original table.
TABLE 45 Comparison of different NMA models for any abstinence (431 data points)
Model Residual deviance DIC SDd (95% CrI) SDD (95% CrI)
Full interaction model, consistency 428.6 2720 0.42 (0.35 to 0.50) –
Random-class model, consistency 426.7 2711 0.14 (0.35 to 0.48) 0.14 (0.01 to 0.31)
Fixed-class model, consistency 426.1 2710 0.42 (0.36 to 0.50) –
Fixed-class model, inconsistency 443.9 2723 0.34 (0.27 to 0.41) –
SDd, standard deviation across treatment effect estimates; SDD, standard deviation across class effect estimates.
This table has been adapted with permission from Thomas et al.67 This is an Open Access article distributed in accordance
with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt
and build upon this work, for commercial use, provided the original work is properly cited. See: https://creativecommons.
org/licenses/by/4.0/. The table includes minor additions and formatting changes to the original table.
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NRT patch (24 hours) ns
NRT sublingual tablet ns
NRT lozenge low





NRT mouth spray std
NRT nasal spray std
NRT patch (16 hours) std





NRT patch (16 hours) high









Bupropion ns + NRT patch (24 hours) ns
Bupropion low + NRT combo high
Bupropion std + NRT inhalator ns
Bupropion std + NRT lozenge ns
Bupropion std + NRT patch (24 hours) ns
Bupropion std + NRT gum std
Bupropion std + NRT combo high
Bupropion std + NRT gum high
Bupropion std + NRT patch (24 hours) high
Varenicline std + NRT patch (16 hours) std
Varenicline std + NRT patch (24 hours) high
Varenicline and bupropion std
E-cigarette high + NRT patch (24 hours) ns
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
1.51 (1.19 to 1.92)
1.05 (0.38 to 2.80)
0.68 (0.45 to 1.01)
1.90 (1.51 to 2.41)
1.97 (1.16 to 3.35)
1.65 (0.89 to 3.03)
1.86 (1.00 to 3.49)
2.05 (1.39 to 3.06)
2.46 (1.36 to 4.53)
1.52 (0.54 to 4.31)
1.97 (0.48 to 7.24)
1.73 (1.38 to 2.18)
3.42 (1.90 to 6.23)
2.59 (1.48 to 4.53)
1.03 (0.41 to 2.56)
2.80 (1.27 to 6.30)
2.61 (1.62 to 4.22)
3.19 (1.77 to 5.75)
0.19 (0.00 to 3.86)
2.12 (0.46 to 9.49)
3.56 (2.20 to 5.93)
3.67 (2.10 to 6.36)
1.62 (0.78 to 3.29)
2.03 (1.09 to 3.78)
2.23 (1.75 to 2.80)
0.19 (0.01 to 1.48)
2.97 (1.38 to 6.42)
1.84 (1.57 to 2.16)
4.06 (1.43 to 11.82)
1.52 (0.84 to 2.75)
2.72 (2.29 to 3.22)
3.29 (1.14 to 10.80)
2.59 (0.94 to 7.10)
1.17 (0.25 to 4.85)
5.28 (1.62 to 17.29)
2.72 (0.81 to 9.78)
1.84 (0.88 to 3.88)
2.03 (0.70 to 6.05)
1.43 (0.61 to 3.46)
6.36 (0.91 to 59.74)
1.93 (0.83 to 4.53)
2.72 (1.49 to 4.95)
5.58 (2.16 to 14.44)
2.41 (1.14 to 5.05)
3.60 (1.86 to 6.96)
4.81 (0.61 to 49.90)
FIGURE 59 Forest plot with full interaction NMA model results for any abstinence. Ns, not specified; std, standard.
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E-cigarette high + NRT ns
E-cigarette low
Bupropion ns
Bupropion ns + NRT ns
Bupropion std + NRT ns
Bupropion std + NRT high
Bupropion std + NRT std
Bupropion low + NRT high
Varenicline std + NRT std
Varenicline std + NRT high
Varenicline and bupropion std
Bupropion low
Bupropion std
Intervention OR (95% Crl)
1.48 (1.17 to 1.86)
1.12 (0.53 to 2.36)
0.66 (0.45 to 0.96)
1.90 (1.52 to 2.44)
1.52 (0.66 to 3.35)
2.18 (1.75 to 2.80)
2.51 (1.95 to 3.25)
0.18 (0.00 to 1.42)
2.92 (1.38 to 6.17)
1.84 (1.57 to 2.16)
4.10 (1.46 to 11.70)
1.52 (0.85 to 2.75)
2.69 (2.29 to 3.19)
3.29 (1.15 to 10.59)
2.69 (0.98 to 7.32)
1.13 (0.23 to 4.48)
5.58 (1.72 to 18.17)
2.08 (1.17 to 3.74)
1.43 (0.61 to 3.39)
2.56 (1.52 to 4.26)
5.53 (2.18 to 14.15)
2.36 (1.13 to 4.90)
3.56 (1.86 to 6.82)
4.66 (0.61 to 48.42)
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
FIGURE 60 Forest plot with random-class NMA model results for any abstinence. Ns, not specified; std, standard.
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Seven-day point prevalence abstinence
Bupropion std + NRT combo high
Bupropion std + NRT patch (24 hours) ns
Bupropion std + NRT patch (24 hours) high
E-cigarette high + NRT patch (24 hours) ns
Bupropion std + NRT gum high
Varenicline std + NRT patch (16 hours) std
Varenicline std + NRT patch (24 hours) high








NRT patch (24 hours) ns
NRT patch (16 hours) low







NRT mouth spray std
NRT nasal spray std
NRT sublingual tablet ns
Bupropion std + NRT lozenge ns
Bupropion std + NRT inhalator ns






NRT patch (24 hours) high
NRT patch (16 hours) high
Bupropion std + NRT choice ns
FIGURE 61 Network plot for 7-day PPA at treatment level. Ns, not specified; std, standard.





OR (95% CrI) NMA, OR (95% CrI)
No drug treatment 1.02 (0.64 to 1.62) 1.18 (0.87 to 1.61) 1.13 (0.87 to 1.45)
Waitlist – 0.98 (0.53 to 1.79) 0.98 (0.53 to 1.79)
Usual care 0.84 (0.15 to 3.32) 1.10 (0.67 to 1.80) 1.07 (0.66 to 1.72)
NRT not specified 1.60 (1.22 to 2.12) 1.87 (1.48 to 2.35) 1.75 (1.48 to 2.08)
NRT low – 1.48 (0.70 to 3.13) 1.48 (0.70 to 3.13)
NRT standard 1.58 (1.21 to 2.12) – 1.58 (1.21 to 2.12)
NRT high 2.20 (1.73 to 2.80) 1.75 (1.34 to 2.29) 1.99 (1.67 to 2.39)
Bupropion low 1.21 (0.78 to 1.90) – 1.21 (0.78 to 1.90)
Bupropion standard 1.67 (1.48 to 1.88) – 1.67 (1.48 to 1.88)
Varenicline not specified 2.56 (1.21 to 5.42) – 2.56 (1.21 to 5.42)
Varenicline low 1.70 (0.90 to 3.19) 2.18 (0.40 to 11.8) 1.75 (0.97 to 3.13)
Varenicline standard 2.14 (1.86 to 2.46) – 2.14 (1.86 to 2.46)
Bupropion low plus NRT high – 4.76 (1.82 to 12.7) 4.76 (1.82 to 12.7)
Bupropion standard plus NRT not specified 1.77 (1.01 to 3.13) 1.87 (1.29 to 2.73) 1.84 (1.35 to 2.53)
Bupropion standard plus NRT high 2.46 (1.57 to 3.90) 1.91 (1.24 to 2.96) 2.16 (1.57 to 2.97)
Varenicline standard plus NRT standard – 4.01 (2.16 to 7.54) 4.01 (2.16 to 7.54)
Varenicline standard plus NRT high – 2.14 (0.91 to 4.85) 2.14 (0.91 to 4.85)
Varenicline plus bupropion standard 1.75 (0.90 to 3.53) 2.79 (1.58 to 4.90) 2.29 (1.48 to 3.56)
E-cigarette high plus NRT not specified – 4.10 (0.63 to 37.7) 4.10 (0.63 to 37.7)
This table is reproduced with permission from Thomas et al.67 This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and
build upon this work, for commercial use, provided the original work is properly cited. See: https://creativecommons.org/
licenses/by/4.0/. The table includes minor additions and formatting changes to the original table.
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OR (95% CrI) NMA, OR (95% CrI)
Bupropion standard vs. NRT standard – 1.05 (0.78 to 1.41) 1.05 (0.78 to 1.41)
Varenicline standard vs. NRT standard – 1.35 (0.99 to 1.82) 1.35 (0.99 to 1.82)
Varenicline standard plus NRT standard vs. NRT standard – 2.54 (1.28 to 4.98) 2.54 (1.28 to 4.98)
Varenicline plus bupropion standard vs. NRT standard – 1.44 (0.86 to 2.42) 1.44 (0.86 to 2.42)
Varenicline standard vs. bupropion standard – 1.28 (1.08 to 1.53) 1.28 (1.08 to 1.53)
Varenicline standard plus NRT standard vs. bupropion
standard
– 2.42 (1.28 to 4.57) 2.42 (1.28 to 4.57)
Varenicline plus bupropion standard vs. bupropion
standard
– 1.38 (0.88 to 2.17) 1.38 (0.88 to 2.17)
Varenicline standard plus NRT standard vs. varenicline
standard
1.88 (1.02 to 3.46) – 1.88 (1.02 to 3.46)
Varenicline plus bupropion standard vs. varenicline
standard
1.40 (0.79 to 2.49) 0.81 (0.44 to 1.46) 1.07 (0.70 to 1.63)
Varenicline plus bupropion standard vs. varenicline
standard plus NRT standard
– 0.57 (0.27 to 1.20) 0.57 (0.27 to 1.20)
This table is reproduced with permission from Thomas et al.67 This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and
build upon this work, for commercial use, provided the original work is properly cited. See: https://creativecommons.org/
licenses/by/4.0/. The table includes minor additions and formatting changes to the original table.
TABLE 48 Comparison of different NMA models for 7-day PPA (265 data points)
Model Residual deviance DIC SDd (95% CrI) SDD (95% CrI)
Full interaction model, consistency 272.3 1672 0.23 (0.14 to 0.33) –
Random-class model, consistency 275.0 1663 0.22 (0.13 to 0.31) 0.12 (0.01 to 0.34)
Fixed-class model, consistency 274.8 1662 0.23 (0.15 to 0.32) –
Fixed-class model, inconsistency 276.0 1671 0.21 (0.12 to 0.31) –
SDd, standard deviation across treatment effect estimates; SDD, standard deviation across class effect estimates.
This table has been adapted with permission from Thomas et al.67 This is an Open Access article distributed in
accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: https://creativecommons.org/licenses/by/4.0/. The table includes minor additions and formatting changes to the
original table.
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NRT patch (24 hours) ns
NRT sublingual tablet ns
NRT patch (16 hours) low
NRT gum std
NRT inhalator std
NRT mouth spray std
NRT nasal spray std





NRT patch (16 hours) high






Bupropion low + NRT combo high
Bupropion std + NRT inhalator ns
Bupropion std + NRT lozenge ns
Bupropion std + NRT choice ns
Bupropion std + NRT patch (24 hours) ns
Bupropion std + NRT combo high
Bupropion std + NRT gum high
Bupropion std + NRT patch (24 hours) high
Varenicline std + NRT patch (16 hours) std
Varenicline std + NRT patch (24 hours) high
Varenicline and bupropion std
E-cigarette high + NRT patch (24 hours) ns
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
1.09 (0.83 to 1.46)
1.01 (0.44 to 2.27)
1.43 (0.81 to 2.51)
1.79 (1.32 to 2.44)
1.63 (0.99 to 2.72)
1.88 (1.32 to 2.72)
1.95 (1.43 to 2.69)
1.95 (0.90 to 4.31)
1.45 (0.67 to 3.16)
1.42 (1.02 to 1.99)
9.58 (1.32 to 249.64)
3.46 (1.32 to 10.49)
1.72 (0.77 to 3.82)
0.14 (0.00 to 2.56)
2.01 (0.61 to 6.82)
3.35 (2.08 to 5.58)
1.84 (0.89 to 4.01)
1.54 (0.73 to 3.25)
1.82 (0.83 to 4.01)
1.88 (1.52 to 2.34)
1.21 (0.77 to 1.90)
1.67 (1.46 to 1.88)
2.53 (1.21 to 5.37)
1.77 (0.98 to 3.19)
2.16 (1.88 to 2.48)
4.44 (1.73 to 11.94)
5.70 (1.99 to 17.81)
1.70 (1.03 to 2.80)
1.54 (0.90 to 2.69)
1.90 (0.81 to 4.48)
3.29 (0.42 to 30.27)
1.88 (0.99 to 3.60)
2.25 (1.48 to 3.42)
4.06 (2.18 to 7.69)
2.25 (0.91 to 5.26)
2.29 (1.48 to 3.56)
4.48 (0.60 to 46.53)
FIGURE 62 Forest plot with full interaction NMA model results for 7-day PPA. Ns, not specified; std, standard.
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Bupropion low + NRT high
Bupropion std + NRT ns
Bupropion std + NRT high
Varenicline and bupropion std
Varenicline std + NRT std
Varenicline std + NRT high
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
1.12 (0.86 to 1.46)
1.00 (0.54 to 1.84)
1.09 (0.67 to 1.77)
1.79 (1.42 to 2.27)
1.49 (0.71 to 3.13)
1.65 (1.19 to 2.46)
2.03 (1.58 to 2.66)
1.21 (0.79 to 1.88)
1.67 (1.48 to 1.88)
2.53 (1.23 to 5.31)
1.77 (0.99 to 3.16)
2.14 (1.88 to 2.46)
4.53 (1.75 to 12.06)
4.06 (2.18 to 7.54)
2.14 (0.93 to 4.85)
2.32 (1.49 to 3.53)
4.18 (0.64 to 40.45)
1.88 (1.31 to 2.75)
2.12 (1.42 to 3.19)
FIGURE 63 Forest plot with random-class NMA model results for 7-day PPA. Ns, not specified; std, standard.
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Appendix 6 Threshold analyses
List of treatment codes
Treatment classes in bold are the subset used for ranking and threshold analysis.
1. Placebo.
2. No drug treatment.
3. Waitlist.
4. Usual care.




9. Bupropion not specified.
10. Bupropion low.
11. Bupropion standard.




16. E-cigarette not specified.
17. E-cigarette low.
18. E-cigarette high.
19. Bupropion not specified plus NRT not specified.
20. Bupropion low plus NRT high.
21. Bupropion standard plus NRT not specified.
22. Bupropion standard plus NRT standard.
23. Bupropion standard plus NRT high.
24. Varenicline low plus NRT standard.
25. Null.
26. Varenicline standard plus NRT standard.
27. Varenicline standard plus NRT high.
28. Varenicline plus bupropion standard.
29. E-cigarette high plus NRT not specified.
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Appendix 7 Primary and secondary safety
outcome analyses
TABLE 49 List and frequency of treatments delivered in randomised trials included in safety analyses
Treatment Frequency
Bupropion low 9
Bupropion low plus NRT combination high 1
Bupropion not specified plus NRT choice not specified 1
Bupropion standard 79
Bupropion standard plus NRT choice not specified 1
Bupropion standard plus NRT combination high 1
Bupropion standard plus NRT gum not specified 4
Bupropion standard plus NRT gum standard 1
Bupropion standard plus NRT inhalator not specified 1
Bupropion standard plus NRT lozenge not specified 2
Bupropion standard plus NRT patch (24 hours) high 8
E-cigarette high 3
E-cigarette high plus NRT patch (24 hours) not specified 1
E-cigarette low 5
E-cigarette not specified 1
No drug treatment 40
NRT choice not specified 20
NRT choice standard 1
NRT combination high 7
NRT combination not specified 9
NRT combination standard 6
NRT gum high 10
NRT gum not specified 8
NRT gum standard 28
NRT inhalator standard 7
NRT lozenge high 8
NRT lozenge low 2
NRT lozenge not specified 9
NRT lozenge standard 4
NRT mouth spray standard 2
NRT nasal spray not specified 1
NRT nasal spray standard 6
continued
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TABLE 49 List and frequency of treatments delivered in randomised trials included in safety analyses (continued )
Treatment Frequency
NRT not specified 52
NRT patch (16 hours) high 1
NRT patch (16 hours) low 5
NRT patch (16 hours) not specified 1
NRT patch (16 hours) standard 15
NRT patch (24 hours) high 61
NRT patch (24 hours) low 1
NRT patch (24 hours) not specified 30
NRT patch (24 hours) standard 1
NRT sublingual tablet not specified 4
Placebo 244
Usual care 23
Varenicline standard plus bupropion standard 4
Varenicline high 1
Varenicline low 13
Varenicline low plus NRT gum standard 1
Varenicline not specified 2
Varenicline standard 91
Varenicline standard plus NRT gum standard 1
Varenicline standard plus NRT patch (16 hours) standard 2
Varenicline standard plus NRT patch (24 hours) high 3
Waitlist 2
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TABLE 50 List and frequency of treatments delivered in non-randomised studies included in safety analyses
Treatment Frequency
Bupropion low 2
Bupropion not specified plus NRT choice not specified 2
Bupropion not specified 12
Bupropion standard plus NRT choice not specified 2
Bupropion standard plus NRT patch (24 hours) not specified 1
Bupropion standard plus NRT patch (24 hours) standard 1
Bupropion standard 4
Dual use standard 1
E-cigarette standard 1
No treatment 17
NRT choice not specified 12
NRT combination high 2
NRT combination not specified 4
NRT gum high 2
NRT gum not specified 2
NRT gum standard 2
NRT inhalator low 1
NRT inhalator not specified 1
NRT lozenge not specified 1
NRT not specified 8
NRT patch (16 hours) standard 2
NRT patch (24 hours) not specified 15
Usual care 1
Varenicline low 1
Varenicline not specified plus NRT choice not specified 1
Varenicline not specified 20
Varenicline standard plus bupropion standard 1
Varenicline standard plus NRT choice not specified 1
Varenicline standard plus NRT combination not specified 1
Varenicline standard 8
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Bupropion low + NRT combo high
Bupropion std + NRT lozenge ns
[Bupropion std + NRT inhalator ns]
Bupropion std +
NRT patch (24 hours) high
Varenicline std + NRT patch (24 hours) high
Varenicline std + NRT patch (16 hours) std
Varenicline low + NRT gum std
[Varenicline std + NRT gum std]
Placebo
[Usual care]
NRT patch (24 hours) high
FIGURE 64 Network plot for SAEs at treatment level. Square brackets denote interventions that were excluded from
the NMA. Ns, not specified; std, standard.
Varenicline + bupropion std
Varenicline std + NRT patch (16 hours) std





NRT patch (24 hours) ns
NRT sublingual tablet ns












Bupropion std + NRT inhalator ns
Bupropion low + NRT combo high
Bupropion std + NRT lozenge ns
Bupropion std + NRT patch (24 hours) high
Dual smoking
Varenicline low + NRT gum std
Varenicline std + NRT gum std
Placebo
Usual care
NRT patch (24 hours) high
NRT lorenge high
FIGURE 65 Network plot for SAEs incorporating non-randomised evidence at treatment level. Ns, not specified;
std, standard.
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TABLE 51 Comparison of different NMA models for serious AEs (219 data points)
Model Residual deviance DIC SDd (95% CrI) SDD (95% CrI)
Full interaction model, consistency 207.1 1021 0.09 (0.01 to 0.29) –
Random-class model, consistency 205.6 1014 0.07 (0 to 0.28) 0.2 (0.01 to 0.68)
Fixed-class model, consistency 205.8 1012 0.09 (0 to 0.28) –
Fixed-class model, inconsistency 211.1 1027 0.09 (0.01 to 0.29) –
SDd, standard deviation across treatment effect estimates; SDD, standard deviation across class effect estimates.
This table has been adapted with permission from Thomas et al.67 This is an Open Access article distributed in
accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.






NRT mouth spray std
NRT combo high
NRT lozenge high
NRT patch (24 hours) high
NRT choice ns
NRT patch (24 hours) ns








Bupropion low + NRT combo high
Bupropion std + NRT lozenge ns
Bupropion std + NRT patch (24 hours) high
Varenicline and bupropion std
Varenicline std + NRT patch (16 hours) std
Varenicline std + NRT patch (24 hours) high
Intervention OR (95% Crl)
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
1.09 (0.55 to 2.27)
1.13 (0.82 to 1.51)
1.43 (0.69 to 3.13)
1.63 (0.60 to 4.48)
0.74 (0.39 to 1.45)
2.20 (0.36 to 14.01)
0.79 (0.32 to 2.05)
1.57 (0.66 to 3.71)
1.23 (0.70 to 2.12)
2.10 (0.63 to 7.54)
2.29 (1.02 to 5.00)
1.15 (0.82 to 1.70)
0.26 (0.02 to 1.25)
1.30 (1.05 to 1.60)
1.08 (0.54 to 2.29)
1.08 (0.90 to 1.31)
2.10 (0.97 to 4.66)
1.11 (0.19 to 8.85)
0.50 (0.02 to 3.29)
1.34 (0.49 to 3.10)
1.54 (0.37 to 6.17)
1.09 (0.30 to 3.82)
1.72 (0.83 to 3.82)
7.61 (0.57 to 678.58)
FIGURE 66 Forest plot with full interaction NMA model results for SAEs. Ns, not specified; std, standard.
DOI: 10.3310/hta25590 Health Technology Assessment 2021 Vol. 25 No. 59
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Thomas et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
189











Bupropion low + NRT high
Bupropion std + NRT ns
Bupropion std + NRT high
Varenicline and bupropion std
Varenicline std + NRT std
Varenicline std + NRT high
1.12 (0.63 to 2.14)
1.15 (0.77 to 1.77)
1.13 (0.68 to 2.05)
1.36 (0.87 to 2.53)
0.25 (0.02 to 1.32)
1.30 (1.05 to 1.60)
1.19 (0.59 to 2.29)
1.09 (0.92 to 1.32)
7.92 (0.59 to 6310.69)
1.77 (0.99 to 3.25)
1.26 (0.23 to 6.96)
0.48 (0.02 to 3.25)
1.38 (0.57 to 3.32)
1.39 (0.36 to 5.81)
1.12 (0.25 to 3.71)
1.88 (0.82 to 4.01)
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
FIGURE 67 Forest plot with random-class NMA model results for SAEs. Ns, not specified; std, standard.
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Sensitivity analyses
Analysis excluding studies at high risk of bias
This analysis was based on 76 studies. The estimate of the SD between class effects was 0.11
(0.01, 0.33).










Bupropion std + NRT high
Varenicline and bupropion std
Varenicline std + NRT std
Varenicline std + NRT high
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
0.86 (0.29 to 2.41)
1.09 (0.79 to 1.51)
1.21 (0.78 to 1.99)
1.32 (0.93 to 1.93)
0.28 (0.02 to 1.54)
1.26 (1.01 to 1.60)
1.11 (0.41 to 3.00)
1.09 (0.90 to 1.32)
2.36 (1.05 to 5.21)
1.40 (0.47 to 3.46)
1.45 (0.33 to 9.30)
1.07 (0.26 to 3.63)
1.88 (0.90 to 3.94)
FIGURE 68 Forest plot with fixed-class NMA model results for SAEs without studies at high risk of bias. Ns, not
specified; std, standard.
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Sensitivity analysis excluding studies of pharmacological treatment plus counselling
(if counselling is not given in all study arms)
This analysis was based on 97 studies. The estimate of the SD between class effects was 0.09
(0.01, 0.27), which is nearly identical to that for the main analysis.
Intervention OR (95% Crl)
0.2 0.5 1.0 2.0 5.0












Bupropion low + NRT high
Bupropion std + NRT ns
Varenicline and bupropion std
Varenicline low + NRT std
Varenicline std + NRT std
Varenicline std + NRT high
1.13 (0.53 to 2.20)
0.31 (0.02 to 2.44)
1.14 (0.87 to 1.48)
1.22 (0.72 to 1.95)
1.23 (0.83 to 1.68)
0.30 (0.03 to 1.48)
1.30 (1.03 to 1.60)
1.09 (0.59 to 2.20)
1.11 (0.92 to 1.32)
7.32 (0.55 to 1619.71)
1.70 (1.03 to 2.94)
1.31 (0.21 to 7.69)
0.56 (0.03 to 3.42)
8.50 (0.16 to 2779.43)
1.48 (0.31 to 7.77)
1.11 (0.27 to 3.67)
1.92 (0.87 to 4.06)
FIGURE 69 Forest plot with fixed-class NMA model results for SAEs without studies that include pharmacological
treatment plus counselling (unless counselling included in all arms). Ns, not specified; std, standard.
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Meta-regressions
Industry sponsorship as covariate
This analysis was based on 96 studies. There was inconclusive evidence of effect modification based on
industry sponsorship (B = –0.87, –195.4 to 197.5). The estimate of the SD between class effects was
0.09 (0.00, 0.29).
Intervention OR (95% Crl)
0.2 0.5 1.0 2.0 5.0












Bupropion low + NRT high
Bupropion std + NRT ns
Varenicline and bupropion std
Varenicline low + NRT std
Varenicline std + NRT std
Varenicline std + NRT high
1.13 (0.53 to 2.20)
0.31 (0.02 to 2.44)
1.14 (0.87 to 1.48)
1.22 (0.72 to 1.95)
1.23 (0.83 to 1.68)
0.30 (0.03 to 1.48)
1.30 (1.03 to 1.60)
1.09 (0.59 to 2.20)
1.11 (0.92 to 1.32)
7.32 (0.55 to 1619.71)
1.70 (1.03 to 2.94)
1.31 (0.21 to 7.69)
0.56 (0.03 to 3.42)
8.50 (0.16 to 2779.43)
1.48 (0.31 to 7.77)
1.11 (0.27 to 3.67)
1.92 (0.87 to 4.06)
FIGURE 70 Forest plot with fixed-class NMA model results for SAEs adjusted for sponsorship. Ns, not specified;
std, standard.
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Placebo type as covariate
This analysis was based on 84 studies. There was inconclusive evidence of effect modification based on
type of placebo (B = –0.23, –195.1 to 196.5). The estimate of the SD between class effects was 0.12
(0.01, 0.33).








Bupropion std + NRT high
Varenicline and bupropion std
Varenicline std + NRT high
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
1.06 (0.79 to 1.49)
1.13 (0.76 to 1.72)
1.40 (0.95 to 2.08)
0.29 (0.02 to 1.70)
1.28 (1.05 to 1.62)
1.14 (0.55 to 2.41)
1.09 (0.91 to 1.32)
1.38 (0.47 to 3.35)
1.06 (0.27 to 3.46)
1.86 (0.84 to 3.94)
FIGURE 71 Forest plot with fixed-class NMA model results for SAEs adjusted for type of placebo. Ns, not specified;
std, standard.
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Treatment duration as covariate
This analysis was based on 98 studies. There was inconclusive evidence of effect modification as a
function of treatment duration (B = 0.03, –0.04 to 0.10). The estimate of the SD between class effects
was 0.16 (0.01, 0.58).









Bupropion low + NRT high
Bupropion std + NRT high
Varenicline and bupropion std
Varenicline low + NRT std
Varenicline std + NRT std
Varenicline std + NRT high
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
1.63 (0.31 to 21.33)
1.25 (0.16 to 22.42)
1.67 (0.32 to 23.57)
0.05 (0.00 to 3.06)
1.79 (0.35 to 21.98)
1.09 (0.23 to 15.64)
1.16 (0.22 to 14.73)
3.53 (0.51 to 61.56)
1.14 (0.07 to 29.08)
3.42 (0.45 to 59.74)
14.01 (0.15 to 5767.53)
2.29 (0.21 to 73.70)
2.01 (0.24 to 36.60)
1.93 (0.27 to 30.57)
FIGURE 72 Forest plot with fixed-class NMA model results for SAEs adjusted for treatment duration. Ns, not specified;
std, standard.
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Counselling as covariate
This analysis was based on 101 studies. There was inconclusive evidence of effect modification as a
function of counselling (B = –0.26, –2.29 to 1.75). The estimate of the SD between class effects was
0.11 (0, 0.28).












Bupropion low + NRT high
Bupropion std + NRT ns
Varenicline and bupropion std
Varenicline low + NRT std
Varenicline std + NRT std
Varenicline std + NRT high
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
1.11 (0.58 to 2.20)
0.17 (0.00 to 2.83)
1.12 (0.85 to 1.45)
1.09 (0.72 to 1.70)
1.20 (0.90 to 1.67)
0.27 (0.03 to 1.52)
1.30 (1.05 to 1.60)
1.14 (0.54 to 2.41)
1.09 (0.91 to 1.31)
14.59 (0.66 to 5541.39)
1.68 (1.01 to 2.83)
1.12 (0.18 to 6.05)
0.42 (0.02 to 2.39)
5.81 (0.18 to 934.49)
1.42 (0.32 to 7.61)
1.07 (0.30 to 3.71)
1.79 (0.86 to 3.94)
FIGURE 73 Forest plot with fixed-class NMA model results for SAEs adjusted for counselling. Ns, not specified;
std, standard.
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Dependence as covariate
This analysis was based on 70 studies. There was inconclusive evidence of effect modification as a
function of dependence (B = 0.12, –0.28 to 0.47). The estimate of the SD between class effects was
0.09 (0.01, 0.31).











Bupropion low + NRT high
Bupropion std + NRT ns
Bupropion std + NRT high
Varenicline and bupropion std
Varenicline std + NRT std
Varenicline std + NRT high
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
1.32 (0.59 to 2.66)
0.23 (0.01 to 2.18)
1.27 (0.93 to 1.67)
1.19 (0.76 to 1.80)
1.51 (0.93 to 2.44)
0.11 (0.00 to 0.98)
1.40 (1.08 to 1.75)
1.08 (0.47 to 2.25)
1.14 (0.95 to 1.36)
1.99 (1.16 to 3.53)
1.57 (0.25 to 10.91)
0.38 (0.01 to 3.03)
1.55 (0.57 to 3.71)
1.36 (0.35 to 6.82)
1.07 (0.26 to 3.78)
1.95 (0.91 to 4.44)
FIGURE 74 Forest plot with fixed-class NMA model results for SAEs adjusted for dependence. Ns, not specified;
std, standard.
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Comorbidities as covariate
This analysis was based on 101 studies. There was inconclusive evidence of effect modification as a
function of the covariate (B = –0.24, –196.8 to 195.1). The estimate of the SD between class effects
was 0.09 (0.01, 0.28).













Bupropion low + NRT high
Bupropion std + NRT ns
Bupropion std + NRT high
Varenicline and bupropion std
Varenicline std + NRT std
Varenicline low + NRT std
Varenicline std + NRT high
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
1.11 (0.58 to 2.20)
0.24 (0.01 to 1.95)
1.12 (0.88 to 1.43)
1.11 (0.70 to 1.68)
1.20 (0.90 to 1.70)
0.26 (0.02 to 1.80)
1.30 (1.06 to 1.62)
11.94 (0.78 to 1312.91)
1.11 (0.54 to 2.36)
1.11 (0.93 to 1.31)
11.25 (0.82 to 10,509.13)
1.68 (1.03 to 2.86)
1.20 (0.22 to 7.54)
0.41 (0.02 to 2.46)
1.31 (0.54 to 3.32)
9.21 (0.14 to 4769.52)
1.63 (0.32 to 6.75)
1.09 (0.30 to 3.42)
1.82 (0.82 to 4.18)
FIGURE 75 Forest plot with fixed-class NMA model results for SAEs adjusted for comorbidities. Ns, not specified;
std, standard.
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Psychiatric comorbidities as covariate
This analysis was based on 101 studies. There was inconclusive evidence of effect modification as a
function of the covariate (B = –0.24, –196.8 to 195.1). The estimate of the SD between class effects
was 0.09 (0.01, 0.28).













Bupropion low + NRT high
Bupropion std + NRT ns
Bupropion std + NRT high
Varenicline and bupropion std
Varenicline std + NRT std
Varenicline low + NRT std
Varenicline std + NRT high
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
1.11 (0.58 to 2.20)
0.24 (0.01 to 1.95)
1.12 (0.88 to 1.43)
1.11 (0.70 to 1.68)
1.20 (0.90 to 1.70)
0.26 (0.02 to 1.80)
1.30 (1.06 to 1.62)
11.94 (0.78 to 1312.91)
1.11 (0.54 to 2.36)
1.11 (0.93 to 1.31)
11.25 (0.82 to 10,509.13)
1.68 (1.03 to 2.86)
1.20 (0.22 to 7.54)
0.41 (0.02 to 2.46)
1.31 (0.54 to 3.32)
9.21 (0.14 to 4769.52)
1.63 (0.32 to 6.75)
1.09 (0.30 to 3.42)
1.82 (0.82 to 4.18)
FIGURE 76 Forest plot with fixed-class NMA model results for SAEs adjusted for psychiatric comorbidities. Ns, not
specified; std, standard.
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Willingness to quit as covariate
This analysis was based on 101 studies. There was inconclusive evidence of effect modification as a
function of the covariate (B = –0.24, –196.8 to 195.1). The estimate of the SD between class effects
was 0.09 (0.01, 0.28).













Bupropion low + NRT high
Bupropion std + NRT ns
Bupropion std + NRT high
Varenicline and bupropion std
Varenicline std + NRT std
Varenicline low + NRT std
Varenicline std + NRT high
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
1.11 (0.58 to 2.20)
0.24 (0.01 to 1.95)
1.12 (0.88 to 1.43)
1.11 (0.70 to 1.68)
1.20 (0.90 to 1.70)
0.26 (0.02 to 1.80)
1.30 (1.06 to 1.62)
11.94 (0.78 to 1312.91)
1.11 (0.54 to 2.36)
1.11 (0.93 to 1.31)
11.25 (0.82 to 10,509.13)
1.68 (1.03 to 2.86)
1.20 (0.22 to 7.54)
0.41 (0.02 to 2.46)
1.31 (0.54 to 3.32)
9.21 (0.14 to 4769.52)
1.63 (0.32 to 6.75)
1.09 (0.30 to 3.42)
1.82 (0.82 to 4.18)
FIGURE 77 Forest plot with fixed-class NMA model results for SAEs adjusted for willingness to quit. Ns, not specified;
std, standard.
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Smokeless tobacco as covariate
This analysis was based on 101 studies. There was inconclusive evidence of effect modification as a
function of the covariate (B = –0.24, –196.8 to 195.1). The estimate of the SD between class effects
was 0.09 (0.01, 0.28).













Bupropion low + NRT high
Bupropion std + NRT ns
Bupropion std + NRT high
Varenicline and bupropion std
Varenicline std + NRT std
Varenicline low + NRT std
Varenicline std + NRT high
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
1.11 (0.58 to 2.20)
0.24 (0.01 to 1.95)
1.12 (0.88 to 1.43)
1.11 (0.70 to 1.68)
1.20 (0.90 to 1.70)
0.26 (0.02 to 1.80)
1.30 (1.06 to 1.62)
11.94 (0.78 to 1312.91)
1.11 (0.54 to 2.36)
1.11 (0.93 to 1.31)
11.25 (0.82 to 10,509.13)
1.68 (1.03 to 2.86)
1.20 (0.22 to 7.54)
0.41 (0.02 to 2.46)
1.31 (0.54 to 3.32)
9.21 (0.14 to 4769.52)
1.63 (0.32 to 6.75)
1.09 (0.30 to 3.42)
1.82 (0.82 to 4.18)
FIGURE 78 Forest plot with fixed-class NMA model results for SAEs adjusted for smokeless tobacco. Ns, not specified;
std, standard.
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Smoking level as covariate
This analysis was based on 78 studies. There was inconclusive evidence of effect modification as a
function of the covariate (B = 0.01, –0.53 to 0.48). The estimate of the SD between class effects was
0.09 (0, 0.30).
Intervention OR (95% Crl)
1.13 (0.54 to 2.29)
0.26 (0.00 to 2.18)
1.17 (0.89 to 1.57)
1.13 (0.74 to 1.75)
1.25 (0.91 to 1.75)
0.32 (0.02 to 1.86)
1.28 (1.04 to 1.62)
17.81 (0.82 to 10,509.13)
1.06 (0.49 to 2.12)
1.08 (0.90 to 1.32)
1.34 (0.54 to 3.42)
1.43 (0.35 to 6.30)
1.09 (0.23 to 3.97)
1.86 (0.90 to 4.18)
2.27 (1.01 to 5.21)
0.44 (0.00 to 3.06)
0.2 0.5 1.0 2.0 5.0












Bupropion std + NRT high
Bupropion std + NRT ns
Varenicline and bupropion std
Varenicline std + NRT std
Varenicline std + NRT high
FIGURE 79 Forest plot with fixed-class NMA model results for SAEs adjusted for smoking level. Ns, not specified;
std, standard.
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
202
Publication year as covariate
This analysis was based on 96 studies. There was inconclusive evidence of effect modification based
on publication year (B = 0.14, –196.2 to 194.9). The estimate of the SD between class effects was
0.41 (0.01, 0.29).
Intervention OR (95% Crl)
0.2 0.5 1.0 2.0 5.0












Bupropion low + NRT high
Bupropion std + NRT ns
Varenicline and bupropion std
Varenicline std + NRT std
Varenicline low + NRT std
Varenicline std + NRT high
1.13 (0.53 to 2.20)
0.31 (0.02 to 2.44)
1.14 (0.87 to 1.48)
1.22 (0.72 to 1.95)
1.23 (0.83 to 1.68)
0.30 (0.03 to 1.48)
1.30 (1.03 to 1.60)
1.09 (0.59 to 2.20)
1.11 (0.92 to 1.32)
1.70 (1.03 to 2.94)
1.31 (0.21 to 7.69)
0.56 (0.03 to 3.42)
8.50 (0.16 to 2779.43)
1.11 (0.27 to 3.67)
1.92 (0.87 to 4.06)
1.48 (0.31 to 7.77)
7.32 (0.55 to 1619.71)
FIGURE 80 Forest plot with fixed-class NMA model results for SAEs adjusted for publication year. Ns, not specified;
std, standard.
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Major adverse cardiovascular events





NRT patch (16 hours) std








[Bupropion std + NRT inhalator ns]
Bupropion std + NRT gum std
Bupropion  std + NRT patch (24 hours) high
Varenicline std + NRT patch (24 hours) high
Placebo
[Usual care]
NRT patch (24 hours) high
FIGURE 81 Network plot for major adverse cardiovascular events at treatment level. Square brackets denote
interventions that were not included in the NMA. Ns, not specified; std, standard.





NRT patch (24 hours) ns











Bupropion std + NRT inhalator ns
Bupropion std + NRT gum std
Bupropion std + NRT patch (24 hours) high
Dual smoking
Varenicline std + NRT patch (24 hours) high
Placebo
Usual care
NRT patch (16 hours) std
NRT patch (24 hours) high
FIGURE 82 Network plot for major adverse cardiovascular events (including randomised and non-randomised studies)
at treatment level. Ns, not specified; std, standard.
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TABLE 52 Comparison of different NMA models for major adverse cardiovascular events (91 data points)
Model Residual deviance DIC SDd (95% CrI) SDD (95% CrI)
Full interaction model, consistency 82.49 341.1 0.26 (0.01 to 0.82) –
Random-class model, consistency 80.3 366.7 0.26 (0.02 to 0.79) 0.54 (0.02 to 2.75)
Fixed-class model, consistency 79.51 334 0.23 (0.01 to 0.73) –
Fixed-class model, inconsistency 80.61 338.3 0.22 (0.01 to 0.72) –
SDd, standard deviation across treatment effect estimates; SDD, standard deviation across class effect estimates.
This table has been adapted with permission from Thomas et al.67 This is an Open Access article distributed in
accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: https://creativecommons.org/licenses/by/4.0/. The table includes minor additions and formatting changes to the
original table.







NRT mouth spray std
NRT patch (16 hours) std





Bupropion std + NRT gum std
Bupropion std + NRT patch (24 hours) high
Varenicline and bupropion std
Varenicline std + NRT patch (24 hours) high
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
1.09 (0.24 to 5.37)
0.70 (0.30 to 1.67)
0.51 (0.05 to 4.35)
1.99 (0.05 to 59.15)
0.63 (0.02 to 21.76)
2.83 (0.26 to 88.23)
0.18 (0.00 to 5.64)
1.68 (0.09 to 43.38)
1.01 (0.32 to 3.63)
0.17 (0.00 to 4.95)
1.26 (0.70 to 2.27)
0.72 (0.40 to 1.26)
4.90 (0.70 to 43.38)
0.35 (0.00 to 6.05)
0.10 (0.00 to 1.90)
0.45 (0.03 to 4.95)
0.09 (0.00 to 1.62)
FIGURE 83 Forest plot with full interaction NMA model results for major adverse cardiovascular events. Ns, not
specified; std, standard.
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Bupropion std + NRT std
Bupropion std + NRT high
Varenicline and bupropion std
Varenicline std + NRT high
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
1.09 (0.23 to 5.42)
0.74 (0.14 to 4.31)
0.95 (0.12 to 7.39)
1.15 (0.19 to 9.12)
0.12 (0.00 to 3.22)
1.23 (0.68 to 2.27)
0.73 (0.40 to 1.26)
4.18 (0.75 to 30.27)
0.31 (0.00 to 5.93)
0.10 (0.00 to 2.01)
0.43 (0.02 to 4.22)
0.10 (0.00 to 1.80)
FIGURE 84 Forest plot with random-class NMA model results for major adverse cardiovascular events. Ns, not specified;
std, standard.
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This analysis was based on 40 studies. There was inconclusive evidence of effect modification based
on comorbidities (B = –1.01, –197.3 to 195). The estimate of the SD between class effects was 0.23
(0.02, 0.76).
Intervention OR (95% Crl)
1.15 (0.23 to 5.47)
0.73 (0.32 to 1.70)
1.02 (0.23 to 5.21)
1.11 (0.41 to 3.10)
0.17 (0.00 to 3.42)
1.28 (0.70 to 2.39)
0.74 (0.41 to 1.26)
3.46 (0.79 to 23.81)
0.38 (0.00 to 6.96)
0.10 (0.00 to 2.29)
0.46 (0.03 to 4.81)









Bupropion std + NRT std
Bupropion std + NRT high
Varenicline and bupropion std
Varenicline std + NRT high
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
FIGURE 85 Forest plot with fixed-class NMA model results for MACE adjusted for comorbidities. Ns, not specified;
std, standard.
DOI: 10.3310/hta25590 Health Technology Assessment 2021 Vol. 25 No. 59
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Thomas et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
207
Smoking level as covariate
This analysis was based on 33 studies. There was inconclusive evidence of effect modification based
on smoking level (B = –0.29, –6.12 to 3). The estimate of the SD between class effects was 0.37
(0.02, 1.06).








Bupropion std + NRT std
Bupropion std + NRT high
Varenicline and bupropion std
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
1.22 (0.23 to 6.23)
1.09 (0.17 to 8.67)
0.98 (0.26 to 3.82)
0.15 (0.00 to 3.74)
1.16 (0.51 to 2.56)
0.83 (0.40 to 1.55)
4.57 (0.66 to 49.90)
0.29 (0.00 to 7.17)
0.09 (0.00 to 2.29)
0.11 (0.00 to 2.03)
FIGURE 86 Forest plot with fixed-class NMA model results for MACE adjusted for smoking level. Std, standard.
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Major adverse neuropsychiatric events






NRT patch (24 hours) ns
NRT mouth spray std














NRT patch (24 hours) high
Varenicline std + NRT patch (16 hours) std
Varenicline std + NRT patch (24 hours) high
Placebo
Usual care
NRT patch (24 hours) high
FIGURE 87 Network plot for major adverse neuropsychiatric events at treatment level. Ns, not specified; std, standard.






NRT patch (24 hours) ns
NRT mouth spray std








Bupropion std + NRT inhalator ns
Bupropion ns + NRT choice ns
Varenicline ns + NRT choice ns
Varenicline std + NRT choice ns
Bupropion std + NRT lozenge ns
Bupropion std + NRT choice ns
Bupropion std +
NRT patch (24 hours) high
Bupropion std +
NRT patch (24 hours) std
Varenicline std + NRT patch (16 hours) std
Varenicline std + NRT patch (24 hours) high
Placebo
Usual care
NRT patch (24 hours) std
FIGURE 88 Network plot for major adverse neuropsychiatric events (combining randomised and non-randomised
evidence) at treatment level. Ns, not specified; std, standard.
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TABLE 53 Comparison of different NMA models for major adverse neuropsychiatric events (158 data points)
Model Residual deviance DIC SDd (95% CrI) SDD (95% CrI)
Full interaction model, consistency 154.2 717.5 0.15 (0.01 to 0.44) –
Random-class model, consistency 153.9 717.1 0.17 (0.01 to 0.45) 0.92 (0.18 to 2.32)
Fixed-class model, consistency 154.4 717.5 0.33 (0.05 to 0.60) –
Fixed-class model, inconsistency 158.2 722.5 0.18 (0.02 to 0.47) –
SDd, standard deviation across treatment effect estimates; SDD: standard deviation across class effect estimates.
This table has been adapted with permission from Thomas et al.67 This is an Open Access article distributed in
accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: https://creativecommons.org/licenses/by/4.0/. The table includes minor additions and formatting changes to the
original table.









Bupropion std + NRT lozenge ns
Bupropion std + NRT choice ns
Bupropion std + NRT patch (24 hours) high
Varenicline std + NRT patch (16 hours) std
Varenicline std + NRT patch (24 hours) high
Varenicline and bupropion std
NRT lozenge ns
NRT choice ns
NRT mouth spray std
NRT combo high
NRT gum high
NRT patch (24 hours) high
NRT patch (24 hours) ns
0.26 (0.06 to 0.98)
0.02 (0.00 to 0.31)
0.73 (0.49 to 1.02)
1.03 (0.35 to 3.56)
0.54 (0.07 to 3.53)
0.06 (0.00 to 0.24)
0.16 (0.00 to 1.42)
0.12 (0.00 to 2.03)
1.36 (0.21 to 17.29)
1.54 (0.54 to 4.06)
0.46 (0.19 to 1.05)
0.63 (0.46 to 0.81)
1.60 (0.25 to 14.88)
1.12 (0.09 to 9.87)
0.94 (0.78 to 1.14)
2.25 (0.08 to 28.79)
0.49 (0.17 to 1.27)
0.28 (0.05 to 0.98)
1.79 (0.39 to 8.41)
0.79 (0.27 to 2.18)
0.12 (0.00 to 0.88)
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
FIGURE 89 Forest plot with full interaction NMA model results for major adverse neuropsychiatric events. Ns, not
specified; std, standard.
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Intervention OR (95% Crl)
0.2 0.5 1.0 2.0 5.0









Bupropion std + NRT ns
Bupropion std + NRT high
Varenicline std + NRT std
Varenicline std + NRT high
Varenicline and bupropion std
NRT high
0.28 (0.05 to 1.02)
0.03 (0.00 to 0.34)
0.41 (0.11 to 1.22)
0.10 (0.00 to 2.51)
0.85 (0.19 to 3.94)
0.64 (0.48 to 0.84)
1.60 (0.23 to 12.06)
1.12 (0.04 to 10.38)
0.94 (0.79 to 1.15)
0.80 (0.11 to 5.64)
0.26 (0.05 to 1.00)
1.62 (0.38 to 9.58)
0.74 (0.24 to 2.10)
0.12 (0.00 to 0.81)
FIGURE 90 Forest plot with random-class NMA model results for major adverse neuropsychiatric events. Ns, not
specified; std, standard.
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Meta-regressions
Psychiatric comorbidities as covariate
This analysis was based on 71 studies. There was inconclusive evidence of effect modification based on
psychiatric comorbidities (B = 0.38, –196 to 195.2). The estimate of the SD between class effects was
0.33 (0.04, 0.61).










Bupropion std + NRT ns
Bupropion std + NRT high
Varenicline std + NRT std
Varenicline std + NRT high
Varenicline and bupropion std
NRT high
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
0.27 (0.05 to 1.12)
0.03 (0.00 to 0.40)
0.48 (0.05 to 3.97)
0.60 (0.38 to 0.89)
0.12 (0.00 to 2.18)
0.74 (0.41 to 1.34)
0.67 (0.47 to 0.92)
1.63 (0.22 to 15.96)
1.01 (0.08 to 11.70)
0.96 (0.77 to 1.21)
1.12 (0.40 to 2.97)
0.22 (0.04 to 0.95)
1.73 (0.33 to 10.49)
0.64 (0.18 to 2.14)
0.15 (0.00 to 0.98)
FIGURE 91 Forest plot with fixed-class NMA model results for MANE adjusted for psychiatric comorbidities. Ns, not
specified; std, standard.
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Appendix 8 Tertiary and other safety
outcome analyses







NRT patch (24 hours) ns
NRT sublingual tablet ns
NRT gum std
NRT lozenge std
NRT mouth spray std
NRT nasal spray std
NRT patch (16 hours) std












[E-cigarette high + NRT patch (24 hours) ns]
Bupropion std + NRT inhalator ns
Bupropion low + NRT combined ns
[Varenicline low + NRT gum std]
[Varenicline std + NRT gum std]
Bupropion std + NRT lozenge ns
Bupropion std + NRT combined ns
Bupropion std + NRT patch (24 hours) high
Varenicline std + NRT patch (16 hours) std




NRT patch (24 hours) std
FIGURE 92 Network plot for nausea at treatment level. Square brackets denote interventions that were not included in
the NMA. Ns, not specified; std, standard.
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Bupropion low + NRT ns
Bupropion std + NRT high
Varenicline std + NRT std
Varenicline std + NRT high






Bupropion std + NRT ns
0.18 (0.08 to 0.39)
0.41 (0.01 to 3.22)
0.75 (0.16 to 3.10)
1.62 (1.30 to 2.05)
3.00 (0.84 to 11.36)
1.43 (0.95 to 2.18)
3.86 (3.25 to 4.62)
19.11 (5.75 to 64.07)
3.67 (0.80 to 17.81)
1.95 (0.95 to 4.01)
5.21 (2.32 to 11.70)
2.01 (0.91 to 4.44)
2.92 (1.49 to 5.64)
2.20 (1.40 to 3.71)
0.62 (0.19 to 1.93)
1.45 (0.92 to 2.29)
1.82 (1.01 to 3.46)
2.48 (0.61 to 12.18)
2.36 (1.03 to 5.70)
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
FIGURE 93 Random-class NMA results for nausea. Ns, not specified; std, standard.
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NRT patch (24 hours) ns
NRT sublingual tablet ns
NRT lozenge low
NRT patch (16 hours) low
NRT gum std
NRT  inhalator std
NRT lozenge low
NRT mouth spray std
NRT nasal spray std
NRT patch (16 hours) std
NRT gum high
NRT lozenge high








Bupropion low + NRT combined ns
Bupropion std + NRT inhalator ns
Bupropion std + NRT lozenge ns
Bupropion std + NRT combined ns
Bupropion std + NRT patch (24 hours) high
Varenicline std + NRT patch (16 hours) std
Varenicline std + NRT patch (24 hours) high
Varenicline and bupropion std
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
0.20 (0.09 to 0.43)
0.38 (0.01 to 3.10)
0.46 (0.01 to 5.21)
1.03 (0.71 to 1.49)
2.77 (1.73 to 4.48)
3.49 (0.90 to 13.87)
4.62 (2.39 to 9.12)
1.65 (0.90 to 3.06)
4.18 (1.65 to 11.02)
0.64 (0.15 to 2.53)
0.51 (0.11 to 2.05)
1.62 (0.84 to 3.06)
1.35 (0.63 to 2.92)
2.48 (1.28 to 4.85)
1.46 (0.50 to 4.26)
1.58 (0.88 to 2.83)
0.76 (0.38 to 1.52)
2.18 (1.03 to 4.62)
2.46 (1.27 to 4.71)
1.52 (1.07 to 2.16)
1.63 (1.30 to 2.05)
2.97 (0.83 to 11.02)
1.43 (0.94 to 2.16)
3.82 (3.19 to 4.57)
19.11 (5.70 to 64.07)
2.66 (0.55 to 14.73)
2.77 (0.29 to 217.02)
3.53 (0.75 to 17.81)
1.27 (0.02 to 21.33)
1.77 (0.81 to 3.74)
4.90 (1.72 to 14.30)
1.77 (0.87 to 3.63)
5.16 (2.25 to 11.70)
1.84 (0.83 to 4.10)
2.86 (1.46 to 5.64)
FIGURE 94 Standard NMA results for nausea. Ns, not specified; std, standard.
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NRT patch (24 hours) ns
NRT sublingual tablet ns
NRT gum std
NRT lozenge std
NRT mouth spray std
NRT nasal spray std
NRT patch (16 hours) std
NRT gum high
NRT lozenge high
NRT patch (16 hours) high









[E-cigarette high + NRT patch (24 hours) ns]
[Bupropion std + NRT inhalator ns]
Bupropion low + NRT combined ns
[Varenicline low + NRT gum std]
[Varenicline std + NRT gum std]
Bupropion std + NRT lozenge ns
Bupropion std + NRT combined ns
Bupropion std + NRT patch (24 hours) high
Varenicline std + NRT patch (16 hours) std




[NRT patch (24 hours) std]
FIGURE 95 Network plot for headache at treatment level. Square brackets denote interventions that were not included
in the NMA. Ns, not specified; std, standard.
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Bupropion low + NRT ns
Bupropion std + NRT high
Varenicline std + NRT std
Varenicline std + NRT high





Bupropion std + NRT ns
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
0.26 (0.13 to 0.48)
1.79 (0.34 to 7.03)
0.92 (0.58 to 1.48)
1.00 (0.88 to 1.15)
1.30 (0.61 to 2.83)
1.17 (0.88 to 1.55)
1.09 (0.96 to 1.25)
1.19 (0.34 to 4.26)
0.99 (0.26 to 3.71)
0.90 (0.61 to 1.31)
1.00 (0.49 to 2.01)
0.83 (0.45 to 1.49)
0.98 (0.64 to 1.51)
1.02 (0.82 to 1.27)
1.15 (0.87 to 1.48)
1.03 (0.81 to 1.34)
0.54 (0.23 to 1.17)
1.09 (0.68 to 1.73)
FIGURE 96 Random-class NMA results for headache. Ns, not specified; std, standard.
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Intervention OR (95% Crl)
0.2 0.5 1.0 2.0 5.0







NRT patch (24 hours) ns
NRT sublingual tablet ns
NRT gum std
NRT lozenge std
NRT mouth spray std
NRT nasal spray std
NRT patch (16 hours) std
NRT gum high
NRT lozenge high
NRT patch (16 hours) high









Bupropion low + NRT combined ns
Bupropion std + NRT lozenge ns
Bupropion std + NRT combined ns
Bupropion std + NRT patch (24 hours) high
Varenicline std + NRT patch (16 hours) std
Varenicline std + NRT patch (24 hours) high
Varenicline and bupropion std
0.21 (0.10 to 0.41)
1.75 (0.31 to 7.39)
1.00 (0.81 to 1.23)
0.87 (0.63 to 1.21)
1.31 (0.45 to 4.01)
0.95 (0.52 to 1.70)
1.22 (0.76 to 1.95)
0.94 (0.24 to 3.90)
0.86 (0.35 to 2.18)
0.98 (0.51 to 1.84)
0.85 (0.46 to 1.58)
1.30 (0.92 to 1.82)
1.48 (0.84 to 2.56)
1.17 (0.76 to 1.84)
1.39 (0.88 to 2.20)
1.04 (0.54 to 1.99)
0.87 (0.68 to 1.12)
0.91 (0.57 to 1.46)
1.00 (0.87 to 1.15)
1.30 (0.58 to 2.89)
1.16 (0.86 to 1.55)
1.08 (0.95 to 1.22)
1.21 (0.34 to 4.31)
0.79 (0.27 to 2.29)
0.37 (0.13 to 1.00)
0.88 (0.23 to 3.42)
0.98 (0.54 to 1.75)
1.11 (0.55 to 2.14)
0.89 (0.59 to 1.32)
0.99 (0.49 to 2.03)
0.82 (0.44 to 1.51)
0.97 (0.62 to 1.51)
FIGURE 97 Standard NMA results for headache. Ns, not specified; std, standard.
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[Bupropion std + NRT inhalator ns]
Bupropion std + NRT lozenge ns
Bupropion std + NRT combined ns
Varenicline std + NRT patch (24 hours) high
Bupropion std + NRT patch (24 hours) high
Varenicline std
Varenicline low
NRT patch (24 hours) high
NRT mouth spray std
NRT inhalator std




FIGURE 98 Network plot for dry mouth at treatment level. Square brackets denote interventions that were not included
in the NMA. Ns, not specified; std, standard.
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Intervention OR (95% Crl)
0.05 (0.00 to 0.36)
0.23 (0.03 to 1.12)
0.93 (0.49 to 1.79)
1.65 (0.90 to 3.03)
1.92 (1.58 to 2.34)
1.11 (0.58 to 2.12)
1.13 (0.89 to 1.43)
1.99 (1.20 to 3.42)
0.53 (0.20 to 1.32)
2.44 (1.28 to 4.66)
3.86 (1.08 to 12.30)
0.83 (0.28 to 1.62)
0.90 (0.29 to 2.89)
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
No treatment
Varenicline and bupropion std
Bupropion std + NRT high
Varenicline std + NRT high









FIGURE 99 Random-class NMA results for dry mouth. Ns, not specified; std, standard.
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Intervention OR (95% Crl)
No treatment
Varenicline and bupropion std
Bupropion std + NRT patch (24 hours) high
Bupropion std + NRT lozenge ns
Varenicline std + NRT patch (24 hours) high





NRT patch (24 hours) high





NRT patch (24 hours) ns
NRT combined ns
NRT ns
0.04 (0.00 to 0.34)
0.23 (0.03 to 1.08)
1.04 (0.68 to 1.62)
0.63 (0.33 to 1.20)
0.04 (0.00 to 0.50)
1.45 (0.66 to 3.22)
0.96 (0.08 to 10.18)
0.84 (0.20 to 3.49)
0.92 (0.35 to 2.48)
0.90 (0.47 to 1.73)
1.65 (0.90 to 3.00)
1.92 (1.58 to 2.34)
1.12 (0.58 to 2.12)
1.14 (0.89 to 1.46)
4.71 (1.93 to 11.70)
2.39 (0.96 to 5.93)
2.08 (1.23 to 3.53)
0.55 (0.21 to 1.40)
2.46 (1.31 to 4.66)
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
FIGURE 100 Standard NMA results for dry mouth. Ns, not specified; std, standard.
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Bupropion std + NRT patch (24 hours) high




NRT patch (24 hours) high
NRT patch (16 hours) high
NRT patch (16 hours) std
NRT patch (24 hours) ns
NRT gum std
[NRT gum high]Bupropion std
Bupropion low
FIGURE 101 Network plot for skin rash at treatment level. Square brackets denote interventions that were not included
in the NMA. Ns, not specified; std, standard.
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Intervention OR (95% Crl)
No treatment





Bupropion low + NRT ns




OR (compared with placebo)
0.03 (0.00 to 0.65)
0.68 (0.01 to 11.82)
2.23 (1.06 to 4.76)
0.41 (0.01 to 6.23)
0.88 (0.51 to 1.54)
3.29 (0.53 to 21.76)
1.80 (0.11 to 18.17)
0.41 (0.02 to 4.14)
1.99 (0.78 to 6.23)
1.43 (0.23 to 7.69)
2.25 (0.54 to 8.76)
0.2 0.5 1.0 2.0 5.0
FIGURE 102 Random-class NMA results for skin rash. Ns, not specified; std, standard.
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Intervention OR (95% Crl)
No treatment
Varenicline and bupropion std
Bupropion std + NRT patch (24 hours) high





NRT patch (24 hours) high
NRT patch (16 hours) high
NRT patch (16 hours) std
NRT gum std
NRT patch (24 hours) ns
NRT combined ns
NRT ns
0.04 (0.00 to 0.79)
1.52 (0.79 to 2.97)
2.97 (1.00 to 8.50)
2.77 (0.63 to 10.80)
0.48 (0.00 to 26.84)
1.65 (0.36 to 7.69)
1.70 (0.32 to 9.58)
2.18 (0.75 to 6.82)
0.68 (0.01 to 12.43)
2.23 (1.06 to 4.95)
0.39 (0.01 to 5.70)
0.91 (0.52 to 1.62)
1.80 (0.11 to 19.11)
3.13 (0.44 to 23.57)
0.44 (0.03 to 4.53)
0.2 0.5 1.0 2.0 5.0
OR (compared with placebo)
FIGURE 103 Standard NMA results for skin rash. Ns, not specified; std, standard.
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